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Abstract: Childhood attention-deficit/hyperactivity disorder (ADHD) is a risk factor for the develop-
ment of substance abuse and substance use disorders (SUD) in adolescence and (early) adulthood.
ADHD and SUD also frequently co-occur in treatment-seeking adolescents, which complicates diag-
nosis and treatment, and is associated with poor treatment outcomes. In this study, we provide a
systematic review of controlled studies on the effectiveness of pharmacological, psychosocial, and
complementary treatments of ADHD in adolescents with and without comorbid SUD. In addition,
we review the longitudinal association between pharmacotherapy for childhood ADHD and the
development of SUD in adolescence and early adulthood. We conducted a systematic review of
the research literature published since 2000 using Medline, PsycINFO, and the Cochrane Database
of Systematic Reviews databases to select randomized clinical trials, observational studies, and
meta-analyses. The quality of the evidence from each study was rated using the SIGN grading
system. Based on the limited evidence available, strong clinical recommendations are not justified,
but provisionally, we conclude that stimulant treatment in children with ADHD may prevent the
development of SUD in adolescence or young adulthood, that high-dose stimulant treatment could
be an effective treatment for adolescents with ADHD and SUD comorbidity, that cognitive behavior
therapy might have a small beneficial effect in these patients, and that alternative treatments are
probably not effective. More studies are needed to draw definitive conclusions that will allow for
strong clinical recommendations.
Keywords: review; ADHD; SUD; comorbidity; adolescents; treatment
1. Introduction
Childhood attention-deficit/hyperactivity disorder (ADHD) is a risk factor for early
substance use initiation and the development of substance use disorders (SUD) in ado-
lescence and (early) adulthood [1,2]. Although we know little about the prevalence of
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co-occurring ADHD and SUD among adolescents in the general population [3,4], re-
searchers have found high comorbidity rates among adolescents in mental health and
substance abuse treatment [5,6]. For example, a meta-analysis on pooled data of nearly
4000 adolescents in substance abuse treatment revealed that 24% of these adolescents were
also diagnosed with ADHD [4].
Studies suggest that the co-occurrence of ADHD and SUD can be partly explained by
common vulnerability factors, including genetic predispositions [7–9] and (associated) dys-
functions in the inhibitory and reward system in the brain [10,11]. In addition, symptoms
of ADHD and their consequences may increase the risk of addiction problems, particularly
in those with co-occurring oppositional defiant disorder and conduct disorder [1,12]. The
reverse relationship—in which substance use results in ADHD—is unlikely, given that
ADHD generally develops before initial alcohol or drug use [13,14].
ADHD is found to be more common in males than in females by ratios ranging
between 3:1 to 1.5:1 in population-based studies, and ratios ranging between 5:1 and 9:1
in clinical samples. However, an increasing number of studies suggest that females with
ADHD face more severe outcomes and more often experience delayed and insufficient
treatments than males with ADHD. Sex differences have been reported in the onset and/or
type of symptoms, medication use, and quality of life [15,16].
Differences in SUD prevalence rates between males and females are becoming smaller
worldwide, with a substantial variation within cultures, with higher rates in cultures where
men have better access to substances relative to women. These sex differences in ADHD
and SUD have been shown to arise from differences in genetic, hormonal, socioeconomic,
environmental, and psychosocial influences; gender bias; and differences in the access to
specialty care [17]. Importantly, it seems that there are no sex differences in the prevalence
of comorbid ADHD in SUD patients [4], whereas there seem to be slightly more female
than male ADHD patients with comorbid SUD [15].
Existing guidelines on ADHD pay relatively little attention to adolescence as a distinc-
tive developmental phase, even though important hormonal, physical, neurobiological,
and psychosocial changes take place during this period. These alterations are likely to
affect the course of, as well as adherence and response to, ADHD treatment. Moreover,
most guidelines pay little or no attention to adolescents with concurrent ADHD and SUD
as a distinctive subgroup, and only provide some general advice to screen adolescents with
ADHD for symptoms of substance misuse and SUD, to use medications with little or no
abuse potential, and to be alert for signs of misuse or diversion of ADHD medication in
this group (in countries such as the Netherlands [18], Australia [19], Scotland [20], Ger-
many [21], Canada [22], the UK [23], and the USA [24]). Moreover, recommendations are
directed only towards medical practitioners that already have experience in the treatment
of ADHD and SUD, and fail to provide guidance to general practitioners, general child
psychiatrists and psychologists, or general addiction physicians. All guidelines reflect that
the evidence-base pertaining to the treatment of adolescents with concurrent ADHD and
SUD is small, and that there is a paucity of research on this comorbidity. Hence, the (few)
recommendations for treatment provided on concurrent ADHD and SUD in the guidelines
are largely practice-based.
There are several effective treatments for adolescents with ADHD and—although
less well studied—for those with SUD. However, the co-occurrence of ADHD and SUD
complicates treatment of both disorders and is likely to negatively affect treatment
outcomes [25–27]. Nevertheless, those developing treatment protocols for the different
disorders pay little attention to “the other problem”, and we have no international guide-
lines for the diagnosis and treatment of their comorbidity in adolescents. In addition,
ADHD often remains unrecognized—and hence, untreated—in youth with substance use
disorders, and the same is true for the lack of detection of SUD among ADHD patients in
youth mental health care [28].
Here, we provide a systematic review of controlled studies on the effectiveness of
pharmacological, psychosocial, and complementary treatments of ADHD in adolescents
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with concurrent ADHD and SUD. As we knew in advance that the literature on the
treatment of these comorbid adolescents is limited, controlled studies pertaining to the
treatment of adolescents with ADHD but without SUD are also included. Moreover,
the inclusion of studies on adolescent ADHD patients with and without SUD will allow
us to explore the question of whether poor treatment outcomes in adolescent ADHD
patients with concurrent SUD may be related to SUD comorbidity or to lower efficacy
of ADHD treatments during the adolescent phase of life. In contrast to most studies on
ADHD in youths, we only include studies that exclusively focus on adolescents or report
separate outcomes for children and adolescents. We also review the longitudinal association
between (stimulant) pharmacotherapy for childhood ADHD and the development of SUD
in adolescence and early adulthood.
2. Methods
Systematic literature searches were conducted in Medline, PsycINFO, and the Cochrane
Database of Systematic Reviews, using the following inclusion criteria:
(a) Studies were original studies published between 2000 and 2021 (11 April 2021) in
peer-reviewed, English-language journals.
(b) Studies evaluated the effectiveness of treatment of ADHD in adolescents (12–20 years
old) with or without concurrent SUD.
(c) Study treatments involved a pharmacological, psychosocial, or complementary (e.g., di-
etary) intervention targeted at ADHD.
(d) Diagnoses of ADHD and SUD were based on the DSM-IV/-5 [29] or ICD-10/-11
criteria [30].
(e) Studies were randomized controlled trials (RCTs), controlled clinical trials, random-
ized cross-over studies, or relevant meta-analyses.
(f) Outcome measures included validated rating scales for ADHD, and—in studies
involving patients with comorbid SUD—a quantitative measure of consumption of
substances (e.g., days/frequency of use/abstinence).
(g) Studies had to include a minimum of 10 (ADHD plus SUD) or a minimum of 20
(ADHD without SUD) adolescent patients per treatment condition.
(h) Studies in mixed samples of children and adolescents, or adolescents and adults had
to meet inclusion criterion.
(i) Studies in mixed samples of children and adolescents, or adolescents and adults had
to have separate outcomes analyzed and reported for the adolescent subgroup.
Next, we conducted an additional manual search of the reference sections in the
selected papers in order to identify relevant articles, reports, or books that were missed
in the systematic searches. Study authors H.Ö., R.S., and V.H. reviewed the titles and
abstracts of all identified studies, retrieved and read the full-text manuscripts of those
that seemed to meet the inclusion criteria, and made a final decision as to the eligibility of
each manuscript, based on consensus. The key characteristics and findings of the included
studies were recorded, and risk of bias of each study was assessed, using the updated
risk-of-bias tool of the Cochrane Collaboration (RoB-2) [31]. The quality of the evidence
from each study (i.e., considering the study design and its methodological quality) was
rated using the SIGN grading system [32] (see Table S1 in Supplementary Materials). We
followed the Prisma guidelines (see Supplementary Materials Figure S1).
3. Results
3.1. Literature Search
Outcomes of the literature search are presented in the flowchart in Figure 1. The
applied search terms are presented in Table S2 in the Supplementary Materials. Initial
database searching resulted in 1402, 1407, and 921 unique records for pharmacological,
psychosocial, and complementary interventions, respectively. Based on the first screening,
many studies were excluded due to the lack of a controlled design and/or not addressing
the effectiveness of an ADHD-focused intervention. Based on a thorough assessment of
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the remaining articles, we selected 15 papers that included 16 trials for the synthesis on
pharmacotherapy, 13 papers with 13 trials on the effectiveness of psychosocial interventions,
and 6 papers including 5 trials on the effectiveness of complementary interventions. The
main reasons for excluding articles from the final selection were lack of separate outcome
data for adolescents, small sample size, and no reporting of an ADHD outcome measure.
3.2. Pharmacological Interventions
We identified 16 RCTs on pharmacological treatment that met the selection criteria
of our literature search: four placebo-controlled randomized trials in adolescents with
concurrent ADHD and SUD (458 enrolled patients; Table 1), and 12 placebo-controlled
randomized trials in adolescents with ADHD but without SUD comorbidity (2675 patients;
Table 1), with three of them comparing two active medications with placebo [33,34]. In
addition, we found one systematic review with a meta-analysis pertaining to the efficacy
and safety of the pharmacological treatment of patients with concurrent ADHD and
SUD [35].




Figure 1. Flowchart. . l chart.
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Table 1. Placebo-controlled studies of pharmacological treatment in adolescents with ADHD and comorbid SUD, and in adolescents without comorbid SUD.
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Note: Pelham 2013 and Newcorn 2017a and 2017b are three-armed studies that investigated two active medications and placebo. ADHD—attention deficit/hyperactivity disorder; SUD—substance use disorder;
CD—conduct disorder; RCT—randomized controlled trial; DB—double blind; SB—single blind; PC—placebo controlled; Tx—treatment; OROS-MPH—osmotic-release oral system methylphenidate; MPH-
SODAS—extended release formulation of methylphenidate; MTS—methylphenidate transdermal system; IR-MPH—immediate release methylphenidate; LDX—lisdexamfetamine dimesylate; MAS-XR—mixed
amfetamine salts extended release; GXR—guanfacine extended release; CBT—cognitive behavioral therapy; MET—motivational enhancement therapy; DSM-IV —Diagnostic and Statistical Manual of Mental
Disorders; ADHD-RS-IV—DSM-IV ADHD Rating Scale; SNAP-IV—Swanson, Nolan, and Pelham Scale, version IV; CHI —Conners Hyperactivity-Impulsivity scale; IOWA-CRS—IOWA Conners Rating Scale;
CDRS-R—Children’s Depression Rating Scale-Revised; CGI—Clinical Global Impression scale; TLFB—Time Line Follow-Back calendar method; NA—not applicable; ns—not significant. Mechanisms of action
for each pharmacological treatment mentioned: Methylphenidate: increases dopaminergic and noradrenergic activity in the prefrontal cortex by inhibiting dopamine and noradrenaline reuptake. Pemoline:
increases dopaminergic activity by blocking dopamine reuptake. Atomoxetine: not fully known but thought to be related to increased noradrenergic activity in the prefrontal cortex via selective noradrenaline
reuptake inhibition. (Lis)dexamfetamine/mixed amfetamine salts: increases monoamine neurotransmitter release (including dopamine, norepinephrine, and serotonin) and prevents their reuptake. Guanfacine:
not fully known but thought to be related to the stimulation of alpha2 adrenergic receptors in the brain.
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In their meta-analysis of randomized placebo-controlled trials, Cunill et al. (2014)
included four studies on adolescents and nine studies on adults with concurrent ADHD
and SUD (1271 patients) using the following ADHD medications: methylphenidate (n = 8),
atomoxetine (n = 3), pemoline (n = 1), bupropion (n = 1), and lisdexamphetamine (n = 1).
The mean pooled effect size on ADHD symptoms from all of the studies amounted to an
odds-ratio (OR) of 1.93 (small effect). Compared with placebo, methylphenidate (OR = 2.02)
and atomoxetine (OR = 1.71) significantly reduced ADHD symptoms, but the other medi-
cations did not [35]. None of the medications were effective in increasing abstinence from
substances (OR = 1.09). Age of the patients (in years) did not moderate the effect on ADHD
symptoms. Unfortunately, this meta-analysis did not distinguish between adolescent and
adult patients, and did not consider the heterogeneity within and between samples nor
the methodological differences between the studies and the variations in dosing. The four
trials on adolescents with ADHD and SUD in the meta-analysis of Cunill et al. (2014) [35]
are part of our selection for the present systematic review.
3.2.1. Adolescents with Concurrent ADHD and SUD
Two of the four studies in adolescents with ADHD and SUD involved methylphenidate
(MPH) [36,37], one study involved pemoline [38], and one study involved atomoxetine [39]
(Table 1). From these, one study required a minimum level of ADHD symptom severity to
be included [39], and none of the studies required adolescents to be abstinent at the start of
the study treatment.
Riggs et al. (2011) investigated OROS-MPH vs. placebo in a 16-week RCT in 303
adolescents with ADHD and mixed (non-nicotine and non-opioid) SUD, with both treat-
ment groups concurrently receiving once-weekly combined cognitive behavioral therapy
(CBT) and motivational interviewing (MI) for SUD. On the primary outcome measures,
they found significant baseline to endpoint reductions in self-reported ADHD symptoms
and self-reported number of substance use days in both treatment groups, but no between-
group difference on either measure. However, some secondary outcomes, including
parent-reported ADHD symptoms at week 8 (p = 0.02) and week 16 (p < 0.001) and the
number of negative urine drug screens (p = 0.05) favored OROS-MPH, leading the authors
to conclude that “(...) further consideration of potential reasons for failed efficacy on the
primary outcome measure is warranted (...)” [37] (p. 911).
Szobot et al. (2008) conducted a 6-week randomized cross-over study in 16 male
adolescents with ADHD and a comorbid cannabis or cocaine use disorder. They found
MPH-SODAS to be more effective than placebo at improving ADHD symptoms and global
functioning, but not at reducing substance use [36].
Riggs et al. (2004) compared pemoline with placebo in a 12-week RCT of 69 adolescents
with ADHD and comorbid mixed (non-nicotine) SUD and conduct disorder (CD), and
the results showed a significant between-group effect in favor of pemoline in terms of the
percentage of adolescents with clinician-rated “much improved” or “very much improved”
ADHD symptom severity at the study endpoint (p = 0.05), but no effect on parent-rated
ADHD symptom severity (p = 0.13), substance use (adolescent-report: p = 0.80; urinalysis:
p = 0.33), and CD symptoms (p = 0.44). Due to hepatotoxicity concerns, pemoline was
withdrawn from the market in 2005 [38].
Lastly, Thurstone et al. (2010) conducted a 12-week RCT comparing atomoxetine max.
100 mg/day and placebo in 70 adolescents with ADHD and mixed (non-nicotine) SUD
who concurrently received once-weekly CBT/MI for SUD, and found no between-group
difference in improvement for neither ADHD or substance use, both based on self-report
and urinalysis [39].
In all four trials, pharmacological treatment was well tolerated. Adverse events (AEs)
and/or treatment emergent AEs (TEAEs) were generally more prevalent in patients in the
active medication groups, but these were mostly mild in intensity and transient. In the
trial of pemoline, no elevation of liver enzyme levels was observed. Study-related serious
adverse events (SAEs) in the active medication groups were absent or rare (≤1 SAE) in all
J. Clin. Med. 2021, 10, 3908 12 of 37
studies, with no excess of SAEs in any active medication group compared with placebo.
Adverse pharmacological interactions between the study medication and the adolescent’s
substance use at the same day were only reported in the trial of Riggs et al. (2011) [37],
and only by four (2.8%) and three (2.1%) of the patients taking OROS-MPH and placebo,
respectively. In the three trials that investigated stimulants, no indication was found that
stimulant medication led to SUD deterioration.
Planned treatment duration in these trials ranged from 6–16 weeks (1 of 4 studies
>12 weeks), and no subsequent extension studies were conducted to investigate the long-
term effects of ADHD medication in the study samples. Hence, pertaining to adolescents
with comorbid ADHD and SUD, only data on the short-term effects of ADHD medication
are available to date. We assessed the risk of bias as being low in the studies of Riggs (2011)
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly
due to missing outcome data (Table 2).
Table 2. Risk of bias in the included studies on pharmacological interventions.
Study Bias Arising from/Due to:
Rnd Int Mis Mea Sel Overall
Adolescents with ADHD + SUD
Riggs, 2011 [37]
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s bgro p. Our selected it rature included a meta-anal sis by Cerrillo-Urbina et al. (2018) 
f 15 RCTs comp ring stimulant a d on-stimula t medications with p ac bo in children 
and adolescents with ADHD [48]. Only our of these, 15 trial  focu e  on adolescents only. 
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studi s, with no excess of SAEs n any ac ve medic tion gr u  com ared with placebo. 
Adverse pharmacolog cal interactions between the study me ic tio  and the adole cent’s 
substance use at th  sam  day were only r ported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of th  patients taking OROS-MPH and placebo, 
resp ctively. In h ree ri ls hat inve tig ted stimulants,  i ication w s found that 
stimulant medication led to SUD deterioration. 
Plan ed trea ment duration in hes trials ranged fr m 6–16 weeks (1 of 4 studies >12 
w eks), and no s b equent extension studies w r  co uc ed o inv sti at  the long-term 
effects of ADHD me ication in the study samples. Hence, pertaining to adolescents with 
comorbid ADHD and SUD, only da a on the shor -term effects of ADHD m dic tion are 
av ilable to date. We asses ed the ri k of bias as being l w in the studies of Riggs (2011) 
a d Thursto e (2010), a d as high in the studies of Szobot (2 08) and Riggs (2004), mainly 
due to missing outcom  d ta (Table 2). 
Table 2. Risk of bias  the included tudies o  pharma ological i erventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Me  Se  Overall 
dolescents with ADHD + SUD      
Riggs, 2011 [37]      
Szobot, 2008 [36]      
Riggs, 2004 [38]      
Thurstone, 2010 [39]      
dolescents with ADHD      
Pelham, 2013 [33]      
Findling, 010 [27]      
Wilens, 2 06 [40]      
Findling, 2011 [42]      
Spencer, 2006 [41]      
Bostic, 2000 [43]      
Bangs, 2007 [44]      
Biederman, 2008 [45]      
Sallee, 2009 [46]      
Wilens, 2015 [47]      
Newcorn, 2017a [34]      
Newcorn, 2017b [34]      
Note:       low ri k/high risk/s m  c ncerns. Rnd—rand m zation proces; Int—intended 
i erventions; Mi —missing outcome data; M —measurement f h  outc me; Sel—selection of 
the reported result. 
To conclude, the evidence base on pharmacological ADHD treatment in adolescents 
with co curre t ADHD and SUD limited, with les tha  500 pat nts included across 
fou  contr lled tri l  of a short duration, none f w ich show d  robust tr atment effect 
on either A HD or SUD. 
3.2.2. dolescents with ADH  but without SUD Comorbidity 
Most trials on the efficacy f pharmacological ADHD tre tment in youth have been 
con uct d in m xed samples f childr n and adolescen s t n age group typically ranging 
from 5 to 18 ye rs, without sep rate analysis or reporting of outcomes in the adolescent 
s bgro p. Our selected literature included  meta-anal sis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co par ng stimulant a d non-stimulant medicat ons w th placebo in children 
a d adolescents with ADHD [48]. Only four of these, 15 trial  focuse  n adolescents only. 
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stud es, with no excess of SAEs in ny active medicati n gr up compared with placebo. 
Adverse pha macological in eractions be ween he stu y me ic tion and th  adole cent’s 
subs ance use at th  sam  da were only r p rt d in the trial of Riggs et al. (2011) [37], 
and only by four 8 and three (2.1%) of th  patients taki g OROS-MPH and placebo, 
r spectively. In th ree ri ls that i vestig ted stimulants, no indication w s found that 
stimulant medication led t  SUD deterioration. 
Planned tre m nt duratio  in hese trials ranged from 6–16 weeks (1 of 4 studies >12 
we ks), and no bseq e t extensi  studies were con ucted t investi a  the long-term 
effects of ADHD medication in the study samples. H nce, pertaining o adolescents with 
com rbid ADHD nd SUD, only da a on the short-t rm effects of ADHD medic tion are 
av il bl  to dat . We as essed th  ri k f bias as being low in the studies of Riggs (2011) 
a d T ursto e (2010), a d as high in the stu ies of Szobot 8  and Riggs (2004), mainly 
due to missing outcome d ta (Table 2). 
Table 2. Risk of bias  the in luded tudies o  ph rma ological i erventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis M a Sel Overall 
Adolescents with ADHD + SUD     
Riggs, 2011 [37]     
Szobot, 2008 [36]     
Riggs, 2004 [38]     
Thurstone, 2010 [39]     
Adolescents with ADHD     
Pelham, 2013 [33]     
Findling, 010 [27]     
Wilens, 2 06 [40]     
Findling, 2011 [42]     
Spencer, 2006 [41]     
Bostic, 2000 [43]     
Bangs, 2007 [44]     
Biederman, 2008 [45]     
Sallee, 2009 [46]     
Wilens, 2015 [47]     
Newcorn, 2017a [34]     
Newcorn, 2017b [34]     
Note:          l w ri k/high risk/s  concerns. Rnd—ra domiza ion proces; Int—intended 
i erventi ns; Mis—missing outcome da a; M — asurement f h  outcome; Sel—selection of 
the reported result. 
To co lud , the evidence base on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD  limited, with l ss tha  500 p t nts included across 
fou  contr lle tri l  of short duration, none f w ich showed robust tr a ment effect 
n either A HD or SUD. 
3.2.2. Adolescents it  ADH  but without SUD Comorbidity 
Most tri ls on the efficacy f pharmacological ADHD treatment i  youth have been 
con ucted in mixe samples of childr n and dolescents at  age group typically ranging 
from 5 to 18 years, without sep rate a alys s or reporti g of outcomes in the adolescent 
s bgro p. O  s lect d literature i c ud d m ta-a l sis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co par g stimulan  a d non-stimu nt medi atio s with placebo in children 
and adolescents with ADHD [48]. Only four f these, 15 tria focu e  n adolescents only. 
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ud es, with no ex s of SAEs n ny activ  edication group c mpared with placebo. 
Advers  ph rm ological int ract o s b twee th  s udy medication a d the adolescent’s 
bstanc use at the sam day w r  only reported n th  trial of Riggs et al. (2011) [37], 
a d only by f ur (2.8%) and ree (2.1%) of he patients taking OROS-MPH and placebo, 
spec ively. In t e h e  ri ls h t vestigated tim l s, o indicatio  was found that 
stimul nt medication le  to SUD deterioration. 
Plann d treatme t du ation  thes  tri ls rang d from 6–16 we ks (1 of 4 studies >12 
week ), a d no ubseque t xt si n studi s wer  c duc d to investigate the long-term 
effects of A HD medication in the study samples. Hence, pert ining t  adolescents with 
comorbid A H and SUD, ly da a on  sho t- erm effects of A HD medication are 
available o date. We a se sed the risk of bia  as being low in the tudies of Riggs (2011) 
and Thurstone (2010), nd as high in the s udies of Szobot (2008) and Riggs (2004), mainly 
d e t  missing utcome dat (Table 2). 
Table 2. Risk of bia  i  the include stud es on pha macological interventions. 
Study Bias Arising fr m/Due to:  
 Rnd Int Mis Mea S l Overall 
Adolescents with A HD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with A HD       
Pelham, 2013 [33]       
F dling, 2010 [27]       
Wilens, 2006 [40]       
F dling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:         low risk/h gh risk/some co ce s. Rnd—randomization proc s; I t—intended 
interventi n ; Mis—mi sing utc e data; Mea—m a ur e t of the u c me; S l—selection of 
the epo ted result. 
To conclud , th  vide ce b se on ph rm cological A HD tr tment in adolescents 
with concurrent A H an SUD is l mit d, with l ss ha 500 patie t  included across 
four c n rolled trials f a s rt duration, none of hich showed a robust treatment effect 
on either A HD or SUD. 
3.2.2. Adolescents wi h A HD but without SUD Comorbidity 
Most tri ls n t e eff cy of ph rm cological A HD tr atment in youth hav  been 
c nducted in mixed samples of childre nd adol scents at an ge grou  typically ranging 
f om 5 to 18 y ars, with ut separate analysis r rep r ing of utcomes in the adolescent 
ubgroup. Our s lected lite ture included  met -analysis by Cerrillo-Urbin  et al. (2018) 
of 15 RCTs comparing stimula t d no - timul nt medicati ns with placebo in children 
nd adolescents with A HD [48]. Only ur o  th , 15 tria s fo used o  ad lescents only. 
Szobot, 2008 [36]
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studies, with no excess of SAEs in any active medication group compared with placebo. 
Adverse pharmacological interactions between the study medication and the adolescent’s 
substance use at the same day were only reported in the trial of Riggs t al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the patients taking OROS-MPH and placebo, 
respectively. In the three trials that investigated stimulants, no indication was foun  that 
stimulant medication led to SUD deterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequent extension studies were conducted to investigate the long-term 
effects of ADHD medication in the study samples. Hence, pertaining to adolescents with 
comorbid ADHD and SUD, only data on the short-term effects of ADHD medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
interventions; Mis—missing outcome data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, the evidence base on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patients included across 
four controlled trials of a short duration, none of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth have been 
conducted in mixed samples of children and adolescents at an age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with no excess of SAEs in any active medication group ompared with placebo. 
Adverse pharmacol gical int rac ions betwe n the study medication and the adolescent’s 
substance use at the same day were only reported in the tri l of Riggs et al. (2011) [37], 
and only by four (2.8%) and thr e (2.1%) of the patients taking OROS-MPH and placebo, 
respectiv ly. In the hree tr als that nvestigated stimulants, no indication was found that 
stimulant medication led to SUD deterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (  of 4 studies >12 
weeks), and no subsequent extension studies were conducted to investigate the long-term 
effects of ADHD m dication in the study samples. Hence, pertaini g to adolescents with 
comorbid ADHD and SUD, only data on the short-term effects of ADHD medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as h gh in the studies of Szobot (2008) and Riggs (2004), mainly 
due t  issing outcome data (Table 2). 
Table 2. Risk of bias in th  included studies on pharmacol gical interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:          low risk/high isk/some co cerns. Rnd—randomization proces; Int—intended 
intervent ons; Mis—missing outco  data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, th evidence base on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patients included across 
four controlled rials of a sh rt duration, none of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most tri ls on the efficacy of pharmacological ADHD treatment in youth have been 
con ucted in mixed samples of childr  and dolescents a  an age g oup typically ranging 
from 5 o 18 years, without epa at  analysis or reporting of outcomes i  the adolescent 
subgroup. Our selected literatur  included a meta-analysis y C rri lo-Urbina et al. (2018) 
of 15 RCTs compari g stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 tri ls focused on adolescents only. 
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studies, with no excess of SAEs in any active medication group compared with placebo. 
Ad rse pharm col gical interactions between the study medica ion and the ad lescent’s 
substan e use at th  s me d y wer  only report d in the trial of R ggs et al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the patie ts taking OROS-MPH and pla eb , 
respectively. In the three rials th  investigated stimulants, no indication was found that 
timulant edicatio  led to SUD deteri ration. 
Planned treatment duration i  these trials rang d from 6–16 weeks (1 of 4 s u ies >12 
week ), and no ubsequent xtension st ies were conducted to investigate the long-term 
eff cts of ADHD m dicati n n th  study samples. Hence, pertaining to adolesc n  with 
comorbid ADHD and SUD, only ata on the hort-t rm effects of ADHD medication are 
available to date. We asse sed th  risk of bias as being low in the studies of Riggs (2011) 
and Thursto e (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing utcome data (Table 2). 
Table 2. Risk of bias in the included studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
interventions; Mis—missing outcome data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, the evidence base on pharmacological ADHD treatment in adolescents 
with concurrent  and SUD is limit d, with less than 500 patients included across 
four controlled trials of a short duration, none of which showed a robust treatment effect 
o  eith r ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth have been 
conducted in mixed samples of children nd adolescents at an age group typically ranging 
from 5 to 18 years, without se arate nalysis or reporting of outcomes in the adolescent 
subgr up. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 R Ts comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with no excess of SAEs in any active medi ation group compared with placebo. 
Adv e ar acological interactions between the study m dic ti n and h  adolescent’s 
substance us  at the same day wer  o ly report d in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the patients taking OROS-MPH and placebo, 
resp ctiv ly. In the three trials hat invest gated stimul nts, no indication was found that 
stimulant medication led to SUD deterioration. 
Pla ned treatment durat on in th se trials ranged from 6–16 weeks (1 of 4 studies >12 
week ), and no sub equent xtensi  stu ie  were conducted o investigate the long-term 
effects of ADHD medicati  in the tudy samples. Hence, pertaining t  adolescents with 
comorbid A HD and SUD, only da a on the short-term effects of ADHD medication are 
vailabl  to date. We a sessed the risk of bias as being l w in the stu ies of Riggs (2011) 
and Thurstone (2010), and a  high in the studies of Szobot (2008) and Riggs (2004), mainly 
due o issing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolesc nts with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:          low risk/high risk/some concerns. Rnd—randomizatio  proces; Int—intended 
interventions; Mis—missing outco e data; M a—measurement of the out ome; Sel—selection of 
the reported result. 
To conclud , the evidence b se n pharmacological ADHD treatm  in adolescents 
with co cu rent A HD and SUD is imited, with less than 500 patients included across 
four controlled t ial  of a short duration, none of which show d a robust treatment effect 
on eith r ADHD or SUD. 
3.2.2. Adolescents with ADHD but with ut SUD Comorbidity 
Most tr als on the effic y f pharmacological ADHD treatment in youth have been 
co ducted in mix d samples of chi dren and adolescents at an age group typically ranging 
from 5 to 18 years, without separate analysis or rep rting of outcom  in he adolescent 
sub roup. Our sel cted literatur  included a meta-ana ysis by Cerril o-Urbina et al. (2018) 
f 15 RCTs compa ing stimulant and non-stimulant medic tions wit  placebo in children 
and d le cents with ADHD [48]. Only fou  of these, 15 trials focus d on adolescents only. 
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studies, with no ex ess of SAEs in any active i i  group ompare  with placebo. 
Adverse ph rmacological inter ti n between the study m dic ti n and the adolescent’s 
substance use at t e same day wer  only report d in he trial of Riggs et al. (2011) [37], 
a d only by four (2.8%) a d three (2.1%) of the patie ts t king OROS-MPH and placebo, 
r spectively. In the t re  trials that investigated stimul ts, no indication was found that 
stimulant m dic ti  l d to SUD deteriorati . 
Planned tr atment d ration i  th se trials rang d from 6–16 w eks (1 of 4 studies >12 
weeks), and n  subsequent extension tudies wer  conduct d to investigate t e long-term 
effects f ADHD medic tion i  the study sampl s. Hence, pertaining to adol scents with 
co orbid ADHD and SUD, only d ta on the short-term effects of ADHD medication are 
av i able to date. W  assess d t e risk of bias as being low in the stu ies of Riggs (2011) 
a  Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on ph mac l gical inte ventions.
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 20 6 [41]       
Bostic, 200  [43]       
angs, 2007 [44]       
Biederman 8 5       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
intervention ; Mis—missing out ome data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To n lud , the evidence base on pharm cologic l ADHD treatm t in adol scents 
w th concurren ADHD an  SUD is limited, with less than 500 pati ts included across 
four c ntrolled trial  of a short duration, none of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidit  
Most trials on the efficacy f pharmacological ADHD treatment in youth have been 
conducted in mixed samples of child en d adolescents at an age group typically ranging 
from 5 t  18 yea s, without sep rat  nalysi  or repo ting of outcomes in the dolescent 
subgroup. Ou  selected literat re included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in hildre  
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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stud es, with o exc ss f SAEs in any activ  medication group compared with placebo. 
A vers pharmacological interac ions b tween t e study medication and the adolescent’s 
substanc  us  at the same day were only reported i  the trial of Riggs et al. (2011) [37], 
and only by f ur (2.8%) and three (2.1%) of he patients taking OROS-MPH and placebo, 
spect vely. I  the three trials that i vestigated stim lants, no indication was found that 
stimulant medica ion led to SUD deterioration. 
Planned trea ment uration in thes  rials ran e  from 6–16 weeks (1 of 4 studies >12 
w eks), and no ubseque t x nsi n stud es were c ducted to investigate the long-term 
ffects of ADHD med cation in the study samples. Hence, pertaining to adolescents with 
comorbi ADHD and SUD, only data on the short-term effects of ADHD medication are 
avail ble to date. W  assessed the risk of bias as being low i  the studies of Riggs (2011) 
and Thurst ne (201 ),  as hig  in the studies of Szobot (2008) and Riggs (2004), mainly 
due to mi sing outcome data (Table 2). 
Table 2. Risk of bias in the ncluded studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:          low risk/high ri k/some co c rns. Rnd—randomization proces; Int—intended 
interv ntions; Mis—mi sing utc me data; Mea mea ureme t of the outcome; Sel—selection of 
the reported result. 
T  con lude, the evidence base on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is li ited, with l s than 500 patients included across 
f ur controlled trials of a shor dur tio , none of whi h showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Ad lescents with ADHD but without SUD Comorbidity 
Most tri ls on the efficacy f pharmacological ADHD treatment in youth have been 
c n ucted in mixed samples of ch ldren d adolesc nts at an age group typically ranging 
from 5 to 18 ears, with ut eparate analys s or reporti  of outcomes in the adolescent 
subgroup. Our elected l terature included a met -analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant a d on-stimulant medications with placebo in children 
an  adol scents with ADHD [48]. Only four of th e, 15 trials focused on adolescents only. 
Riggs, 2004 [38]
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studies, with no excess of SAEs in any active medicatio  group comp red with placebo. 
Adverse pharmacological interactions between th  study m dication and t  adolescent’s 
substance use at the same day were only reported in the tri l of Riggs t al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the p tients taking OROS-MPH n  plac bo, 
respectively. In the three trials that investigat d stimulants, no i ic tion was f und that 
stimulant medication led to SUD deterioration. 
Planned treatment duration in these trials ranged fr  6–16 weeks (1 f 4 stu ies >12 
weeks), and no subsequent extension studies were con ucted to investigate the long-t rm 
effects of ADHD medication in the study samples. He ce, pertaini g to a olesc nts with 
comorbid ADHD and SUD, only data on the short-term effects f ADHD medic tion re 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on ph rmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]      
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]      
Adolescents with ADHD       
Pelham, 2013 [33]      
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]      
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]     
Note:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
interventions; Mis—missing outcome data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, the evidence base on pharmac logical ADHD treatment in adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patients included across 
four controlled trials of a short duration, none of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Co orbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth have be n 
conducted in mixed samples of children and adolescents at an a e gro  typic lly ranging 
from 5 to 18 years, without separate analysis or reporti g of utcom s i  the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with no excess of SAEs i  any active medic tion gr up comp red wit  placeb . 
Adverse pharmacol gical int rac ions betw n t  study medication a d th  adole c nt’s 
substance use at the same day were only reported in th  tri l of Riggs et al. (2011) [37], 
and only by four (2.8%) and thr e (2.1%) of the patients taking OROS-MPH and pl cebo, 
respectiv ly. In the hree tr als that nvestigated stimulants, no i dication was f und that 
stimulant medication led to SUD det rioration. 
Planned treatment duration in these trials ranged fr  6–16 weeks (  f 4 studies >12 
weeks), and no subsequent extension studies were conducted to inv tigat  the long-term 
effects of ADHD m dication in the study sampl s. Hence, pert ini g to dolesc ts wit  
comorbid ADHD and SUD, only data o  the short-term effect  of ADHD medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as h gh in the studies of Szobot (2008) and Riggs (2004), mainly 
due t  issing outcome data (Table 2). 
Table 2. Risk of bias in th  included studies on ph rmacol gical interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]      
Szobot, 2008 [36]      
Riggs, 2004 [38]      
Thurstone, 2010 [39]      
Adolescents with ADHD       
Pelham, 2013 [33]      
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]     
Biederman, 2008 [45]      
Sallee, 2009 [46]      
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:          low risk/high isk/some co cerns. Rnd—randomization proces; Int—intended 
intervent ons; Mis—missing outco  data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, th evidence bas  on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patients included across 
four controlled rials of a sh rt duration, none of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Com rbidity 
Most tri ls on the efficacy of pharmacological ADHD tr tm nt in youth h ve b n 
con ucted in mixed samples of childr  and d le cents a  a  age g up typically r ging 
from 5 o 18 years, without ep at  analysis or rep rting of outcomes i  t e adol ce t 
subgroup. Our selected literatur  included a meta-analysis y C rri lo-Urbina et al. (2018) 
of 15 RCTs compari g stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 tri ls focused on adolescents only. 
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tudie , wit  no ex s of SAEs in any ctiv  medica on g oup compar d with placebo.
Ad rse ph rm col gical interactions between the study medicat on and the dolescent’s
substan  use a  th  s me d y w re on y reported in th  trial of Riggs et l. (2011) [37],
a d only by four (2.8%) a d hree (2.1%) of th patien s t king OROS-MPH and placebo, 
resp ctiv ly. I  he three tr ls th i v stig t sti ul nts,  i dicat on was f und that
timulant edicatio  led o SUD d t ri ration. 
Planned tr atme t durat on n thes  trials ranged f om 6–16 we k  (1 of 4 tudies >12
week ), and no u seque t xten i  st ies w r c nducted o inv stigate he long-term
eff cts of ADHD m dicati n in the s udy amples. Henc , pertain  to adol c nts w th
comorbi  ADHD and SUD, only ata on the sh rt-term ffect  ADHD medication are
available t e. We sse sed th  risk of bias as b ing low in the studies of Riggs (2011) 
and Thursto e (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing utcome data (Table 2). 
Table 2. Risk of bias in the included studies on ph rmacological nterventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
iggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]      
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newc r , 2017b [34]       
Note:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
interventions; Mis—missing outcome data; Mea—measurement of the outcome; Sel—selection of 
the rep rted result. 
T  c ncl de, the ev ence base  pharm logi al ADHD reatm nt in adolescen s
with concurrent  and SUD is limit d, with less than 500 patients included across 
four controlled trials of a short duration, none of which showed a robust treatment effect 
o  eith r ADHD or SU . 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
M st trials on the ffic cy of pharmacologic l ADHD t atme t in youth hav  bee
condu t  in mixed sampl s of ch l r n nd do e ents at n ge group typica y r ngi g
from 5 to 18 years, without e ara e nalys s or repor g of outc s  e adolescent
subgr up. Our elected literature ncluded a meta-a alys s by Cerrill -Urbi a et a . (2018)
of 15 R Ts comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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stu ies, with o xc ss f SAEs in any activ  medic tion gr up c mpare  with l . 
Adv rs pharmacological i teractions b tween the st dy edicatio  and the a lescent’s 
ubstance use at the sa day were ly r p rted in the trial f Riggs et al. (2011) [37], 
and only by four (2.8%) a d re (2.1%) of t e p ti nts taking OROS-MPH and plac bo, 
re pectively. I  th  thre  tri l  that i ve tigate  stim lants, no i dication was found that 
stimulant medication led t  SUD eterior ti . 
Planned t e tme t duration in thes  tri ls r nged from 6–16 we ks (1 of 4 studi s >12 
we k ), and no subs quent exten i n stu ies wer  c ducted to i vestig te t  l ng-term 
effects of ADHD me cation i  t e study samples. Henc , pertaining to a olescents with 
c morbid ADHD a d SUD, nly d ta on the sh rt-term effects of ADHD medication are 
avail ble to date. We assess d the risk of bia  as being low in the studies f Riggs (2011) 
and Thurst ne (201 ),  as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Ri k f bias in the ncluded studies pharmacological interventions. 
Study Bias Arisi g from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Ri gs, 2011 [37]       
Szobot, 2008 [36]      
Riggs, 2004 [38]       
Thurstone, 2010 [39]      
Adolescents with ADHD       
Pelham, 2013 [33]      
Findling, 2010 [27]      
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]      
Sallee, 2009 [46]      
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]     
Note:          low risk/high ri k/some co c rns. Rnd—ran omization proces; Int—intended 
interv ntions; Mis is ing utcome data; Mea—measurement  the outcome; Sel—selection of 
the reported result. 
To c lud , the evidence bas  on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is lim ted, with less than 500 patients included across 
f ur contr lled trials of a s or duratio , none of which sho ed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Ad lescents with ADHD b t without SUD Co orbidity 
Most trials on the fficacy f pharm cologi al ADHD treatment in youth h ve bee  
c n ucted in ixe  sample of ch ldre   dolesce t  at n age gr u  typically r nging 
from 5 o 18 years, with  parat  analy is or reporting of utcome  in t  l sc t 
subgroup. Our elec ed l teratu e included a meta-an ysis by Cerrillo-Urbi a et al. (2018) 
of 15 RCTs comp ring ti ulant and on-stimulant medications with placebo in children 
and adol scents wi  ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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stu ies, with no exc ss f SAEs in a y a tive i ti  group comp re  with l . 
Adv r e ph rm cological in er ti n b tween th  st y medic ti n and the ad lescent’s 
ubst nce us at t sam  day were only report d in the trial of Riggs et al. (2011) [37], 
 only by four (2.8%) a d thr e (2.1%) of th  pati ts t king OROS-MPH and placebo, 
r pectiv ly. I  th  t re  rials that i vestigated stimul nts, no i dication was found that 
timul nt med c ti  l d t  SUD det rioration. 
Pl ed tr a m nt duration i  the  trial  rang d fro  6–16 w eks (1 of 4 stu ies >12 
we ks), nd n  u quent xtension tudies wer  conduct d to i vestigate t e long-term 
eff cts of ADHD medic tio  i  t e study sampl s. H ce, pertaining to adol scents with 
co rbid ADHD and SUD, only d ta on the short-t rm effects of ADHD medication are 
avai able to date. W  as ess  the risk f bias as being low in the studies of Riggs (2011) 
a d Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies o  ph rmacological int rventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD      
Riggs, 2011 [37]      
Szobot, 2008 [36]      
Riggs, 2004 [38]      
Thurstone, 2010 [39]      
Adolescents with ADHD      
Pelham, 2013 [33]      
Findling, 2010 [27]      
Wilens, 2006 [40]      
Findling, 2011 [42]      
Spencer, 2006 [41]      
Bostic, 2000 [43]      
Bangs, 2007 [44]      
Biederman, 2008 [45]      
Sallee, 2009 [46]      
Wile s, 2015 [47]      
N wcorn, 2017a [34]      
Newcorn, 2017b [34]     
Note:         low risk/high isk/so e concerns. Rnd—ra domization proces; Int—intended 
intervention ; Mis—missing out ome da a; Mea— easurement of the outcome; Sel—selection of 
the reported result. 
T  conclud , the evidence base on pharm cologic l ADHD treatment in adolescents 
w th concurren ADHD an  SUD is limited, with less than 500 pati ts included across 
four c ntrolled trial  of a short duration, none of which showed a robust treatment effect 
on ei her ADHD or SUD.
3.2.2. Adolesce ts with ADHD but without SUD C morbidit  
Most tri ls o  the efficacy of ph r acol gical ADHD tr atment in youth h ve been 
ducted in ixe s mples of child  a d adol scents at an age grou  ty ically ra ging 
from 5 to 18 years, without sep r t  nal si  or rep ting of u c mes in th  adolescent 
subgroup. Ou  s lected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimul nt medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studi s, with o xc ss f SAEs in any active medication group compared with placebo. 
Adv rs pharm cological inter ctio s tw en t e study medication and the adolescent’s 
sub an   at the s me day ere nly reported in e tri l of Riggs et al. (2011) [37], 
an  only by f ur (2.8%) and three (2.1%) of the patients taking OROS-MPH and placebo, 
espectiv ly. I  the three trials hat investigated stimulant , no indication was found that 
stimulant m di ation l  t  SUD et rior ion.
Planne  tre tm nt durat on  h se trials ranged from 6–16 weeks (1 of 4 studies >12 
w eks), d no ub equent ext nsion stu ies were conducted to investigate the long-term 
ff c  of ADHD m d cat n y amples. Hence, pertaining to adolescents with 
c mor ADHD and SUD, o ly data on the short-term effects of ADHD medication are 
avail l  to date. We assessed th risk of bias as being low in the studies of Riggs (2011) 
and Thurst ne (201 ),  as hig  in the studies of Szobot (2008) and Riggs (2004), mainly 
due to mi sing outco e data (Table 2). 
Table 2. Ri k of bias in the cluded studi s n ph rmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]      
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
New r , 2017  [34]       
N wcorn, 2017b [34]       
Note:          low risk/high ri k/some co c rns. Rnd—randomization proces; Int—intended 
interv ntions; Mis—missing utcome data; Mea measurement of the outcome; Sel—selection of 
the r p rted result. 
T  co lu e, th  evidence bas  n pha macological ADHD treatment in adolescents 
with concurrent ADHD and SUD is li ited, with l s than 500 patients included across 
f ur controlled trials of a shor dur tio , none of whi h showed a robust treatment effect 
on eith r ADHD or SUD. 
3.2.2. Ad lescents with ADHD but without SUD Comorbidity 
M t t ials n th  ffica y f ph rmacol gical ADHD treatment in youth have been 
c n ucted in ixed samp es of ch ldr  d dolesc nts at an age group typically ranging 
fro  5 t  18 years, with ut ep rate ana ysis r reporti of outcomes in the adolescent 
subgroup. Ou  el c ed l tera ur  i cl d  a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 R Ts co paring stimulant and on-stimulant medications with placebo in children 
an  adol scents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
Thurstone, 2010 [39]
J. Clin. Med. 2021, 10, x FOR PEER REVIEW 12 of 34 
 
 
studies, with no excess of SAEs in any active medication group compared with l . 
Adv rse pharmacological interactions between the st dy edication d th  ad lescent’s 
ubstance use at the same day were only reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the pati nts taking OROS-MPH and placebo, 
respectively. In the thre  trials that investigated stimulant , no indication was found that 
stimulant medication led t  SUD deterioration. 
Planned treatment duration i  these trial  ranged from 6–16 w eks (1 of 4 studies >12 
weeks), and no subs quent ext nsion tudi s were conducted to investigat  the long-term 
effects of ADHD medication in t e study samples. H nce, p rtaining to adolesc nts with 
comorbid ADHD and SUD, only data on the short-term effects of ADHD medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on ph rmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]     
Adolescents with ADHD       
Pelham, 2013 [33]     
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]      
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]     
Note:          low risk/high risk/some concerns. Rnd—rand mizatio  p ces; Int—int nded
interventions; Mis—missing outcome data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, the evidence base on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patients included across 
four controlled trials of a short duration, none of hich showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trial  on the efficacy of pharmacological ADHD tr atment in youth h ve be n 
conducted in ixed samples of children and adolescents at an age grou  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in th  adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with no xcess of SAEs in any active medication group co pared with l . 
Adv rse pharmacol gical int rac ions betwe  the st dy medicatio  and the ad lescent’s 
ubstance use at the same day were only reported in the tri l of Riggs et al. (2011) [37], 
and only by four (2.8%) and thr e (2.1%) f the pati nts taking OROS-MPH and placebo, 
respectiv ly. In the hre  tr al  that nvestigated stimulants, no i dication was found that 
sti ulant medication le  t  SUD deterioration. 
Planned treatment duration in th se trial  ranged fr m 6–16 weeks (  of 4 studies >12 
weeks), and no subs quent exten ion studies were conducted to investigate the long-term 
effects of ADHD m dication in t e study samples. Hence, pertaini g to adolescents with 
c morbid ADHD and SUD, only data on the short-term effect  of ADHD edication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as h gh in the studies of Szobot (2008) and Riggs (2004), mainly 
due t  issing outcome data (Table 2). 
Table 2. Risk of bias in th  included studies on ph rmacol gical interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]     
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]      
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017  [34]       
Newcorn, 2017b [34]       
Note:          low risk/high isk/some co cer s. Rnd—randomizati proc ; Int—intend
intervent ons; Mis—missing outco  data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, th evidence base on pharmacological ADH  treatment in adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patients included across 
four controlled rials of a sh rt duration, none f which show d a robust r atment effect 
on ei r ADHD r SUD. 
3.2.2. Adolescents with ADHD but witho t SUD Comor idi y 
Most tri ls on the efficacy of pharmacological ADHD tre tment in youth h ve been 
con ucted in ixed sample  of childr  and dolescents a  an age g ou  typically ranging 
from 5 o 18 years, without epa at  analysis or reporti g of utcomes i  th  adolesce t 
subgroup. Our selected literatur  included a meta-analysis y C rri lo-Urbina et al. (2018) 
of 15 RCTs compari g stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 tri ls focused on adolescents only. 
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stud es, with no exc ss of SAEs in ny activ  edi ation group compared with placebo. 
Adv rse pharmacological interactio s between the st dy medic ti n and he adolescent’s 
substa c  use t the same day were o ly reported in the trial of Riggs t al. (2011) [37], 
and o ly by f ur (2.8%) and three (2.1%) of the patients taking OROS-MPH and placebo, 
re p ct v ly. In the three trials hat i esti ate  stim l nts, no indication was found that 
stimulant medication led to SUD deterioration. 
Pl ned tr atment urat on in th s  trials range  from 6–16 weeks (1 of 4 studies >12 
w ek ), nd no ubseque t ex nsi n stu es were c ducted o investigate the long-term 
ffects of ADHD medication in the tu y samples. Hence, pertaining to adol scents with 
comorbid A HD nd SUD, only da a on the short-term effects of ADHD medication are 
vailable to date. We a sessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due o issing outcome data (Table 2). 
Table 2. Risk of bias in the cluded tud s n pharmacological nterventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]      
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:          low risk/high risk/some concerns. R —ra omizat o proces; I t—inten ed
interventions; Mis—mi sing outc e data; M a—mea ureme t of the out ome; Sel—selection of 
the reported result. 
To conclud , the evidence b se n pharmacological ADHD treatm  in adolescents 
with concurrent A HD and SUD is imited, with l ss than 500 patients included across 
four controlled trials of a short duration, n e f whi h show d a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but with t SUD Comorbidi y 
Most tr ls on the effic y f ph rmacological ADHD treatment in yo th have been 
c ducted i  mixed samples of chi dren and d le cents at age group typically ranging 
from 5 to 18 ears, with ut separate a alys s r r p rting of out om  in he adolesc nt 
subgroup. Our selected literature included a met -ana ysis by Cerril o-Urbina et al. (2018) 
of 15 RCTs comparing stimulant a d non-stimulant medic tions wit  placebo in children 
and adolescents with ADHD [48]. Only fou of th e, 15 trials focus d on adolescents only. 
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Adver pharmacol gical interacti ns b tween the st dy edic ti n and he adolescent’s 
substance use t the same day were o ly reported in the trial f Riggs et al. (2011) [37], 
nd only by four (2.8%) a d hree (2.1%) of the p tients taking OROS-MPH and placebo, 
r p ctiv ly. I  th  three tri l  hat i vestigated stim l nts, o indication was found that 
ti ulant medication led to SUD d terioration. 
Pla ned t e tme t durat on in th s  trials ranged from 6–16 we ks (1 of 4 studi s >12 
we k ), and no sub eque t extensi n stu ies wer  conducted o investigate the l ng-term 
effects of ADHD med cation in the tudy samples. Hence, pertaining to adolescents with 
c morbid A HD and SUD, only da a on the short-ter  effects of ADHD medication are 
vail ble to date. We a sessed the risk of bia  as being low in the studies of Riggs (2011) 
and Thurst ne (201 ),  as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due o issing outcome data (Table 2). 
Table 2. Ri k f bias in the ncluded studies ph rmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall
Adolescents with ADHD + SUD     
Riggs, 1 [ 7]       
Szobot, 2008 [36]      
Riggs, 2004 [38]       
Thurstone, 2010 [39]      
Adolescents with ADHD     
Pelham, 2013 [33]      
Findling, 2010 [27]      
Wilens, 2006 [40]       
Findling, 2011 [42]      
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]      
Sallee, 2009 [46]      
Wile , 2015 [47]       
N wcorn, 2017a [34]       
Newcorn 2017b [34]     
No e:         low isk/ igh ri k/some co c rns. Rnd—ran o izatio roc s; In —inten ed 
interv ntions; Mis is ing utco e data; M a—measurement  the out ome; Sel—selection of 
the reported result. 
T  c lud , the evidence b se n pharmacological ADHD treatm  in adolescents 
with concurrent A HD and SUD is im ted, with less than 500 patients included across 
f ur contr lled trials of a s or duratio , n e of whi h sho d a robus  treatment effect 
on either r SUD. 
3.2.2. Ad lescents with ADHD but w h ut SUD Com rbidity 
Most tr als on th  effic y f pharmacologic l ADHD treatment in youth have been 
c n ucted in mixe  s mple of h dren  dolescents at an age group typically r nging 
from 5 o 18 years, with u  eparat  a aly is or rep rting of outcom  in he adolescent 
subgroup. Our el c ed l terature included a meta-an ysis by Cerril o-Urbina et al. (2018) 
of 15 RCTs comparing sti ulant and on-stimulant medic tions wit  placebo in children 
and adol scents wi  ADHD [48]. Only fou  of these, 15 trials focus d on adolescents only. 
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stud es, with no exc ss of SAEs in any a tive m ication group compared with l . 
Adv r e p rmacol gical in er tion betw en the st y medication and the ad lescent’s 
ubstance use at t same day were only report d in the trial of Riggs et al. (2011) [37], 
 nly by four (2.8%) and thr e (2.1%) of the patients taking OROS-MPH and placebo, 
r pe tively. In the r  rials that investigated stimulants, no indication was found that 
stimul t med cati n led t  SUD deterioration. 
Plan tr a ment duration in these rial  ranged from 6–16 weeks (1 of 4 studies >12 
weeks), a d n  bs quent extension studies were conducted to investigate the long-term 
effects of AD D medicatio  i  t e study samples. H nce, pertaining to adolescents with 
c rbid ADHD and SUD, only d ta on the short-t rm effects of ADHD medication are 
avai able to date. W  as essed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and s high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome ata (Table 2). 
Table 2. Risk of bias in th  included studies o  ph rmacological int rventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD     
Riggs, 2011 [37]      
Szobot, 2008 [36]     
Riggs, 2004 [38]      
Thurstone, 2010 [39]      
Adolescents with ADHD     
Pelham, 2013 [33]      
Findling, 2010 [27]      
Wilens, 2006 [40]      
Findling, 2011 [42]      
Spencer, 2006 [41]      
Bostic, 2000 [43]      
Bangs, 2007 [44]      
Biederman, 2008 [45]      
Sallee, 2009 [46]      
Wilens, 2015 [47]      
Newcorn, 2017a [34]      
Newcor 2017b [34]     
Note:       low risk/h g  isk/so  conc r s. Rnd—r domizati  roc ; Int—inten ed 
intervention ; Mis—missing da a; Mea— easurement of the outcome; Sel—selection of 
the reported result. 
To conclud , the evidence base o  pharmacological ADHD treatment in adolescents 
w th concurren ADHD an  SUD is limit , with less than 500 patients included across 
four con rolled trial  of a short durati n, no e w ich showed  robust treatment effect
o  e ther ADHD r SUD. 
3.2.2. Adolescents with ADHD b t without SUD Comorbid ty 
M st tri ls on the fficacy of pharmacological ADHD treatment in youth h ve been 
con uct d in ixe sampl s of children and dolescents at an age grou  typically ranging 
from 5 to 18 years, with  separate analysis or reporting of u comes in th  adolescent 
subgroup. Ou  s lected lit ature includ d a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs compar ng stimulant and n n-stimul nt medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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stu es, with o xc ss f SAEs in ny activ  medicatio  group compared with placebo. 
Advers ph rmacologica  int ractions b tween the study medication and the adolescent’s 
substanc use at the same day were only reported in the trial of Riggs et al. (2011) [37], 
a d only by f ur ( .8%) and three (2.1%) of the patients taking OROS-MPH and placebo, 
respect vely. I  the t ee trials that i vestigated stim la ts, o indication was found that 
stimulant medication led to SUD deterioration. 
Planned treat ent uration in thes  tri ls range  from 6–16 weeks (1 of 4 studies >12 
w ks), a d no ubseque t ex si n stud  were c ducted to inv tigate the long-term 
effects f A HD me cation in t e study samples. Hence, pertainin  t  adolescents with 
c orbid  an  SUD, only data on t e sho t-term effects of A HD medication are 
avail ble to dat . We a se sed the risk of bias as being low in the studies of Riggs (2011) 
and Thurst ne (201 ), as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing utcome dat  (Table 2). 
Table 2. Risk f bias in the nclude  s udi s n pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with A HD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with A HD       
Pelham, 2013 [33]       
F dling, 2010 [27]       
Wilens, 2006 [40]       
F dling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wil ns, 2015 [47]       
N wcorn, 2017a [34]       
Newcor  2017b [34]       
Not :        low risk/h gh ri k/some co c r s. R d—ra dom zation roc s; I t—inten ed 
interv ntion ; Mis—mi ing utc me data; Mea—mea ureme t of the utcome; S l—selection of 
the epo ted result. 
T  con lud , he vid nce base on ph rmacological A HD treatment in adolescents 
with oncurr  A HD and SUD is limited, with l ss than 500 patie ts included across 
f ur c ntrolled trials o  a sh r dur tio , n e of whi h sh wed  robust treatment ffect 
on ei her A HD or SUD. 
3.2.2. Ad l scents with A HD but without SUD Comorbidity
Most tri ls o  th efficacy f ph rmacological A HD treatment i  youth hav  been 
c n u t d in mixed samples of ch ldren d dolescents at an age grou  typically ranging 
from 5 to 18 ears, with ut eparate analys s or reporting of utcomes in the adolescent 
ubgroup. Our elected l te ature included a met -analysis by Cerrillo-Urbin  et al. (2018) 
of 15 RCTs comparing stimulant a d on-stimulant medications with placebo in children 
nd adol cents with A HD [48]. Only f ur of th e, 15 trials focused on adolescents only. 
Adolescents with ADHD
Pelham, 2013 [33]
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studies, with no exc ss of SAEs in any active medication group compar d with plac o. 
Adverse pharmacological i teracti s betwee  the stu y medicati  and he ad lescent’s 
substance use at th  same day w re only reported in th  trial of Ri gs et l. (2011) [37], 
and nly by four (2.8%) and three (2.1%) of the p tients t king OROS-MPH nd plac bo, 
respectively. In the thr e trials t at investig ted stimul ts, no indic ti n was f und that 
stimulant medication led to SUD deterior tion. 
Planned treatment dur ti n in th se trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequent extension studies were conduct d to investigate t  long-t rm 
effects of ADHD medication in the study samples. Hen e, pertai in  to a olescents wi  
comorbid ADHD and SUD, only data on the short-term effects of ADHD medication are 
available to date. We assessed the risk of bias as being lo  in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the st ie  of Szobot (2008) and Riggs ( 004), m inly 
due to missing outcome data (Table 2). 
Table 2. Risk f bias in the included studies on pharmacological intervent o s. 
Study Bias rising from/Due to:  
 Rnd Int Mi  Mea S l Overall 
Adolescents with ADHD + SUD      
Riggs, 2011 [37]       
Szobot, 2008 [36] 
Riggs, 20 4 [38] 
Thurstone, 2010 [39] 
Adolesce ts with ADHD      
Pelham, 13 33  
Findling, 2 10 [27] 
Wilens, 2006 [40] 
Findling, 2011 [42] 
Spenc r, 2 06 [41] 
Bostic, 2000 [43] 
Bangs, 20 7 [44] 
Bi derman, 2008 45  
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]      
Newcorn, 2017b [34]     
Note:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
interventi s; Mis—missing out ome data; M —measurem t of t outco e; Sel—selecti n of
the reported result. 
To conclude, the evidence base on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patients included across 
four controlled trials of a short d ration, none of hich showed a robust treat e t effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth have been 
conducted in ixed samples of children and adolescents at an age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with no excess of SAEs in any active edication group compared with pl ceb . 
Advers  pharmacological interactions betwee  the study medic tion and th  adol scent’s 
substanc  use at the s me day were only r ported in the trial f Riggs et al. (2011) [37], 
and only by four (2.8%) and thr e (2.1%) of the patients taking OROS-MPH and placebo, 
respectively. In the three tri ls that i v igated stimulant , no indication wa  foun  that 
stimulant edication led to SUD deterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequent extension st i s were conducted to investigate the long-term 
effects of ADHD medicati n in the study samples. Hence, p rtaining to dolesce t  with 
omorbid ADHD and UD, only da a o  he s ort-term effects of ADHD medicati  are 
available to dat . We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the tudies of Szobot (2008) and Riggs (2004), mainly 
due to missing outco e data (Table 2). 
Table 2. Risk of bias in the included stud es n phar acological interventions. 
Study Bias Arising from/Due t :  
Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + UD       
Riggs, 2011 [37]      
Szobot, 2008 [ 6]       
Riggs, 2004 [38]      
Thursto e 39     
Adolescent  with ADHD       
Pelham, 2013 [33]      
Findling, 2010 [27]      
Wilens, 2006 [40]      
Findling, 11 [ 2]      
Spencer, 2006 [41]      
Bostic, 20  [43]      
Bangs, 20 7 [4 ]      
Bi derma , 2008 [45]      
Sallee, 2009 [46]      
Wil ns, 2015 [47]       
Newcorn, 2017a [34]       
New orn, 2017b [34]       
Note:          low risk/ igh risk/ me concerns. Rnd—randomization proces; Int—intended 
i terventions; Mis—missing tcome data; Mea—measurement o  t  outc me; Sel—selection of 
the reported result. 
To conclude, the evidence base on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is li ited, with less than 500 patients included across 
four controlled trials of a short duration, none of which showed a robust treat ent effect 
on either ADHD r SUD. 
3.2.2. Ad lesce ts with ADHD but i ut SUD Com rbidity
Most trials on the efficacy of pharmacological ADHD treatment in youth have been 
conducted in mixed s mples of children and adolescents at an age group typically ranging 
from 5 to 18 ye rs, without separate analysis or reporting of outcomes in the adolescent 
subgroup. Our selected literature inclu ed a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant a d non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
J. Clin. Med. 2021, 10, x FOR PEER REVIEW 12 of 34
 
 
studies, with no exc ss of SAEs i  any active medi ation group compared with placeb . 
Adverse pharm cological interacti s bet ee  the st y me ic ti n and he ad l sc nt’s 
substan e use t the s e day were o ly reported in th  trial of Ri gs et al. (2011) [37], 
and nly by four (2.8%) and three (2 1%) of the pa ients taking OROS-MPH and placebo, 
resp ctiv ly. In the three tri ls at inv stig ted stimul nts, no indication was fou  that 
stimulant medication led to SUD deterioration. 
Pla ned treatment dur t on in th se trials ranged from 6–16 weeks (1 of 4 studies >12 
week ), and no ub equent extension stu ies were conducted o investigate the long-term 
effects of ADHD m dicati n in the tudy samples. Hen e, pertai i g to a olesc nt with 
comorbid A HD and SUD, onl  da a on the hort-ter  eff ct  f A HD medication are 
vailable to date. We a sesse  th  risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studie  of Szobot (2008) and Riggs (2004), mainly 
due o issing outco e data (Table 2). 
Table 2. Risk f bias in the included studies on phar acological interve tions. 
Study Bias Arising from/Due to:  
 Rnd Int Mi  Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36] 
Riggs, 20 4 [38] 
Thurstone, 2010 [39] 
Adolesce ts with ADHD       
Pelham, 13 33  
Findling, 2 10 [27] 
Wilens, 2006 [40] 
Findling, 2011 [42] 
Spenc r, 2 06 [41] 
Bostic, 2000 [43] 
Bangs, 20 7 [44] 
B derma , 2008 45  
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]      
Note:          low risk/high risk/s me concerns. Rnd—ran omizatio  proces; Int—intended 
interventions; Mis—missing outco e data; M a—measurement the out ome; Sel—selection of 
the reported result. 
To conclud , the evidence b se n phar acological  treat  in adolescents 
with concurrent A HD and SUD is imited, with less than 500 patients included across 
four controlled trials of a short duration, none of which show d a robust treat ent effect 
on ei h r ADHD or SUD. 
3.2.2. Adolescents with ADH  but wi h t SUD Comorbid ty 
Most tr als on the effic y f pharmacological ADHD treatment in youth have been 
conducted in mixed samples of chi dren and adolescents at an age group typically ranging 
from 5 to 18 years, without separate analysis or rep rting of outcom  in he adolescent 
subgroup. Our sel cted literature included a meta-ana ysis by Cerril o-Urbina et al. (2018) 
of 15 R Ts comparing stimulant and non-stimulant medic tions wit  placebo in children 
and adolescents with ADHD [48]. Only fou  of these, 15 trials focus d on adolescents only. 
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studies, with no xc ss of SAEs in y active di ation gr up ompared with placeb . 
Adverse p armacological int racti s between the stu y medic ti  and h  ad lesc nt’s 
substan e us  t th  same day w re o ly rep rted i  th  rial of Ri gs et al. (2011) [37], 
and ly by four (2.8%) a d hree (2.1%) of the p tients taking OROS-MPH and plac bo, 
re p ctiv ly. In th  three tri ls t i vestig e  stim l nts, no indication was found th t 
stim lant ed cation led to SUD deteri ration. 
Pla ned t e tme t dur t on in th s  trials rang  from 6–16 weeks (1 of 4 studies >12 
we k ), and no sub equent extension stu ies were conducted o investigate the long-term 
effects of ADHD medicati in the tudy s mples. He e, per ai ing to adolescents w th 
c morbid A HD an  SUD, only a a  the sho t-term effects of ADHD medication are 
vailabl  to date. We a sessed the risk of bia  as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due o issing outco e data (Table 2). 
Table 2. isk f bias in the included studies  pharmacological interventions. 
Study Bias Arising from/Due to:  
 nd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs 1 7      
Szobot, 2008 [36]       
Riggs, 2004 [ 8]      
Thurstone, 2010 [39]      
Ado scents with ADHD       
Pelham, 2013 [33]      
Fi dling, 2010 [27]      
W lens, 2006 [40]      
Findling, 2011 [42]      
Spencer, 2 06 [41]      
Bostic, 2000 [43]      
Bangs, 2007 [44]      
Biederm n, 2008 [45]      
Sallee, 2009 46      
Wil n , 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]      
Not :          low risk/high risk/some concerns. Rnd—ran omizatio  proces; Int—intended 
interv ntions; M s is ing ou co e data; M a—measurement  the out ome; Sel—selection of 
the reported result. 
T  c clud , t e evidence b se n phar ac logical A HD treatm  in adolescents 
with co current A HD and SUD is im ted, with less than 500 patients included across 
f ur contr lled t ial  of a s ort duration, none of which show d a robust treatment effect 
on eith r ADHD or SUD. 
3.2.2. A l sc ts i  D  but wi t SUD Comorbidit  
Most tr als on the effic y f pharmacological ADHD treatment in youth have been 
c ducted in mix  sample of chi dren and adolescents at an age group typically ranging 
from 5 o 18 years, withou  separate analy is or rep rting of outcom  in he adolescent 
subgroup. Our sel c ed literature included a meta-an ysis by Cerril o-Urbina et al. (2018) 
f 15 RCTs comparing sti ulant and non-stimulant medic tions wit  placebo in children 
and adolescents wi  ADHD [48]. Only fou  of these, 15 trials focus d on adolescents only. 
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studi s, with o ex s of SAEs n any activ  i ti  group om a e  i  pl cebo. 
A vers  p ar acological inter cti s between the stu y m dic i  a d the ad lescent’s 
subst nc  use at t  s m  day w r  only eport d i  th  trial of R gs e l. (2011) [37], 
and nly by four (2.8%) nd three (2.1%) f th  p tie t  t k ng O OS-MPH and placebo, 
r spectively. In the t re  rial  t t inve ig ted stimulants, no indication wa found that 
stimulant e ic ti  l d to SUD deterioration. 
Planned treatment d r tion i  th se trials rang d from 6–16 w eks (1 of 4 studies >12 
weeks), and n  s bsequent extension tudies wer  conduct  to investigate t e long-term 
effe ts f ADHD medic tion i  the tudy sa pl s. Hen e, p rtai ing to adol scents with 
comorbid ADHD and SUD, only d ta o  the short-term effects of ADHD m dication a e 
av ilable to date. We assess d t e risk of bias as being low i  the stu ies of Riggs (2011) 
a  hu ston  (2010), a d a  high i  the studie  of Szobot (2008) and igg  (2004), mainly 
due to missing outcome data (Table 2).
Table . Risk f bia  in the included studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD      
Riggs, 2011 [37]       
Szobot, 2008 [36] 
Riggs, 20 4 [38] 
Thurstone, 2010 [39] 
Adolesce ts with ADHD      
Pelham, 13 33  
Findling, 2 10 [27] 
ilens, 2006 [40] 
Findling, 2011 [42] 
Spenc r, 2 6 [41] 
Bostic, 200  [43] 
ng , 20 7 [44] 
Bi derman 8 5  
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newc rn, 2017a [34]     
N wcorn, 2017b [34]       
Note:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
int rv i ; Mis— issing out o e dat ; Me — asurement of the outco ; Sel—selection of 
the reporte  res lt. 
To n lud , the evid nce b se on har cologic l ADHD treatm t in adol scents 
w th concurre t ADHD and SUD is limited, with less than 500 pati ts included across 
four c ntrolled trials of a short duration, none of which showe  a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidit  
Most t ials on the efficacy f ph rmac logical ADHD treatment in youth have been 
conducted in ixed samples of child en d adolesc nts at an age group typically ranging 
from 5 t  18 yea s, without sep rat  nalysi  o  repo ting of outcomes in the dolescent 
subgroup. Our selected literat re included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant nd non-stimulant medications with placebo in hildre  
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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st d es, with o xc ss f SAEs in any activ  medication group compared with placebo. 
Advers pharmacologica  int racti s b tw en t  stu y medication and the ad lescent’s 
subst nc us  t th  same day w r  o ly report d i  th  trial of Ri gs et al. (2011) [37], 
a d nly by f ur (2.8%) and three (2.1%) of th patients taking OROS-MPH and placebo, 
spect vely. I  the thr e trials t at i vestig ted tim lants, no indication was found that 
stimul nt medication led to SUD deterioration. 
Planned treatment dur tion in thes  trials range  from 6–16 weeks (1 of 4 studies >12 
w ks), a d no ubseque t ex nsi n stud es were c ducted to investigate the long-term 
ffects of ADHD med cation in e study samples. Hen e, pertai ing to adolescents with 
comorbi  nd SU , only data on the short-term effects of ADHD medication are 
avail ble to dat . We asse sed the risk of bias as being low in the studies of Riggs (2011) 
and Thur t ne (201 ), as hig  in the studie  of Szobot (2008) and Riggs (2004), mainly 
due to mi sing outco e data (Table 2). 
Table 2. Risk f bias in the ncluded studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36] 
Riggs, 20 4 [38] 
Thurstone, 2010 [39] 
Adolesce ts with ADHD       
Pelham, 13 33  
Findling, 2 10 [27] 
Wilens, 2006 [40] 
Findling, 2011 [42] 
Spenc r, 2 06 [41] 
Bostic, 2000 [43] 
B ngs, 20 7 [44] 
Bi der an, 2008 45  
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newco n, 2017a [34]       
Newcorn, 2017b [34]       
Note:         low risk/hig  ri k/some co c rns. Rn —rand mization proces; Int—intended 
inte v ntions; Mis—mi ing utc me data; Mea mea ureme t of the outcome; Sel—selection of 
the reported result. 
T  c n lud , he evid nce base on pharmacological ADHD treatment in adolescents 
with concurr  ADHD and SUD is li ited, with l s than 500 patients included across 
f ur controlled trials of a shor dur tio , none of whi h showed a robust treatment effect 
on ei her ADHD or SU . 
3.2.2. Ad e cents with ADHD t without SUD C morbidit  
Most tri ls on the efficacy f pharmacological ADHD treatment in youth have been 
c n uct d in mixed samples of ch ldren d adolesc nts at an age group typically ranging 
from 5 to 18 ears, with ut eparate analys s or reporti  of outcomes in the adolescent 
ubgroup. Our elected l terature included a met -analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant a d on-stimulant medications with placebo in children 
and adol cents with ADHD [48]. Only four of th e, 15 trials focused on adolescents only. 
Findling, 2010 [27]
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studies, with no exc ss of SAEs in any active medication group compa ed wi h plac b . 
Adverse pharmacological i teracti s bet ee  the s u y medica i  an  a lesc nt’s 
substance use at th  same day w re only reported in th  trial of Ri gs et al. (2 11) [37],
and nly by four (2.8%) and three (2.1%) of the p t nts t king OROS-MPH n  pl cebo,
respectively. In the thr e trials t at investig ted stimul ts, no indic ti n was found that 
stimulant medication led to SUD deterior tion. 
Planned treatment dur ti n in th se trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequent extension studies were conducted to investigate t e long-term 
effects of ADHD medication in the study samples. Hen e, pertai i  to a olesc nts wi  
comorbid ADHD and SUD, only data o  the short-term effects of ADHD medic tion are 
available to date. We assessed the risk of bias as being low in the stu ies of Riggs (2011) 
and Thurstone (2010), and as high in the studie  of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk f bias in the included studies on ph rmacological intervent ons. 
Study Bias Arising from/Due to:  
 nd Int Mi  Mea Sel Overall
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36] 
Riggs, 20 4 [38] 
Thurstone, 2010 [39] 
Adolesce ts with ADHD       
Pelham, 13 33  
Findling, 2 10 [27] 
ilens, 2006 [40] 
Findling, 2011 [42] 
Spenc r, 2 06 [41] 
Bostic, 2000 [43] 
Bang , 20 7 [44] 
Bi derman, 2008 45  
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]     
Note:          low risk/high risk/some concerns. Rnd—randomization proc s; Int—intend d 
interventions; Mis—missing outcome data; Mea—measurement f the outcome; Sel—s lect n of 
the reported result. 
To conclude, the evidence base on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patients included across 
four controlled trials of a short duration, none of which showed a robust treat ent effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but witho t SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth have been 
conducted in mixed samples of children and adolescents at an age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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To conclude, the evidence base on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is li ited, with less than 500 patients included across 
four controlled trials of a short duration, none of which showed a robust treatment effect 
on either ADHD r SUD. 
3.2.2. Ad lesce ts with ADHD but wi h ut SUD Comorbid t
Most trials on the efficacy of pharmacological ADHD treatment in youth have been 
conducted in mixed s mples of children and adolescents at an age group typically ranging 
from 5 to 18 ye rs, without separate analysis or reporting of outcomes in the adolescent 
subgroup. Our selected literature inclu ed a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant a d non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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stu ies, with exc s f AEs in ny c ive i ti n group mpared ith placeb .
A v r  p armacological int racti s etw en the stu y m dic t on a d th  ad lescent’s
s b c u e at t s m day w re nly r porte i  th trial of R gs et . (2011) [37],
a d l  by four (2.8%) and thre  (2.1%) f th  patie t  t k g O OS-MPH and placebo, 
r pectiv ly. In the t re  rial  t at i ve ig ted timulants, no indication wa found that 
stimula t e ic ti  le  to SUD eterioratio . 
Plann d treatment dur tion in th se trials ranged from 6–16 w eks (1 of 4 studies >12 
weeks), and n  s bsequent extension tudies wer  conduct  to investigate t e long-term 
effe ts f ADHD medic tion in the study sampl s. H n e, pertai ing to adol scents with
comorbid ADHD nd SUD, only d ta o  the short-term effects of ADHD medication are 
available to date. We assess d the risk of bias as being low i  the studies of Riggs (2011) 
a d Thurstone (2010), and a  high in the studie  of Szobot (2008) and Riggs (2004), mainly 
due to missin  outcome data (Table 2).
Table . Risk f bias in the included studies on ph rmacological int rventions. 
Study Bias Arising from/Due to:  
Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD     
Riggs, 2011 [37]       
Szobot, 2008 [36] 
Riggs, 20 4 [38]
Thurston , 201  [39] 
Adolesce ts with ADHD     
Pelham, 13 33  
Findling, 2 10 [27] 
ilens, 2006 [40] 
Findling, 2011 [42] 
Spenc r, 2 06 [41] 
B stic, 2000 [43] 
Bang , 20 7 [44] 
Bi d rman, 2008 45  
Sal ee, 2009 [46]       
Wilens, 2015 [47]       
Newc rn, 2017a [34]      
N wcorn, 2017b [34]      
Note:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
i terve tion ; Mis—m ssing utcome d ta; Mea—measure  of the outc me; Sel—sel ction of 
the report d r sult. 
To onclud , the evid nce b se on har cologic l ADHD treatment in adolescents 
w th concurre t ADHD and SUD is li ited, with less than 500 pati ts included across 
four c ntrolled trials of a short duration, none of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but witho t SUD Comorbidit  
Most t ials on the efficacy of ph rmac logical ADHD treatment in youth have been 
conducted in mixed samples of child en and adolesc nts at an age group typically ranging 
from 5 to 18 years, without sep rat  nalysi  o  repo ting of outcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant nd non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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we ks), a d no subsequent extension studies were conducted to investigate the long-term 
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comorbi   nd SUD, only data o  th short-term effects of ADHD medication are 
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and Thurst ne (201 ),  as hig  in the studies of Szobot (2008) and Riggs (2004), mainly 
due to mi sing outcome data (Table 2). 
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Riggs, 2011 [37]     
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the reported result. 
T  c n lud , he evid nce base on pharmacological ADHD treatment in adolescents 
with concurr  ADHD and SUD is li ited, with l s than 500 patients included across 
f ur controlled trials of a shor dur tio , none of whi h showed a robust treatment effect 
on ei her ADHD or SU . 
3.2.2. Ad e cents with ADHD b t wi h ut SUD C morbidity 
Most trials on the efficacy f pharmacological ADHD treatment in youth have been 
c n uct d in mixed samples of ch ldren d adolesc nts at an age group typically ranging 
from 5 to 18 years, with ut eparate analysis or reporti  of outcomes in the adolescent 
ubgroup. Our elected l terature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and on-stimulant medications with placebo in children 
and adol cents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with no exc ss of SAEs in ny ac ive dication group comp ed with l c .
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comorbid ADHD and SUD, only data o  the short-term effects of ADHD medic tion are
available to date. We assessed the risk of bias as being lo  in the stu ies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missin  outcome data (Table 2). 
Table 2. Risk f bias in the included studies on ph rmacological interventions. 
Study Bias rising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD     
Riggs, 2011 [37]      
Szobot, 2008 [36]     
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD     
Pelham, 2013 [33]       
Findling, 2010 [27]       
ilens, 2006 [40]     
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bang , 2007 [44]       
Biederman, 2008 [45]       
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Note:          low risk/high risk/some concerns. Rnd—randomization proc s; Int—intended 
interventions; Mis—missing outcome data; Me —measure ent of the outcome; Sel—selection of 
the reported result. 
To conclude, the evidence base on phar acological ADHD treatment in adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patie ts inc uded across 
four controlled trials of a short duration, none of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Como bidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve be n 
conducted in ixed samples of children and adolescents at an age grou  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
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studi s, with  ex ss of SAEs i ny c iv  medicati n group comp red i h l ce .
Adv rse phar acological int ractions between he st y m ic t n a d t e ad lesce t’s
sub ta  u e at th  s e ay w re on y report d in th  trial of Riggs et al. (2011) [37],
and only by fo r .8%   hree ( .1%  of th  p t n s t king OROS-MPH and placeb , 
respectively. In the thre  tri l that investigate  stim l nts, o indication was found that 
stimulant medicatio  led to SUD d terioration. 
Planned tr tm nt ur tion n the e trial ranged f om 6–16 we ks (1 of 4 st dies >12 
w eks), nd no u s quent extensio studies w re con uct d to inve tigate th  ong-t rm 
effects of ADHD m dicatio in t e stu y samples. He ce, pertaining to adole cents w th 
morbid ADHD nd SUD, onl data o  the sho t-term ffects f ADHD m dica i n are 
available to date. We assesse  th  risk of bias as being lo  in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missin  outcome data (Table 2). 
Table 2. Risk of bias in the included tud es on ph rmacological interventions. 
Study Bias rising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2 11 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
ilens, 2006 [40]       
Findling, 2011 [42]      
Sp ncer, 2006 [41]       
B stic, 2000 [43]       
B g , 2007 [44]       
Bieder a , 2008 [45]       
Salle , 2009 [46]       
Wilens, 2015 [47]       
New orn, 2017a [34]       
Newcorn, 2017b [34]      
Note:         lo  risk/ igh risk/s me concerns. Rnd—randomization proces; Int—intended 
inte venti ns; Mis—mis ing outc me data; Mea—measure ent h  outcome; S l—sel cti  of 
the reported result. 
To concl e, t  vi ence base on phar c logical ADH  treatmen  in adolescents 
with concurrent ADH  and SUD is li ited, with less than 500 patients included across 
four controlled trials of a short duration, none f hich showed a robust treat ent effect 
on eith r ADH  or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
M st trials on the efficacy of ph rmacological ADHD t tme t in youth h ve been
conducted in ixed samples of childr n and d lescents at n e gro  typica y rangi g 
from 5 to 18 years, without separa e analysis or repor ng of utcomes in the adolescent
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 R Ts comparing stimulant and non-stimulant medications with placebo in children 
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studi s, with o xc s of SAEs in ny ac ive edi tio  g up compared with l ce .
Adv r  p arm c logical i ter cti  b tw n the st y medic tion and the ad lesce t’s
subst n  u e t t  s  y w re nly rep rte  in th  trial of Ri gs et al. (2011) [37],
and l  by four (2.8%) and thre  (2.1%) of the patie ts t ki g OROS-MP  and placeb , 
r pectiv ly. In the t re  trials t at i vesti ted timulants, no indication wa  found that 
stim l nt me icati  led t  SUD deterioration. 
Plann  treatment ur tion in th se trials ranged from 6–16 w eks (1 of 4 studies >12 
w eks), and n  subs quent extension tudies wer  conducted to investigate t e long-term 
effe ts f ADHD medic tio  in t e study sampl s. H n e, pertai ing to adol scents with
comorbid ADHD nd SUD, only d ta o  the short-term effects of ADHD medication are 
available to date. We assess d the risk of bias as being low in the studies of Riggs (2011) 
a d Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missin  outcome data (Table 2). 
Table 2. Risk f bias in the included studies on ph rmacological int rventions. 
Study Bias Arising from/Due to:  
Rnd Int Mis Mea Sel Overall
Adolescents with ADHD + SUD      
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD     
Pelham, 2013 [33]       
Findling, 2010 [27]       
ilens, 2006 [40]       
Fi dling, 2011 [42]       
Spencer, 2006 [41]       
Bosti , 2000 [43]       
B g , 2007 [44]       
Biederm n, 2008 [45]       
Sall , 2009 [46]       
Wilens, 2015 [47]       
Ne c rn, 2017a [34]      
Newcorn, 2017b [34]       
Note:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
i tervention ; Mis—missing outcome ata; Mea—measure ent of the outcome; Sel—selection of 
the eported r s lt. 
To onclud , the evidence base on phar colo ic l ADHD treatmen  in a olesc nts 
w th concurrent ADHD and SUD is limited, with less than 500 pati  i cluded across 
our c n r lled trials of short durati n, none f w ic  show d  robust treatment effect
o  e ther ADHD r SUD. 
3.2.2. Adol scents with ADHD b t without S D Comorbid t  
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve been 
conduct d in ixe  samples of child en and adolescents at an age grou  typically ranging 
from 5 to 18 years, without sep rat  nalysi  or repo ting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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weeks), a  no ubs quent xt nsion studies were conducted to investigate the long-term 
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avail ble to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurst ne (201 ),  as hig  in the studies of Szobot (2008) and Riggs (2004), mainly 
due to mi sin  outcome data (Table 2). 
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Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
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Riggs, 2011 [37]      
Szobot, 2008 [36]       
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Thurstone, 2010 [39]      
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
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Findling, 2011 [42]      
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Bostic, 2000 [43]       
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Note:          low risk/ ig  ri k/s me co c rns. Rn —rand mization proces; Int—intended 
inte v ntions; Mis—missing utcom  data; Mea measurem nt o  the outcome; Sel—selection of 
the report d result. 
To c lude, the evidence base n pha acological ADHD treatment in adolescents 
with concurrent ADHD and SUD is li ited, with s than 500 patients included across 
f ur controlled trials of a shor ur tio , none of whi h showed a robust treatment effect 
on either or SUD. 
3.2.2. Ad lesc nts with ADHD but without SUD Comorbidity 
Most trials on th  efficacy f pharmacological ADHD treatment in youth h ve been 
c ucted i  ixed samples of ch ldren  adolesc nts at a  age grou  typically ranging 
from 5 t  18 years, with ut eparate a a ysis r reporti of utcomes in the adolescent 
subgroup. Our el cted l terature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and on-stimulant medications with placebo in children 
and adol scents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
Findli , 2011 [42]
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studies, with no excess of SAEs in ny ac ive medication gr p c pa e wi h lace .
Adv rse pharmacological interactions b tween the t y edic ti  and t e l scen ’s
substance use t the s me day were only reported in the trial of Ri gs et al. (2011) [37],
and only by four (2.8%) and three (2.1%) of the pat nts taking OROS-MPH and placebo, 
respectively. In the three trials that investigated stimulants, no indication was fou  that 
stimulant medication led t  SUD eterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (1 f 4 studies >12
weeks), and no subsequent extension studies were conducted to investigate the lon -term 
effects of ADHD medication in t e study samples. Hence, per aining to adolesc nts w th 
comorbid ADHD and SUD, only data o  the short-term effects of ADHD medic tion are 
available to date. We assessed the risk of bias as being lo  in the stu ies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly
due to missin  outcome data (Table 2). 
Table 2. Risk of bias in the included studies on ph rmacological interventions. 
Study Bias risi g from/Due to:  
 Rnd Int Mis Mea S l Ov rall 
Adolescents with ADHD + SUD     
Riggs, 2011 [37]      
Szobot, 2008 [36]     
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD     
Pelham, 2013 [33]       
Findling, 2010 [27]      
ilens, 2006 [40]      
Findli g, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bang , 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]      
Newcorn 2017b [34]      
Note:          low risk/high risk/some concerns. Rnd—rand mization roc s; Int—int ed 
interventions; Mis—missing outcome data; Me —measure e t f the outcome; Sel—selection f 
the reported result. 
To conclude, the evidence base on phar acological ADHD treatment i adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patients included across 
four controlled trials of a short duration, none of which showed a r bust treat e t effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Como bidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixed samples of children and adolescents at an age grou  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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stud es, with n  exc ss of SAEs in any activ g oup c mp red with placebo. 
Adverse pharm cological int ractio s betw en he st dy med cat on and t e ad le cent’s 
substa c  u e at the sam day were o ly rep r ed in the trial of Riggs t al. (2011) [37], 
nd o ly by f r (2.8%) a d three (2.1%) of the patients taking OROS-MPH and placebo, 
respect vely. In the three trials that i esti ated stim lants, no indica ion was found that 
stimulant medication led to SUD deterioration. 
Pl nned treatment uration in hes tr als range f om 6–16 weeks (1 f 4 studies >12 
w eks), and no ubseque t ex nsi n stud es were c ducted to investigate the lon -term 
effects of ADHD medication in the stu y s mples. He c , pertaini to adol sce ts w th 
comorbid ADHD and SUD, only data o  th  short-term effects of ADHD medication are 
available to date. We assessed t e risk of bias as being lo  in the studies of Riggs (2011) 
and Thurstone (2010), and as high he s udi s of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome dat  (Table 2). 
Table 2. Risk of bias in the cluded studi s n pharmacological interventions. 
Study Bias rising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]      
ilens, 2006 [40]      
Findli g, 2011 [42]       
Spencer, 2006 [41]     
Bostic, 2000 [43]       
Bang , 2007 [44]       
Bie erman, 2008 [45]       
Sallee 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newco n, 2017b [34]      
Note:         low risk/high risk/some conc rns. Rnd—ran mization proces; Int—inten ed 
interventions; Mis—mi ing outc m  ta; Mea—mea ure t of the outcome; Sel—sel ctio f 
the report d r ult. 
To conclude, the evi enc  base o  pharmacological ADHD treatme t i  a oles ents 
with concurrent ADHD a  SUD is li ited, with l ss than 500 patie ts i c uded across
four co trolled trials of a short duratio , n e of whi h s owed a robus  treat ent effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but w hout SUD Comorbidity 
Most tri ls on the efficacy of pharmacological ADHD treatment in yo th have been 
c ducted i  mixed samples of children and adolescents at a age group typically ranging 
from 5 to 18 ears, with ut separate a alys s r reporting of outcomes in the adolescent 
subgroup. Our selected literature included a met -analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant a d non-stimulant medications with placebo in children 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J. Clin. Med. 2021, 10, x FOR PEER REVIEW 12 of 34 
 
 
st d s, with n  xce s f SAEs in ny ac ive edic tion group compared with lace .
Adv r e p arm cological inter ctions betw n the st dy medication and the ad lescent’s
sub tan e use t e s me day w re only rep rted in the trial of Riggs et al. (2011) [37],
and only by four (2.8%) and three (2.1%) of the pati nts taking OROS-MPH and placebo, 
r pectively. In the ree trials that investigated stimulants, no indication was found that 
stimul t medication led t  SUD deterioration. 
Planne  treatment duration in th e rials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and n subsequent extension studies were conducted to investigate the long-term 
effects f AD D medic ti  i t e y samples. Hence, pertaining t  adolescents with 
c morbid ADHD nd SUD, only data o  the short-term effects of ADHD m dication a e 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurston  (2010), and s high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missin  outcome data (Table 2). 
Table 2. Risk of bias in th  included studies on ph rmacological int rventions. 
Study Bias Arising from/Due to:  
Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD      
Rig s, 11 [37]       
Szobot, 2008 [36]       
iggs, 4 [38]       
Thurston , 201  [39]       
Adolesc nts with ADHD     
P lham, 3 [3 ]      
Findling, 2010 [27]      
ilens, 2006 [40]       
Fin ling, 2011 [42]       
Spencer, 2006 [41]      
Bosti , 2000 [43]       
B ng 2007 [44]       
B derm n, 2008 [45]       
Sall , 2009 [46]       
Wilens, 2015 [47]      
N wc r , 2017a [34]       
Newc rn 2017b [34]     
Note:         low isk/high r k/s me co cer s. R d—randomiza ion roc s; Int—inten ed 
i terv n ion ; Mis—missing  ata; Mea—measure ent f the outcome; Sel—selection of 
he reported r s lt. 
To o cl , the evide ce base on phar acolo ical ADHD treatmen  in a olesc nts 
w th concurrent ADHD and SUD is limit , with less than 500 pati  i clud d across 
ur con r lle  trials of  short durati n, no e  w ic  show d a robust treatme t effect
o  e ther ADHD r SUD. 
3.2.2. Adol scents with ADHD but without S D Comorbidity 
M st trials on the fficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixe  s mpl s of children and dolescents at an age grou  typically ranging 
from 5 to 18 years, with  separate analysis or reporting of utcomes in the adolescent 
subgroup. Our selected lit ature includ d a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs compar ng stimulant and n n-stimulant medications with placebo in children 
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st dies, with n  excess of SAEs in ny ac ive me ication group compa ed wi h lac .
Adv rse pharmacological inter ctions b tw en the t y edic tio  and t e a l scent’s
substance use t the s me d y were only reported in the trial of Riggs et al. (2011) [37],
and only by four (2.8%) and three (2.1%) of the pat ents taking OROS-MPH and placebo, 
respectively. In the three trials that investigate  stimulants, o indicatio  was fou d that 
stimulant medication led t  SUD deterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (1 of 4 studies >1  
weeks), and no subsequent extension studies wer  conducted to investigate the long-term 
effects of ADHD medication in t e study samples. Hence, per aining to a olescents with 
comorbid ADHD and SUD, only data on the short-term effects of ADHD medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurston  (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on ph rmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Rig s, 11 [37]      
Szobot, 2008 [36]       
Riggs, 4 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 3 [3 ]       
Findling, 2010 [27]       
Wilens, 2006 [40]      
Findli g, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]      
Newcorn 2017b [34]      
Note:          low risk/high risk/some concerns. Rnd—rand ization roc s; Int—int ed 
interventions; Mis—missing outcome data; Me —measure e t f the outcome; Sel—select on of 
the reported result. 
To conclude, the eviden e base on phar acological ADHD trea ment i  adolescents 
with concurrent ADHD and SUD is limite , with l ss tha  500 patients incl ded across 
our controlled t ials f a short duratio , one of which sh wed a r b st reat t eff c  
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but with t SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixed samples of children and adolescents at an age grou  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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stud es, with n  exc ss of SAEs i  ny ac iv g oup c pared wi h placebo.
Adverse pharm cological int ractio s betw en he st y medic t on and t e adole cent’s
substa c  u e at the s m day were o ly repor ed in the trial of Riggs t al. (2011) [37],
nd o ly by f r (2.8%) a d three (2.1%) of the pat ents taking OROS-MPH and placebo, 
respect vely. In the three trials that i e ti ated stim lants, no indication was found that 
stimulant medication led to SUD deterioration. 
Pl nned treatment uration in hes  tr als range  f om 6–16 weeks (1 f 4 studies >12 
w eks), and no ubsequ ex nsi n stud es were c ducted to investigate the lon -term 
effects of ADHD medication in the stu y s mples. He c , pertaining to adol ce ts with 
comorbid ADHD and SUD, only data on the short-term effects of ADHD medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
a d Thurstone (2010), and as high in the studies of Szobot ( 08) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the cluded studi s  ph rmacological interventions. 
Study Bias Arisi g from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents ith ADHD + SUD       
Riggs, 2011 [37]      
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]   
Findling, 2010 [27]       
Wilens, 2006 [40]      
Findli g, 2011 [42]      
Spencer, 2006 [41]       
Bosti , 2000 [43]      
Ba gs, 2007 [44]      
Bie erman, 2008 [45]       
Sallee 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newco n, 2017b [34]     
Note:         low risk/high risk/so e conc rns. Rnd—rand mization proces; Int—inten ed 
interventions; Mis—mi ing outc e ta; Mea—m a ur t f the outcome; Sel—sel cti f 
the report d r sult. 
To conclude, the evi enc  base o  phar acological ADHD treatme t in a olescents 
with concurrent ADHD a  SUD i  li ited, ith l ss tha  500 patients i cluded across 
four co trolled trials of a short dura i , n e f whi h owed a robust treat e t effect 
on either ADHD or SUD. 
3.2.2 Adolescents with ADHD but without SUD Comorbidity 
Most tri ls on the efficacy of pharmacological ADHD treatment in yo th have been 
c ducted i  mixed samples of children and adolescents at a age group typically ranging 
from 5 to 18 ears, with ut separate a alys s r reporting of outcomes in the adolescent 
subgroup. Our selected literature included a met -analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant a d non-stimulant medications with placebo in children 
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st d s, with n  exce s f AEs in any c ive dication group ompared with lace .
Adv r e p armacolog cal int r ctions betw en the st dy medication and th  ad lescent’s
sub tance use at e s me day were only r ported in the trial of Riggs et al. (2011) [37],
and only by four (2.8%) and three (2.1%) of the pati nts taking OROS-MPH and placebo, 
r p c ively. In the ree trials that investigated stimulants, no indication was found that 
stimul t medication led t  SUD deterioration. 
Planne  treatment duration in th e rials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and n subsequent extension studies were conducted to investigate the long-term 
effects of AD D medic ti  i  t e tudy sample . Hence, pertaining  adolescents with 
c morbid ADHD and SUD, only data on the short-term effects of ADHD medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurston  (2010), and s high in the studies of Szobot (2008) and Riggs (2004), mainly 
due t  missing outcome data (Table 2). 
Table 2. Risk of bias i  th  included studies on ph rmacological interventions. 
Study Bias Arising from/Due to:  
Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Rig s, 11 [37]       
Szobot, 2008 [36]       
ig s, 4 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD      
P lham, 3 [3 ]    
Findling, 2010 [27]      
Wilens, 2006 [40]       
Findling, 2011 [42]      
Spencer, 2006 [41]       
Bostic, 2000 [43]      
Ba gs, 2007 [44]       
B d rm n, 2008 [45]       
Sal e, 2009 [46]      
Wilens, 2015 [47]      
N cor , 2017a [34]       
Newc rn 2017b [34]    
Note:         low isk/high risk/s e co cer s. Rn —rando iza ion roc s; Int—inten ed 
intervention ; Mis—missing  data; Me —measurement f the outcome; Sel—selection of 
the reported r sul .
To o cl , the evide e base o  phar acological ADHD trea ment in a olescents 
w th concurrent ADHD and SUD is limit , with less than 500 patients includ d across 
ur c r lle  trials of a short durati , none  w ich showed a robust treatme t eff c  
o  e ther ADHD r SUD. 
3.2.2. A with ADHD but with t SUD Comorbidity 
M st trials on the fficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixe  s mpl s of children and dolescents at an age grou  typically ranging 
from 5 to 18 years, with  separate analysis or reporting of utcomes in the adolescent 
subgroup. Our selected lit ature includ d a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs compar ng stimulant and n n-stimulant medications with placebo in children 
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st dies, with no excess of SAEs in any active me ication group compared with lac . 
Adv rse pharmacological int ractions between the st dy medication and th  ad lescent’s 
substance use at the same day were only reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the pati nts taking OROS-MPH an  pl cebo, 
respectively. In the three trials that investigated stimulants, o i dication was found that 
stimulant medication led t  SUD deterioration. 
Planned tre tment duration in th e trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequent extension stu ies wer  conducted to investig te th  lo g-term 
effects of ADHD medication in t e study samples. Hence, pertaining to a olescents ith 
comorbid ADHD and SUD, only data on the sh rt-term eff cts of ADHD medication are 
available to date. We assessed the risk of bias as being ow in the studies of Riggs (2011)
and Thurston  (2010), and as high in the studies of t ( ) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the i cluded studies on ph rmacological interventions. 
Study Bias Arisi g from/Due to: 
 Rnd Int Mis M a S l Overall 
Adolescents with ADHD + SUD      
Rig s, 2011 [37]     
Szobot, 2008 [36]      
Riggs, 2004 [38]      
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]     
Findling, 2010 [27]       
ilens, 2006 [40]      
Findli g, 2011 [42]      
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wil s, 2015 [47]       
Newcorn, 2017a [34]      
Newcorn 2017b [34]      
Note:          low risk/high risk/some concerns. Rnd—rand mization roc ; Int—int n ed 
interventi ns; Mis—m ssing outcome data; Mea—mea ureme t f t  outcome; Sel—s l ction f 
the reported result. 
To conclude, the eviden e base on pharmacological ADHD trea ment i  adolescents 
with concurrent ADHD and SUD is limite , with l ss than 500 patients incl ded across 
our controlled t ials of a short duratio , none of which showed a r bust reat nt eff c  
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but with t SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixed samples of children and adolescents at an age grou  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in t e adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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t i , with n  xc ss of SAEs in any ctive me ication roup compared with placebo. 
Adverse pharm cological inter ctions between the study medication and the adolescent’s 
sub an e use at the s me d y w re on y reported in th  tri l of Riggs et al. (2011) [37],
and only by four (2.8%) and hree (2.1%) of th  patien s taking OROS-MPH and placebo, 
espectively. In the three tri l t at investig ted stimul nt , o indication was found that 
stimulant medicatio  l d to SUD terioration. 
Plann d tre tment durat on n h e tri ls rang d from 6–16 we ks (1 f 4 st dies >12 
w eks), nd no u equent xt nsion st ies were conducted to inve tigate the long-term
effec s of ADHD m dicat o  in the study samples. Hence, pertaining to adole cents with
morbid ADHD and SU , only data on the short-term ffects of ADHD medication are 
avail l  to d te. We assessed th risk of bias as being lo  in the studies of Riggs (2011) 
and Thurston  (2010), and as igh in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outc e data (Table 2). 
Table 2. Risk of bias i  the incl ded studies on pharmacological interventions. 
Study Bias risi g from/Due to:  
 Rnd Int Mis M a Sel Overall 
Adolesce ts with ADHD + SUD       
Rig s 11 37
Szobot 08 36
Riggs, 20  [38] 
Thursto e, 2010 9
Ad lescents wit ADHD      
Pelham, 2013 [33]      
Findling, 2010 [27]      
il ns, 2006 [40]       
Findling, 2011 [42]     
Sp ncer, 2006 [41]    
B stic, 2000 [43]      
B g , 2007 [44]       
B ederman, 2008 [45]       
Sall , 2009 [46]       
Wil s, 2015 [47]      
Ne n, 2017a [34]       
Newc rn 2017b [34]      
Note:         low risk/high risk/some concerns. Rnd—randomizati n roc s; Int—inten ed 
interventi ns; Mi —m ssing tco e data; Mea—meas reme t f the outc me; Sel—selectio  of 
t e report d resul . 
To oncl e, th  vi ence bas  on pharm c logic l ADHD trea me  in a les ents 
with concurrent ADH  and SUD is limite , with l s than 500 pati ts included across 
our con rolled t i ls of  short duratio , n ne f which sh wed  r bust r atment eff  
o  eith r ADH or SUD. 
3.2.2. Adolescents with ADHD but with t SUD Comorbidity 
Most trials on the fficacy of pharmacological ADHD t atme t in youth have been
conducted in mixed samples of childr n and adolesc nts at an ge group typica y rangi g 
from 5 to 18 years, without sep ra e analysis or repor ng of outcomes in the adolescent
subgroup. Our selec ed litera ure incl d  a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 R Ts comparing stimulant and non-stimulant medications with placebo in children 
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st dies, with no excess of SAEs in any ctive i ti  group compared with l ce . 
dv rs  phar acological inter cti s tween t e st dy medic tion and the d l scent’s 
substance u e at t e same ay were nly reported in the trial of Riggs et al. (2011) [37], 
a  nly by four (2.8%) an  three (2.1%) of the pati ts t king OROS-MPH and placebo, 
r spectively. In the t ree trials that investigated stimulants, no indication was found that 
stimul n  medi t  led to SUD teri rat on. 
Planne  tre tment dur tion in th e trials ranged from 6–16 w eks (1 of 4 studies >12 
weeks), and n  subsequent extension tudies wer conducted to investigate t e long-term 
effects of HD medic tion i  t e tudy sa pl s. Hence, pertaining t  adol scents with 
comorbid ADHD nd SUD, only d ta on the short-term effects of ADHD medication are 
available to ate. We assess d the risk of bias as being low in the studies of Riggs (2011) 
a d Thurston  (201 ), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due t  missing outcome data (Table 2). 
Table 2. Risk of bias in the include  studies on ph rmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents w th ADHD + SUD       
R g s, 2011 [37] 
Szobot, 2008 [36] 
ig s, 20 4 [38] 
Thu st n , 2010 [39]      
Adolescents with ADHD      
P lham, 2013 [33]     
Findling, 2010 [27]       
ilens, 2006 [40]       
Fi dling, 2011 [42]   
Spencer, 2006 [41]      
Bostic, 2000 [43]      
Bangs, 2007 [44]       
Bi d rm , 2008 [45]     
Salle , 2009 [46]     
W l ns, 2015 [47]     
Ne cor , 2017a [34]       
Newc rn 2017b [34]      
Note:         low isk/ igh risk/s me co cerns. Rn —randomiza ion roc s; Int—i t n d 
interve ti n ; Mis—m ssing out ome dat ; M a—me s r t f the utcome; Sel—selection of 
the reported r sul . 
To onclud , the eviden e base on phar cologic l ADHD trea ment in a olescents 
w th concurrent ADHD and SUD is limite , with les  than 500 pati ts includ d across 
ur c tr lle  t ials of a short duratio , none of which showed a robust treatment eff c  
o  either ADHD or SUD. 
3.2.2. A with ADHD but with t SUD Comorbidit  
Most tri ls on the efficacy of pharmacological ADHD treatment in youth h ve been 
c ducted i  ixe  samples of child en a d adolescents at an age grou  typically ranging 
from 5 to 18 years, with ut sep rat  nalysi  r repo ting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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st i s, wi h o excess f SAEs in any active medication group compared with placebo. 
Adv rs pharmacological interactions b tween t e study medication and the adolescent’s 
substance us  at the same day were only reported in e trial of Riggs et al. (2011) [37], 
an  only by f ur (2.8%) and three (2.1%) of the patients taking OROS-MPH and placebo, 
pectiv ly. I  the three trials that investigated stimulants, no indication was found that 
mulant m dication le  to SUD det rior ion. 
Pl n d re t ent du ation  th e trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), a no subs quent xtension studies were conducted to investigate the long-term 
ff ct  of ADHD med cation y amples. Hence, pertaining to adolescents with 
comorbi  ADHD and SUD, only data on the short-term effects of ADHD medication are 
avail ble to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurst n  (201 ),  as hig  in the studies of Szobot (2008) and Riggs (2004), mainly 
due to mi sing outcome data (Table 2). 
Table 2. Risk of bias in the ncluded studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
Rnd Int Mis Me  Sel Overall 
Adolescents with ADHD + SUD       
Rig s, 2011 [37]     
Szobot, 2008 [36]      
Riggs, 2004 [38]     
Thurstone, 2010 [39]     
Adoles ts with ADHD      
Pelham, 2013 [33]     
Findling, 2010 [27]       
ilens, 2006 [40]       
Findl g, 2011 [42]     
Spencer, 2006 [41]     
Bostic, 20  [43]      
B ngs, 2007 [44]       
Bi der an, 2008 [45]       
S ll e, 2009 [46]      
Wil , 2015 [47]       
Newcorn, 2017  [34]       
N wcorn 2017b [34]       
Note:          low risk/high ri k/some co c r s. Rnd—randomization roc s; Int—inten ed 
i terv nti ns; Mis—m ssing utcome data; Mea me sur ment f the outcome; Sel—selecti n of 
the report d r sult. 
T  lude, the viden  base n ph macological ADHD trea ment i  adolescents 
with con u ren  ADH  and SUD is li ite , with  than 500 pati nts included ac oss 
ur c ntr lled t ials of a hor dur ti , none of whi h showed a robust treatment eff c  
on either ADHD o  SUD. 
3.2.2. Ad l sce ts with ADHD but with t SUD Como bidity 
Most tria s on the efficacy f pharmacological ADHD treatment in youth have been 
c n ucted in ixed samples of ch ldren d adolesc nts at an age group typically ranging 
from 5 t 18 years, with ut eparate ana ysis r reporti of outcomes in the adolescent 
subgroup. Our el cted l terature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and on-stimulant medications with placebo in children 
and adol scents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
Bangs, 2007 [44]
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studies, with no excess of SAEs in any active me ication group compared with lac . 
Adv rse pharmacological int ractions between the st dy medication and th  ad lescent’s 
substance use at the same day were only reported in the trial of Ri gs et al. (20 1) [37], 
and only by four (2.8%) and three (2.1%) of the pati nts taking OROS-MPH an  pl cebo, 
respectively. In the three trials that investigated stimulants, o i d cation was found that 
stimulant medication led t  SUD deterioration. 
Planned tre tment duration in th e trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequent extension stu ies were conducted to investig te the long-term 
effects of ADHD medication in t e study samples. Hence, pertaining to a olescents ith 
comorbid ADHD and SUD, only data on the sh rt-term effects of ADHD medication are 
available to ate. We assessed the risk of bias as being low in the studies of Riggs (2011)
and Thurston  (201 ), and as high in th  studies of t (20 ) a  Ri gs (200 ), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the i cluded studies on ph rmacological interv ntions.
Study Bias Arisi g from/Due to: 
 Rnd Int Mis Mea Sel Ov rall 
Adolescents with ADHD + SUD     
R ggs, 2011 [37] 
Szobot, 2008 [36] 
Riggs, 20 4 [38] 
Thurst ne, 2010 [39]     
Adolescents with ADHD       
Pelham, 2013 [33]     
Findling, 2010 [27]       
ilens, 2006 [40]       
Findling, 2011 [42]      
Spencer, 2006 [41]      
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederma , 2008 [45]       
Sallee, 2009 [46]       
Wil s, 2015 [47]       
Newcorn, 2017a [34]    
Newcorn 2017b [34]      
Note:          low risk/high risk/some concerns. Rnd—randomization roc ; Int—int n ed 
interventi ns; Mis—missing outcome data; Mea—mea urement f  outcome; Sel—s l ction f 
the reported result. 
To conclude, the eviden e base on phar acological ADHD trea ment i  adolescents 
with concurrent ADHD and SUD is limite , with l ss than 500 patients incl ded across 
our controlled t ials of a short duratio , none of which showed a r bust reat nt eff c  
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but with t SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixed samples of children and adolescents at an age grou  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in t e adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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t i , with n  x ss of SAEs in any ctive medication roup compared with placebo. 
Adverse pharm cological inter ctions between the study medication and the adolescent’s 
sub an e us  at t e s me d y w re on y reported in th  tri l of Riggs et al. (2011) [37],
and only by four (2.8%) and hree (2.1%) of th  patien s taking OROS-MPH and placebo, 
espectively. In he three tri l that investig ted stimul nt , o indication was found that 
stimulant medicatio l d to SUD terioration. 
Planned tre tment duration n h e tri ls rang d from 6–16 we ks (1 of 4 studies >12 
w eks), nd no u equent ext nsion st ies were conducted to i vestigate the long-term 
effec s of ADHD m dicat on in the study samples. Hence, pertaining to adole cents with 
c morb d ADHD and SUD, only data on the short-term ffects of ADHD medication are
avail l  to ate. We assessed th risk of bias as being o  in the studies of Riggs (2011)
and Thurston  (201 ), and as igh in he studies of Szobot (20 8) and Riggs (2004), mainly 
due to missing outc e data (Table 2). 
Table 2. Risk of bias i  the in l ded studies on ph rmacological interventions. 
Study Bias rising from/Due to:  
 Rnd Int Mis M a Sel Overall 
Adolescents with ADHD + SUD       
R ggs, 2 11 [37] 
Szob t, 2008 [36] 
Riggs, 20 4 [38] 
Thurst n , 2010 [39]       
A olesc nts with ADHD      
Pelham, 2013 [33]      
Fin li g, 2010 [27]      
il ns, 2006 [40]       
Findling, 2011 [42]     
Sp ncer, 2006 [41]    
B s ic, 2000 [43]     
B g , 2007 [44]       
B ederma , 2008 [45]       
Sall , 2009 [46]       
Wil s, 2015 [47]      
Ne n, 2017a [34]       
Ne corn, 2017b [34]    
Note:         lo  risk/high risk/some conc rns. Rnd—randomizati n proces; Int—intended 
int rventi ns; Mi — issing tco e data; Mea—m as reme t of the utc me; Sel—sele tio  of 
t e report d resul . 
To oncl e, th  vi en e bas  on phar c logic l ADHD tr a me  in a les e ts 
with concurrent ADH  and SUD is li ite , with l s than 500 pati nts included across 
our c trolled t ials of a short duratio , ne f which sh wed a r bust tr atment eff  
o  eith r ADH or SUD. 
3.2.2. Adolescents with ADHD but with t SUD Comorbidity 
Most trials on the fficacy of pharmacological ADHD t atme t in youth have been
conducted in mixed samples of childr n and adolesc nts at an ge group typica y rangi g 
from 5 to 18 years, without sep ra e analysis or repor ng of outcomes in the adolescent
subgroup. Our selec ed litera ure incl d  a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 R Ts comparing stimulant and non-stimulant medications with placebo in children 
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studies, with no excess of SAEs in any active i ti  group compared with lace . 
dv rs  phar acological inter cti s tween t e st dy medic tion and the d l scent’s 
substance use at t e same day were nly reported in the trial of Riggs et al. (2011) [37], 
a d nly by four (2.8%) and three (2.1%) of the pati ts t king OROS-MPH and placebo, 
r spectively. In the t ree trials that investigated stimulants, no indication was found that 
stimul n  medi ti  led to SUD d teri rat on. 
Planne  tre tment duration in th  trials ranged from 6–16 w eks (1 of 4 studies >12
weeks), and n  subsequent extension tudies er conducted to investigate t e long-term 
effects of ADHD edic tion in t e tudy sa pl s. Hence, pertaining to adol scents with 
comorbid ADHD and SUD, only d ta on the short-term effects of ADHD medication are 
availabl  to at . We assess d the risk of bias as being low in the studies of Riggs (2011) 
a d Thurston  (201 ), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due t  missing outcome data (Table 2).
Table . Ri k of bias in the include  studies on ph rmacolo ical int rventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents w th ADHD + SUD      
R ggs, 2011 [3 ] 
Szobot, 2008 [36]
s, 20 4 [38] 
Thurst n , 2010 [39]      
Adolesc nts with ADHD     
P lham, 2013 [33]     
Findling, 2010 [27]       
ilens, 2006 [40]       
Findling, 2011 [42]     
Spenc r, 2006 [41]     
Bostic, 2000 [43]      
Bangs, 2007 [44]       
Bi d rma , 2008 [45]     
S llee, 2009 [46]     
W l ns, 2015 [47]     
Ne corn, 2017a [34]      
Newc rn 2017b [34]      
Note:         low risk/high risk/some concerns. Rnd— andomization roces; Int—i ten ed 
interve ti n ; Mis—missing outco e dat ; M a—me s r  f the utcome; Sel—selection of 
the reported r sul . 
To onclud , the eviden e base on phar cologic l ADHD trea ment in a olescents 
w th concurrent ADHD and SUD is limite , with l s  than 500 pati ts includ d across 
ur c tr lle  t ials of a short duratio , none of which showed a robust treatment eff c  
o  either ADHD or SUD. 
3.2.2. A with ADHD but with t SUD Comorbidit  
Most tri ls on the efficacy of pharmacological ADHD treatment in youth h ve been 
c ducted i  ixe  samples of child en a d adolescents at an age grou  typically ranging 
from 5 to 18 years, with ut sep rat  nalysi  r repo ting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studi s, wi h  excess f SAEs in any active medication group compared with placebo. 
Adv rs pharmacological interactions b tween t e study medication and the adolescent’s 
substance us  at the same day were only reported in e trial of Riggs et al. (2011) [37], 
an  only by f ur (2.8%) and three (2.1%) of the patients taking OROS-MPH and placebo, 
pectiv ly. I  the three trials that investigated stimulants, no indication was found that 
mulant m dication le  to SUD det rior ion. 
Pl n ed re t ent durati n  the e trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), a d no subs quent extension studies were conducted to investigate the long-term 
ff ct  of ADHD med cation y amples. Hence, pertaining to adolescents with 
comorbi  ADHD and SUD, only data on the short-term effects of ADHD medication are 
avail ble to ate. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurst n  (201 ),  as hig  in the studies of Szobot (2008) and Riggs (2004), mainly 
due to i sing outcome data (Table 2). 
Table 2. Ri k of bias in th  ncluded studies on ph rmacological interventions. 
Study Bias Arising from/Due to:  
Rnd Int Mis Me  Sel Overall 
Adolescents with ADHD + SUD       
R ggs, 2011 [37] 
Szobot, 2008 [36] 
Riggs, 20 4 [38] 
Thurst ne, 2010 [39]      
Adolesce ts with ADHD      
Pelham, 2013 [33]     
Fi dling, 2010 [27]       
ilens, 2006 [40]       
Findl g, 2011 [42]     
Spencer, 2006 [41]    
Bostic, 2000 [43]      
B ngs, 2007 [44]      
Bi der a , 2008 [45]       
S llee, 2009 [46]      
Wilen , 2015 [47]      
Newcor , 2017  [34]       
N wcorn, 2017b [34]      
Note:          low risk/high ri k/some co c r . Rnd—randomization proc s; Int—intended 
i t rventi ns; Mi —m ssing utcome data; Mea me sur ment of the outcome; Sel—selecti n of 
the report d result. 
T  lude, the viden e base n ph ac l gical ADHD trea ment i  adolescents 
with con urren  ADH  and SUD is li ited, with  than 500 pati nts included ac oss 
ur co tr lled t i ls of a hor dur ti , none of w i h showed a robust treatment eff c  
on either ADHD o  SUD. 
3.2.2. Ad lescents with ADHD but with t SUD Como bidity 
Most tria s on the efficacy f pharmacological ADHD treatment in youth have been 
c n ucted in ixed samples of ch ldren d adolesc nts at an age group typically ranging 
from 5 t 18 years, with ut eparate ana ysis r reporti of outcomes in the adolescent 
subgroup. Our el cted l terature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and on-stimulant medications with placebo in children 
and adol scents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
Biederman 08 [45]
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studies, with no excess of SAEs in any ac ive medicati n gr up compared w th lace .
Adv rse pharmacol gical interactions between the st dy edication and th  ad lescent’s 
substance use at the same day were only reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the pati nts taking O OS-MPH an  pl cebo, 
respectively. In the three trial  that inv stigated stimulants, no indication was fou d that 
stimulant medication led t  SUD deterioration. 
Planned tre tment duration in th e trials ranged fro  6–16 weeks (1 of 4 studies >1  
weeks), and no subsequent extension studies were co ucted to investi ate the lo -term 
effects of ADHD medication in t e study samples. Hence, pertaining to adolescents ith 
comorbid ADHD and SUD, only data on the short-term effects of ADHD medication are
available to ate. We assessed the risk of bias as being ow in the studies f igg (2011)
and Thurston  (201 ), and as high in the studies of Szobot (20 8) a  Ri gs (200 ), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on ph rmacological interv ntions. 
Study Bias Arising from/Due to: 
Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD     
R ggs 11 37
Szobot, 08 [36] 
Riggs, 20 4 [38] 
Thurst ne, 2010 [39] 
Adolescents with ADHD      
Pelham, 3 [3 ] 
Findling, 0 [27] 
ilens, 2006 [40]       
Findling, 2011 [42]      
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederma , 2008 [45]       
Sallee, 2009 [46]       
Wil s, 2015 [47]      
Newcorn, 2017a [34]     
Newcorn 2017b [34]      
Note:        low risk/high risk/some co cerns. Rnd—ra domization r c s; Int—int n ed 
interven i ns; Mis—missing outcome dat ; Mea—measureme t of the ou c e; Sel—s l ction of 
the reported result. 
To conclude, the eviden e base on phar acological ADHD trea ment i  dolescen s 
with concurrent ADHD and SUD is limite , with l ss than 500 patie ts incl d d across 
our controlled t ials of a sho t duratio , none of w ich howed a r bu t reat n  eff c  
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but with  SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixed samples of children and adolescents at an age grou  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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studies, with no ex ss of SAEs in any c ive medication group comp red with lace .
Adv rse pharm col gical interactions be we n the st dy medication and t e a lescent’s 
sub tan e use at the s me day w re on y reported in th  trial of Riggs et al. (2011) [37],
and o ly by four (2.8%) and hree (2.1%) of th  pat en s taking OROS-MPH and placebo, 
respecti ly. I  the three tr l that vestig ted stimul nts, o indication was found that 
stimulant medicatio d t  SUD d terioration. 
Planned tre tment duration n th e tri ls rang d from 6–16 we ks (1 of 4 studies >12 
w eks), and no u sequent extension st ies were con ucted to i vestigate the long-term 
effects of ADHD m dicat on in t e study samples. He ce, pertaining to adole cents with 
comorbid D D a d SUD, o ly data on the short-term ffects of ADHD medication are 
available to ate. We assessed th risk of bias as being o  in the studies of Riggs (2011) 
and Thurston  (201 ), and as igh in he studies of Szobot (20 8) and Riggs (2004), mainly 
due to missing outco e data (Table 2). 
Table 2. Risk of bias i  the in l ded studies on ph rmacological interventions. 
Study Bias rising from/Due to:  
Rnd Int Mis M a Sel Overall 
Adolescents with ADHD + SUD       
R gg 11 37
Szob t, 08 [36] 
Rigg , 20 4 [38] 
Thurst ne, 2010 [39] 
A olesc nts with ADHD      
Pelham, 3 [3 ] 
Findling, 0 [27] 
il ns, 2006 [40]       
Findling, 2011 [42]     
Sp ncer, 2006 [41]    
B stic, 2000 [43]      
Bang , 2007 [44]       
B eder a , 2008 [45]     
Sall , 2009 [46]       
Wil s, 2015 [47]      
Ne orn, 2017a [34]       
N w orn, 2017b [34]      
Not :      lo  ri k/ igh risk/som  co c rns. R d—ra domizati n proces; Int—intended 
interven i ns; Mis—missi g outco e dat ; Mea— eas reme t of the outc me; Sel—selection of 
t e report d result. 
To concl e, th  vi ence base on phar c logical ADHD treatmen  in adolescents 
with concu rent ADH  and SUD is li ite , with l s than 500 patients included across 
four trolled tri ls of a short dur tion, ne f which sh wed a r bust tr atment effe t 
o  eith r ADH or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbi ity 
Most trials on the efficacy of pharmacological ADHD t atme t in youth h ve been
conducted in ixed samples of childr n and adolescents at n e gro  typica y rangi g 
from 5 to 18 years, without separa e analysis or repor ng of utcomes in the adolescent
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 R Ts comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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Most trials on the efficacy f pharmacological ADHD treatment in youth have been 
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from 5 to 18 years, with t parate a alysis or reporting of outcome  in the ad lescent 
subgroup. Our elected l teratu e included a meta-analysis by Cerrillo-Urbi a et al. (2018) 
of 15 RCTs comp ring timulant and on-stimulant medications with placebo in children 
and adol scents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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of 15 RCTs comparing stimulant and non-stimul nt medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with no ex ss of SAEs in any c ive medication group comp red with lace . 
Adv rse pharm c l gical interactions betwe n the st dy medication and t e a lescent’s 
sub tan e use at the s me day w re on y reported in th  trial of Riggs et al. (2011) [37],
and o ly by four (2.8%) and hree ( . %) o  th  pati n s taking OROS-MPH and placebo, 
respecti ly. In the three tr l that vestigated s imul nt , o indicat on was f u that 
timulant medicati  l d t  SUD d terioration. 
Planned treatment duration n these trials ranged from 6–16 we ks (1 of 4 studies >12 
w eks), and no u seque t extension st ies were co ucted to i vestigate the long-term 
effects of ADHD m dicat on in t e study samples. He ce, pertaining to adole cents with
comorbid D D a d SUD, only ata o the short-term ffects of ADHD medication are 
available to date. We assessed th risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as igh in he studies of Szobot (2008) and Riggs (2004), mainly
due to missing outco e data (Table 2). 
Table 2. Risk of bias i  the in l ded studies on ph rmacologic l interventions. 
Study Bias Arising from/Due to:  
Rnd Int Mis M a Sel Overall 
Adolescents with ADHD + SUD       
Rigg 11 37
Sz b t, 8 [36] 
Riggs, 2004 [38] 
Thurst , 2010 [39] 
A oles nts wi h ADHD    
Pelham, 3 [3 ] 
Fin li g, 0 [27] 
Wilens, 2006 [40]       
Findli g, 2011 [42]     
Sp ncer, 2006 [41]     
B stic, 2000 [43]      
Ba g , 2007 [44]      
B d an, 2 08 [45]     
Sall , 2009 [46]       
Wil s, 2015 [47]      
Ne orn, 2017a [34]       
N w or 2017b [34]       
Not :         lo  ri k/ igh risk/som  co cerns. R d—ra domizati n roces; Int—inten ed 
interven ions; Mis—missi g outco e dat ; Mea— eas reme t of the outc me; Sel—selection of 
t e report d res lt. 
To concl e, th  vi ence base on phar c logical ADHD treatment in adolescents 
with concu rent ADH  and SUD is limite , with l s than 500 patients included across 
four trolled tri ls of a short dur tion, ne f which sh wed a r bust tr atment effe t 
o  eith r ADH or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbi ity 
Most trials on the efficacy of pharmacological ADHD t atme t in youth h ve been
conducted in ixed samples of childr n and adolescents at n e gro  typica y rangi g 
from 5 to 18 years, without separa e analysis or repor ng of utcomes in the adolescent
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 R Ts comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
J. Clin. Med. 2021, 10, x FOR PEER REVIEW 12 of 34 
 
 
studies, with o exc s f AEs in a y active e ication gr up c mpare  with placebo. 
Advers pharmacol ical interactions b tween the study edication and the adolescent’s 
substance se at the same day wer  o ly reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and t ree (2.1%) of t e pati ts taking O OS-MPH a d pl c bo, 
respectiv ly. I  the thr e rials that i ve tigate  stimulants, o i icatio  was found that
sti ulant medication led to UD deterioration. 
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avail ble to ate. We ass sed the risk of bias as being low in the studies of Riggs (2011) 
a d Thurst n  (201 ),  as high in the tudies of Szobot (20 8) and Riggs (2004), mainly 
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 Rnd Int Mis Mea Sel Overall
Adolesc n s with ADHD + SUD     
R ggs, 20 1 [37] 
Szobot, 20 8 [36] 
Riggs, 2 4 [38] 
Thu st ne, 2010 [39]    
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Findling, 2010 [27]      
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Findling, 2011 [4 ]    
Spence , 2006 [41]      
Bo tic, 2000 [43]      
Bang , 2007 [44]      
Bi erm , 2008 [45]       
Sallee, 2009 [46]      
Wil ns, 2015 [47]      
N wc , 2017  [34]       
Newc rn, 2017b [34]      
Note:          low risk/hi h ri k/some c c rns. R d—randomization proces; Int—i ended 
interv nti ns; Mis—missing tc me ata; M —meas reme t of he tc me; S l—selecti n f 
the reported resul . 
T  con lud , the evidence base on pharmacolog cal ADHD treat ent in adolesc n s 
with con urren ADHD a  SUD is limited, with less t an 500 pati ts included cross 
f r co r lled tri ls of  shor duratio , none of which sho ed  r bus  treatme t effec  
on eith r or SUD. 
3.2.2. Ad lescents with ADHD but w hout SU  Co orbidity 
Most trials on the efficacy f pharmacological ADHD treatment in youth have been 
con ucted in mixed samples of ch ldren  dolescents at an age group typically r nging 
from 5 to 18 years, with t parate a alysis or reporting of outcome  in the ad lescent 
subgroup. Our elected l teratu e included a meta-analysis by Cerrillo-Urbi a et al. (2018) 
of 15 RCTs comp ring timulant and on-stimulant medications with placebo in children 
and adol scents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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effects of ADHD medic tion i t e study sampl s. Hence, pertaining t  adol scents with 
com rbi  DHD nd SUD, only d ta on the short-t r  effects of ADHD medication are 
availabl  to ate. We as ess d the risk of bias as being low in the studies of Riggs (2011) 
a d Thurston  (201 ), and as high in the studies of Szobot (2008) a d Riggs (2004), mai ly 
ue t  mi sing outcome data (Table 2).
Table 2. Risk of bi s in the include  st dies o  ph rmacological int rventions. 
Study Bias Arising from/Due to:  
Rnd Int Mis Mea Sel Overall 
Adole cents w th A HD + SUD     
R ggs 11 37
Sz bot, 08 [36] 
ig s, 20 4 [38] 
Thu st n , 2010 [39]
A ol sc ts with ADHD      
P lham, 3 [3 ] 
Fin ling, 0 [27]  
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Findli g, 2011 [42]    
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N te:        low isk/high isk/so e co cerns. Rnd—ra do iza ion roc s; Int—i ten ed 
interven i n ; Mis—missi g outco e da ; Mea— asureme t f the tcom ; Sel—selection of 
the reported r sult. 
To conclud , the eviden e base on p r cologic l ADHD trea ment in adolescents 
w th concurrent ADHD and SUD is limite , with l ss than 500 pati ts includ d across 
ur c r lle  t ials a short durati , non f w ich showed a robust treatment eff c  
o  e ther ADHD r SUD. 
3.2.2. A with ADHD but with t SUD Comorbidit  
Most tri ls on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixe samples of child en and adolescents at an age grou  typically ranging 
from 5 to 18 years, without sep rat  nalysi  or repo ting of u comes in the adolescent 
subgroup. Our s lected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimul nt medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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weeks), a d no subsequent extension studies were conducted to investigate the long-term 
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i terv ions; Mis—m ssing outcome dat ; M a measureme t f the outcome; Sel—select n of 
the reported result. 
T  co lude, the evidence base n ph acol gical ADHD treatment in adolescents 
with concurrent ADH  and SUD is li ited, with l s than 500 pati nts included ac oss 
f ur co trolled tri ls of a shor dur tio , none of w i h showed a robust treatment effect 
on eith r o  SUD. 
3.2.2. Ad les ents with ADHD but without SUD Como bidity 
Most trials on the efficacy f pharmacological ADHD treatment in youth h ve been 
c n ucted in ixed samples of ch ldren  adolesc nts at an age grou  typically ranging 
from 5 t  18 years, with ut eparate a a ysis r reporti of utcomes in the adolescent 
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Riggs, 2004 [38] 
Thu sto e, 2010 [ 9] 
Adolescents wit  ADHD      
Pelham, 3 [3 ] 
Findling, 0 [27] 
ilens, 2006 [40]       
Findli g, 2011 [42]       
Spencer, 2006 [41]     
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wil s, 2015 [47]      
Newcor , 2017a [34]       
Newcorn 2017b [34]       
Note:          low risk/high risk/some co cerns. Rnd—ra d mization r c s; Int—int n ed 
interven i ns; Mis—missing outcome dat ; Mea—measureme t f the ou c e; Sel—sel ction of 
the reported result. 
To conclude, the eviden e base on phar acological ADHD trea ment i  adolescents 
with concurrent ADHD and SUD is limite , with l ss than 500 patients incl ded across 
our controlled t ials of a short duratio , none of which showed a r bust reat nt eff c  
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but with t SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixed samples of children and adolescents at an a e gro  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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studies, with no ex ss of SAEs in any c ive medication group compared with l ce .
Adv rse ph rm col gical interactions betwe n the st dy medic tion a d t e a lescent’s 
sub tan e se t the s me day w re on y reported in th  trial of Riggs et al. (2011) [37],
a d only by f ur (2.8%) and hree (2.1%) o  th  pati n s taking OROS-MPH and placebo, 
respecti ly. In he three tr l that v stigated s imul nt ,  indication was f u that
timulant medication l d  SUD d terioration. 
Planned treatment duration n these trials ranged from 6–16 w k (1 of 4 studies >12 
w eks), a d no u equent exten on s ies were co ucted to i vestigate the long-term 
eff cts of ADHD m dicat n i  t e study samples. He ce, pertaining to adole cents with 
c morbid  a d SU , only ata o  the short-term ffects of ADHD medication are 
vailable to te. We a s ssed th  risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as igh in he studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outco e ata (Table 2). 
Table 2. Risk of bias i  the in l ded s udies on ph rmacologic l interventions. 
Study Bias Arising from/Due to:  
 Rnd Int M s Mea Sel Overall 
Adole cents with ADHD + SUD      
Rigg 11 37
Sz b t, 8 [36] 
Riggs, 2004 [38] 
Thu s e, 2010 [ 9] 
Adolesc wit ADHD     
Pelham, 3 [3 ] 
Fi li g, 0 [27]  
Wilens, 2006 [40]       
Findli g, 2011 [42]   
Sp ncer, 2006 [4 ]       
B stic, 2000 [43]      
Ba g , 2007 [44]      
B an, 2 08 [45]      
Sall 2009 [46]       
Wilens, 2015 [47]      
Ne o n, 2017a [34]       
Newc r 2017b [34]       
Note:         lo  ri k/ igh risk/som  co cerns. Rnd—ra do iz ti  ro es; Int—inten ed 
interven ions; Mis—mi si g utco e dat ; Me — eas reme t of t  outc me; Sel—sel cti  f 
t e report d res lt. 
To concl e, th  vi en e base on pharm c logic l ADHD rea m nt in adoles ents 
with co current ADH  and SUD is limite , with l s than 500 pati nts included across 
our c trolled t ials of a short duratio , ne f which sh wed a robust tr atment eff  
o  eith r ADH r SUD. 
3.2.2. Adolescents with ADHD but with t SUD Comorbidity 
Mos  trials on the efficacy of pharmacological ADHD t atme t in youth h ve been
condu in ixed samples of childr  nd adolescents at n e gro  typica y rangi g 
from 5 to 18 years, without separa e analys s or repor ng of utcomes in the adolescent
subgroup. Our selected literature included a meta-analysis by C rrillo-Urbina et al. (2018) 
of 15 R Ts comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with o exc s  f AEs in a y active me ication gr up c mpare  with lace . 
Adv rs pharmacol gical interactions b tween the st dy medication and the ad lescent’s 
substance use at the same day ere o ly reported in the trial f Riggs et al. (2011) [37], 
and only by four (2.8%) and t ree (2.1%) of e pati ts taking OROS-MPH a d pl c bo, 
respectiv ly. I  the thr e rials that i vesti ate  stimulants, o i icatio  was found that
sti ulant medication led t  SUD deterioration. 
Pl nned treat e t duration n these tr als ra g  from 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequent ext si n studies were conducted to investigate the l ng-term 
effects of ADHD me catio  in t e study samples. He c , pertaining to a ol sce ts with 
comorbid ADHD and SUD, only d ta on the short-term effects of ADHD medication are 
avail ble to date. We ass sed the risk of bias as being low in the studies of Riggs (2011) 
and Thurst ne (201 ),  as high in the tudies of Szobot (20 8) and Riggs (2004), mainly 
due to missing outcome ata (T bl  2). 
Table 2. R k of bias in the ncluded studi s o  ph rmacological interventions. 
Study Bias ris g from/Due to:  
 Rn  In  Mis M Sel Overal  
Adolesc nts with ADHD + SUD      
Riggs, 20 1 [37]      
Szobot, 2008 [36]      
Riggs, 2004 [38]      
Thurst ne, 2 10 [39]    
Adol scents with ADHD      
Pelham, 2013 [33]     
Findling, 2010 [27]      
Wilens, 2006 [40]     
Findli g, 2011 [4 ]      
Spencer, 2006 [41]    
Bo tic, 2000 [43]      
Bang , 2007 [44]      
Bi e m n, 2008 [45]       
Sallee, 2009 [46]      
Wil ns, 2015 [47]      
N wc , 2017  [34]       
Newc rn, 2017b [34]      
Note:          low risk/hi h ri k/some c c rns. R d—randomization proc s; Int—i ended 
interv nti ns; Mis—missing tc m  ata; M —meas reme t of he tc me; S l—selecti n f 
the reported resul . 
T  con lud , the evidence base on pharmacolog cal ADHD treat ent in adolesc n s 
with con urren ADHD an  SUD is li ited, with less t an 500 pati nts included cross 
f r co tr lled trials of a shor duratio , none of which sho ed a robus  treatme t effec  
on either or SUD. 
3.2.2. Ad lescents with ADHD but w hout SU  Co orbidity 
Most trials on the efficacy f pharmacological ADHD treatment in youth h ve been 
con ucted in ixed samples of ch ldren  dolescents at an age grou  typically r nging 
from 5 to 18 years, with t parate a alysis or reporting of utcome  in the ad lescent 
subgroup. Our elected l teratu e included a meta-analysis by Cerrillo-Urbi a et al. (2018) 
of 15 RCTs comp ring timulant and on-stimulant medications with placebo in children 
and adol scents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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stu es, with no exc ss of SAEs in a y a ve i ti group compared with lace .
dv rse pharmacol gical in er cti ns between the st y medic tion and the ad lescent’s 
substance s  at t same day were only report d in the trial of Riggs et al. (2011) [37], 
 only by four (2.8%) and three (2.1%) of the pati ts t king OROS-MPH and placebo, 
r pec ively. In the t ree rials that investigated s imulants, no indication was found that 
stimul t med c ti  led t  SUD deterioration. 
Plan e  tre me t durati n in th e trials ranged from 6–16 w eks (1 of 4 studies >12 
weeks), and n  su sequent exte sion tudies wer  conducted to investigate t e long-term 
eff t  of ADHD medic tion i t e tu y sampl s. Hence, pertaining t  adol scents with 
com rbi  AD D and SU , only d ta on the short-t r effects of ADHD medication ar  
avail bl  to d te. We as ess d the risk of bias as being low in the studies of Riggs (2011) 
a d Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mai ly 
due t  mi sing outcome data (Table 2).
Table 2. Risk of bi s in the include  st dies o  ph rmacological int rventions. 
Study Bias Arising from/Due to:  
Rn I Mis Mea S Ov rall 
A ole cents w th A HD + SUD    
Riggs 11 37
Sz bot, 8 [36] 
Rig s, 2004 [38] 
Th sto , 2010 [ 9]
Adolesc ts wit  ADHD      
P lham, 3 [3 ] 
Findling, 0 [27] 
ilens, 2006 [40]      
Fin li g, 2011 [42]    
S enc r, 2006 [41]     
Bosti , 2000 [43]    
Bangs, 2007 [44]      
Bi d r n, 2008 [45]      
Salle , 2009 [46]    
Wil , 2015 [47]     
N wcor , 2017a [34]      
Newc rn 2017b [34]     
N te:        low isk/high isk/so e co cerns. Rnd—ra do iza ion roc s; Int—i ten ed 
interven i n ; Mis—missi g outco e da ; Mea— asureme t f the utcom ; Sel—sel ction of 
the reported r sult. 
To conclud , the eviden e base on phar cologic l ADHD trea ment in adolescents 
w th concurrent ADHD and SUD is limite , with l ss than 500 pati ts includ d across 
ur co r lle  t ials of a short durati , none f w ich showed a robust treatment eff c  
o  e ther ADHD r SUD. 
3.2.2. A with ADHD but with t SUD Comorbidit  
Most tri ls on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixe samples of child e  and adolescents at an age grou  typically ranging 
from 5 to 18 years, wit out sep r t  nalysi  or repo ting of u comes in the adolescent 
subgroup. Our s lected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimul nt medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studi s, with  excess f AEs in any ac ive medication group compared with l ce .
Adv rs pharm col gical interactions b tween t e st dy medication and the ad lescent’s 
sub tan  s  at the s me day were only reported in e trial of Riggs et al. (2011) [37], 
an  only by f ur (2.8%) and three (2.1%) of the pati nts taking OROS-MPH and placebo, 
pectiv ly. I  the thr e trial that investigated s imulants, no indication was found that 
sti ulant m dication l  t  SUD det rior ion. 
Planned treatment duration these trials ranged from 6–16 weeks (1 of 4 studies >12 
w eks), a d no ubsequent extension studies were conducted to investigate the long-term 
ff ct  of ADHD m d cation y amples. Hence, pertaining to adolescents with 
c morbid ADHD and SU , only data on the short-term effects of ADHD medication are 
av l ble to d te. We asse sed th risk of bias as being low in the studies of Riggs (2011) 
and Thurst ne (201 ),  as hig  in the studies of Szobot (2008) a d Riggs (2004), m inly 
due to i sing outcome data (Table 2). 
Table 2. Ri k of bias in the ncluded studies on ph rmacological interventions. 
Study Bias Arising from/Due to:  
Rnd Int Mis Me  Sel Overall 
A olesc n s with ADHD + SUD       
Riggs 11 37
Sz bot, 8 [36] 
Riggs, 2004 [38] 
Thu st e, 2 10 [ 9] 
Ad lesce ts wit ADHD       
Pelham, 3 [3 ]
Fi dling, 0 [27]
Wilens, 2006 [40]      
Fi dli g, 2011 [42]      
Spencer, 2006 [41]      
Bo ic, 2000 [43]      
Ba g , 007 [44]      
B de man, 2008 [45]      
S llee, 2009 [46]      
Wilens, 2015 [47]     
N w or , 2017  [34]       
Newcor 2017b [34]       
Note:         low risk/hi h ri k/so e co c r s. Rnd—ra omization roc s; Int—inten ed 
interv ion ; Mis—m s ing outc me da ; M a measureme t f the outcome; Sel—sel cti n of 
the reported result. 
To co lude, th  eviden e base n ph macol gical ADHD trea ment in adolescents 
with con urren  ADH  and SUD is li ite , with l s than 500 pati nts included ac oss 
ur co tr lled t i ls of a shor dur tio , none of w i h showed a robust treatment eff c  
on eith r o  SUD. 
3.2.2. Ad lescents with ADHD but with t SUD Como bidity 
M st trials on the efficacy f pharmacological ADHD treatment in youth h ve been 
c n ucted in ixed samples of ch ldren  adolesc nts at an age grou  typically ranging 
from 5 t  18 years, with ut eparate a a ysis r reporti of utcomes in the adolescent 
subgroup. Our el cted l terature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 R Ts co paring stimulant and on-stimulant medications with placebo in children 
and adol scents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
Newco , 2017a [34]
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studies, with no excess of SAEs in any ac ive me ication group compare  with l ce .
Adv rse pharmacol gical interactions between the st dy dication and t  ad lescent’s 
substance se at e same day were only reported in the trial f Ri gs et al. (2011) [37], 
and only by four (2.8%) and thre  (2.1%) of the pati nts taking OROS-MPH an  pl cebo, 
respectively. In the three trials that investigated s imulants, no indication was found that
stimulant medication led t  SUD deterioration. 
Planned tre tment duration in th e trials ranged from 6–16 w eks (1 of 4 studies > 2 
weeks), and no subsequent extension studies were conducted to investigate th  l ng-term 
effects of ADHD medicati n in t e study samples. He ce, pertaini g to a olesce ts with 
comorbid ADHD and SU , o ly data on the short-term effects of ADHD medication are
available to d t . We assessed the risk of bi s as bei g low in the studies f iggs (20 1) 
and Thurstone (2010), and as high in t e studi s of Szobot (20 8) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on ph rmacological interv ntions. 
Study Bias Aris ng from/Due to:  
Rnd Int is M a Sel Over ll
Adolescents with ADHD + SUD       
Riggs 11 37
Szobot, 8 [36] 
Riggs, 20 4 [38] 
Thu sto e, 2010 [ 9] 
Adolescents wit  ADHD       
Pelham, 3 [3 ]  
Findling, 0 [27] 
il s, 2006 [40]       
Findli g, 2011 [42]       
Spencer, 2006 [41]     
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wil s, 2015 [47]       
Newcorn, 2017a [34]      
Newcorn 2017b [34]       
Note:          low risk/high risk/some co cerns. Rnd—ra d mization r c s; Int—int n ed 
interven i ns; Mis—missing outc e dat ; Mea—measureme t f the outc e; Sel—s l ctio  of 
the reported result. 
To conclude, the eviden e base on phar acological ADHD trea ment i  adolescents 
with concurrent ADHD and SUD is limite , with l ss than 500 patients included across 
our controlled t ials of a short duratio , none of which showed a r bust reat nt eff c  
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but with t SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixed samples of children and adolescents at an a e gro  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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studi s, with n  ex ss of SAEs in any c ive edication group compared with lace . 
v rse ph rm col gical interactions between the st dy medic tion a d t e a lescent’s 
ub tan e se t e s me day w re on y reported in h  trial of Riggs et al. (2011) [37],
and only by f ur (2.8%) and ree (2.1%) of th  p ti n s taking OROS-MPH and placebo, 
respecti ly. In he three tr l that v stigated s imul nt ,  indication was f u that 
stimulant medicatio  l d  SUD d terioration. 
Planned tre tment duration n th e tri ls ranged from 6–16 w k (1 of 4 studies >12 
w eks), and no u eque t exten on s ies were con ucted to i vestigate the long-term 
eff cts of ADHD m dicat n in t e study samples. He ce, pertaining to adole cents with 
c morbid  a d SU , o ly at o  the short-term ffects of ADHD medication are
vailable to te. We a s ssed th  risk of bias as being lo  in the studies of Riggs (2011)
and Thurstone (201 ), and s igh in he studies of Szobot (2008) and Riggs (2004), mainly 
due to mi sing outco e data (Table 2). 
Table 2. Risk of bias i  the incl ded s udies on ph rmacological interventions. 
Study Bias rising from/Due to:  
 Rnd I  Mea Sel Over ll 
Adol sce ts with ADHD + SUD       
Rigg , 11 [37]     
Sz b t, 08 [36]      
Riggs, 20 4 [38]      
Thu s , 2010 [ 9]      
Adolesc wit  ADHD      
Pel am, 2013 [33]      
Fin li g, 2010 [27]      
il s, 2006 [40]     
Findli g, 2011 [42]     
S ncer, 2006 [41]       
Bostic, 2000 [43]      
Ba g , 2007 [44]      
B d an, 2 08 [45]      
Sall  2009 [46]       
Wil s, 2015 [47]      
Ne o n, 2017a [34]       
Newcorn 2017b [34]      
Note:         lo  ri k/ igh risk/som  concerns. Rnd—rando iz ti  ro s; Int—inten ed 
interventi ns; Mis—mi si g utco e data; Me —meas reme t of the outc me; Sel—sel ction f 
t e report d result. 
To concl e, th  vi en e base on pharm c logic l ADHD rea m nt in adoles ents 
with co current ADH  and SUD is limite , with l s than 500 pati nts included across 
our c trolled t ials of a short duratio , one f which sh wed a robust tr atment eff  
o  eith r ADH r SUD. 
3.2.2. Adolescents with ADHD but with t SUD Comorbidity 
Mos  trials on the efficacy of pharmacological ADHD t atme t in youth h ve been
condu in ixed samples of childr  nd adolescents at n e gro  typica y rangi g 
from 5 to 18 years, without separa e analys s or repor ng of utcomes in the adolescent
subgroup. Our selected literature included a meta-analysis by C rrillo-Urbina et al. (2018) 
of 15 R Ts comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with o exc ss f AEs i  a y active me ication gr up c p r  with lace . 
Adv rs pharmac l gic l int raction  b t een the st dy medication and the ad lesc nt’s 
substance se at the same day ere o ly reported in the trial f Ri gs et al. (2011) [37], 
and o ly by f ur (2. %) and ree (2.1%) f t e pati ts taking OROS-MPH a  pl c bo, 
respectively. I  the thr e rials that i vestigate  stimulants, o i icatio  was found that
sti ulant medication led t  SUD deterioration. 
Pl nned treat ent duration n these tr als ra g  from 6–16 w eks (1 of 4 studies >12 
weeks), an  no subsequent extensi n studies were conducted to investigate the l ng-term 
ffects of ADHD me catio  in t e study amples. He c , pertaining to a ol sce ts with 
comorbid ADHD and SUD, only d ta on the short-term effects of ADHD medication are 
avail ble to dat . We ass ssed the risk of bias as being lo  in the studies of Riggs (2011) 
and Thurst n (201 ),  as high in the tudies of Szobot (20 8) and Riggs (2004), mainly 
due o missing outcom ata (T bl  2).
Tabl  2. Ri k of bias in the ncluded studi s o  ph r acological interventions. 
Study Bias ris g f om/Due to:  
 R d Int Mis M a Sel Overall
Adol sc nt with ADHD + SUD      
Riggs, 1 ]      
Sz bo , 08 [36]      
Riggs, 04 [38]      
Thu st ne, 2 10 [39]   
Adol scents with ADHD       
Pelham, 2013 [33]     
Find ing, 2010 [27]    
Wilens, 2006 [40]       
Fi dli , 2011 [4 ]       
Spencer, 2006 [41]    
B t , 2000 [43]       
Bang , 2007 [44]      
Bi e m n, 2008 [45]       
Sallee, 2009 [46]      
Wil ns, 2015 [47]      
N wcor , 2017  [34]       
N w orn 2017b [34]      
Not :          low risk/hi h ri k/some c c rns. R d—randomization roc s; Int—i en ed 
interv nti ns; Mis—mi sing utc m  data; M —measureme t f the tc me; S l—s lecti n f 
the reported resul . 
T  con lud , the evidence base on pharmacolog cal ADHD treat ent in adolesc n s 
with con urren ADHD an  SUD is li ited, with less t an 500 pati nts included cross 
f r co tr lled trials of a shor duratio , none of which sho ed a robus  treatme t effec  
on either or SUD. 
3.2.2. Ad lescents with ADHD but w hout SU  Co orbidity 
Most trials on the efficacy f pharmacological ADHD treatment in youth h ve been 
con ucted in ixed samples of ch ldren  dolescents at an age grou  typically r nging 
from 5 to 18 years, with t parate a alysis or reporting of utcome  in the ad lescent 
subgroup. Our elected l teratu e included a meta-analysis by Cerrillo-Urbi a et al. (2018) 
of 15 RCTs comp ring timulant and on-stimulant medications with placebo in children 
and adol scents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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tu , with n  exc s of S Es n a y a ive i ti group compared with lace .
dv rse pharmacol gical in er cti ns etween the st y medic tion and the d l scent’s 
sub tance s  at  same day were nly report d in the trial of Riggs et al. (2011) [37], 
 nly by four (2.8%) and three (2.1%) of the pati ts t king OROS-MPH and placebo, 
r pec ively. In the t r e rials that investigated s imulants, no indication was found that 
stimul t med ti  led t  SUD d teri rat on. 
Plan e  tre ment durati n in th e trials anged from 6–16 w eks (1 of 4 studies >12 
weeks), and n u sequent exte sion tudie  wer  conducted to investigate t e long-term 
eff ct  of ADHD medic tion i t  tu y sampl s. Hence, pertaining t  adol scents with 
com rbi  AD D a d SU , only d ta on the short-t rm effects of ADHD medication ar  
avail bl  to d t . We as ess d the risk of bias as being l w in the studies of Riggs (2011) 
a d Th rst n  (201 ), and as high in th studies of Szobot (2008) and Riggs (2004), mai ly 
due t mi sing outcome data (Table 2).
Table 2. Risk of bi s in the include  st dies o  ph rmacological int rventions. 
Study Bia  Ar in  from/Due o:  
Rn I t Mis Mea Sel Overall 
Adolescents th A HD + SUD   
Riggs 11 37
Sz b t, 8 [36] 
Riggs, 20 4 [38] 
Th sto , 2010 [ 9]
A olesc ts wit  ADH     
P lha , 3 [3 ] 
Findli g, 0 [27] 
il ns, 2006 [40]      
Fin li g, 2011 [42]    
S ncer, 2006 [41]     
Bosti , 2000 [43]    
Bangs, 2007 [44]      
Bi d r n, 2008 [45]      
Salle , 2009 [46]      
Wil s, 2015 [47]      
Newcor , 2017a [34]      
Newc rn 2017b [34]      
N te:       low isk/hig isk/so e co cerns. Rnd—ra domiza i n roc s; Int—i ten ed 
interve i n ; Mis—missing outco e da ; Mea— easur  f the utcome; Sel—sel ction of 
the reported r sult. 
To conclud , the eviden e base on phar cologic l ADHD trea ment in adolescents 
w th concurrent ADHD and SUD is limite , with l ss than 500 pati ts includ d across 
ur co r lle  t ials of a short durati , none f w ich showed a robust treatment eff c  
o  e ther ADHD r SUD. 
3.2.2. A with ADHD but with t SUD Comorbidit  
Most tri ls on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixe samples of child e  and adolescents at an age grou  typically ranging 
from 5 to 18 years, wit out sep r t  nalysi  or repo ting of u comes in the adolescent 
subgroup. Our s lected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimul nt medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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stu es, with n  excess of SAEs n a y ac ive dic tion group compared with lace .
dv rse p armacol gical inter ctions etw e  the st dy medic tion and the d l scent’s 
sub tance s  at e same day were nly reported in the trial of Riggs et al. (2011) [37], 
a d nly by f ur (2.8%) and three (2.1%) of the pati nts taking OROS-MPH and placebo, 
r p ctively. In the r e tri ls that investigated s imulants, no indication was found that 
stimul t med ation led t  SUD d teri rat on. 
Plann  tre tment duration in th e rials anged from 6–16 weeks (1 of 4 studies >12
weeks), and n su sequent exte sion studie  ere conducted to investigate the long-term 
eff ct  of AD D medicatio  i t  tu y samples. Hence, pertaining t  adolescents with 
c m rbi  AD D and SU , only a  on the short-term effects of ADHD medication ar  
avail bl  to d te. We assessed he risk of bias as bein l w in the studies of Riggs (2011) 
a d Th rst n  (201 ), and s high in th  studies of Szobot (2008) and Riggs (2004), mai ly 
due t mi sing ou come data (Tab e 2).
Table 2. Ri k of bi s in th  includ d st dies on ph rmacol gi al int rv ntions. 
Study Bia  Ar in  fro /Due o:  
Rn  I t Mis Mea Se  Overall 
Adolescents wit  A HD + SUD   
Riggs 11 37
Szob t, 8 [36] 
Rig s, 20 4 [38] 
Th sto , 2010 [ 9]
A olesc ts wit  ADH      
P lham, 3 [3 ] 
Findli g, 0 [27] 
il s, 2006 [40]       
Fin ling, 2011 [42]     
Sp cer, 2006 [41]     
Bosti , 2000 [43]    
Bangs, 2007 [44]       
Bi rm n, 2008 [45]       
Salle , 2009 [46]       
Wil s, 2015 [47]       
Newcor , 2017a [34]      
Newc rn 2017b [34]       
N te:        low isk/hig risk/some co cer s. Rnd—ra domiza i n roc s; Int—i ten ed 
interve i n ; Mis—missing dat ; Mea—measur  f the utcome; Sel—sel ction of 
the reported r sult. 
To onclud , the eviden e base o  phar acological ADHD trea ment in adolescents 
w th concur t ADHD and SUD is limit , wi h l ss than 500 patients includ d across 
ur co r lle  t ials of a sh rt durati , no  w ich showed a robust treatment eff c  
o  e her ADHD r SUD. 
3.2.2. A with ADHD but with t SUD C morbidity 
M st trials on the fficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixe  s mpl s of childre  and dolescents at an age grou  typically ranging 
from 5 to 18 years, wit  separ te analysis or reporting of utcomes in the adolescent 
subgroup. Our selected lit ature includ d a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs compar ng stimulant and n n-stimulant medications with placebo in children 
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t dies, with n  exce s of SAEs in any active medicatio  group c mp r  wi h p acebo. 
Adv rse pharmacological interactions b tween the stu y dicat o  and th  d l s e t’s 
substance use at the same day were only ported in the rial of Riggs l. (2011) [37],
and only by four ( .8%) and three (2.1%) of the patients taking O OS-MPH an  p ac bo, 
resp ctively. In the three tri ls that investig ted stimula ts, no i icat  was fo d that 
stimulant m dication led to SUD deteri ration. 
Planned treat ent durat on in these trials ranged fr 6–1 week  (1 of 4 es >1  
we ks), and o s bsequent extension stu ies were co ucted o inves igate the l -ter
effects of ADHD medication in the study samples. Hence, pertaining to adolescent wit  
comorbid ADHD and SUD, only data on h  short-term effects of ADHD medicatio  ar  
available to ate. We ass ssed the risk of bi s as being l w in th  st dies f Riggs ( 1 )
and Thurstone (2010), and s high in the studies of Sz b t ( 8) and Riggs ( 4), mainly
due to missing outcom  data (Table 2). 
Table 2. Risk of bias in the included studies on phar acological interv ti ns. 
Study Bias Arisi g from/Du  to: 
 Rnd Int Mis M a Sel Overall 
Adolesc ts with ADHD + SUD       
Riggs, 2011 [37]   
Sz bot 8 36      
Riggs, 2004 [38]     
Thurst e, 2 10 [39]      
Adolescents with A HD      
Pelham 3 33       
Findling 0 [27]      
Wilens, 6 [ 0]      
Findling, 2011 [42]       
Sp cer, 2006 [41]     
Bostic, 20 0 [43]      
Bangs, 2007 [44]       
Bie rman, 2008 [45]      
S ll e, 2009 [46]      
Wilen , 2015 [47]     
Newcorn, 2017a [34]      
New orn, 2017b [34]       
Not :          low risk/high risk/s me onc rns. Rnd—randomizatio  p oc s; Int—inte ded 
interventions; Mis—missing tcome data; Mea—meas re ent of the utcome; Sel—selectio  of 
the rep rted result. 
T  c nclude, the evidenc ase on pharmac log al ADHD reat in d lesce ts 
with c ncurrent ADHD and SUD is imited, wi h less than 5 0 patien s included ross 
four controlled trials of a short duratio , one f which showe  a r bust trea ment ffect 
o  either ADHD or SU . 
3.2.2. Adolescents with ADHD but without SUD o orbidity 
M st trials on e efficacy of pharmacological ADHD t eatme t i youth have be  
conducted in mixed sampl s of children and adolescents at an ag  gr u  typical y ranging 
from 5 to 18 years, without separate analysis or reporti g of utc es i  the ad le cent 
subgroup. Our elected literature included a meta-analysis by Cerrillo-Urbina t al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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Adolescents with ADHD       
Pelham, 2013 [33]      
Findli g, 2010 [27]       
Wilens, 2006 [40]     
Findli g, 2011 [42]     
Spencer, 2006 [41]    
Bostic, 2000 [43]      
Bangs, 2007 [44]      
Biederman, 2008 [45]   
Salle , 2009 [46]    
Wilen , 2015 [47]  
Newc rn, 2017a [34]       
Newcorn, 2017b [34]      
Note:          l w risk/high risk/some concerns. Rnd—randomiz ti  proc s; I t—intend  
interventions; Mis—missing outcome data; Mea—measurement of e utc me; Sel—sel ctio
the reported result. 
To conclude, evid c  bas on pharmacologic l ADHD rea me t in doles nt
with concurrent ADHD and SUD is li ited, with less th n 500 pati n s includ d cross 
four controlled tri ls f a short durati n, none of which how  a r bust trea m nt eff  
on either ADHD o  SUD. 
3.2.2. Adolesce ts with ADHD but without SUD Co orbi ity 
Most trials on th  efficacy of pharm cological ADHD t e tment in youth have bee  
conducted in mixed samples of children and dol sce ts at an ge g up typically ranging 
from 5 to 18 years, witho t parate analysis or reporting of utcome  in th  adolescent 
subgroup. Our selected literatu e included a meta-analysis by Cerrillo-Urbi a et al. (2018) 
of 15 RCTs comp ring timulant and non-stimulant medica ions with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
low risk/high r sk/s m on erns. Rnd—ran omization proc ; I t intend d in erven ions; Mis—missing outc e
data; M a—measurem nt of the outcome; Sel selection of the reported result.
To co c e, t evidence b se o phar c logical ADHD tr at ent i dolescents
wi h co u rent ADHD a d SUD is li ite , w th le s than 500 pati nts inc u d across
f r controll d trials f a rt duration, one f w c showed a robust treatment ffect
o eith r ADHD or SUD.
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3.2.2. Adolescents with ADHD but without SUD Comorbidity
Most trials on the efficacy of pharmacological ADHD treatment in youth have been
conducted in mixed samples of children and adolescents at an age group typically ranging
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018)
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents
only. The pooled standardized mean effect size (SMD; equal to Cohen’s d) of the three
adolescent studies of stimulant medications on ADHD symptoms was 0.66, with substantial
heterogeneity (I2 = 77%; p = 0.01), and the SMD of the one non-stimulant medication was
0.52. We included all four adolescent studies from this meta-analysis in our review below.
In our literature search, we found 12 trials in adolescents with ADHD without SUD
comorbidity that met our selection criteria. Five of these involved MPH [27,33,34,40], one
study involved lisdexamfetamine (LDX) [42], one study involved mixed amphetamine
salts extended release (MAS-XR) [41], two studies were about pemoline (one of which
compared both pemoline and MPH with placebo) [33,43], one study used atomoxetine [44],
and three studies tested the effect of guanfacine [45–47] (Table 1). From these, six studies
required a minimum ADHD symptom severity to be included [34,42,44,46,47], six studies
excluded patients with a history of non-response to the study medication or to stimulants
prior to study entry [27,34,40–42], and one study required a favorable response to the
study medication in the open-label titration phase to be included in the double-blind study
phase [40].
With the exception of one pemoline study [33] and the adolescent subgroups in
two guanfacine studies [45,46], all studies reported significant improvements in ADHD
symptoms in the active medication compared with the placebo groups, with moderate to
large effect sizes of Cohen’s d = 0.53–1.33 for MPH, d = 0.80–1.23 for LDX, d = 0.80 for
MAS-XR, d = 2.05 for pemoline, d = 0.99 for atomoxetine, and d = 0.52 for guanfacine
(Table 1).
As in adolescents with ADHD and SUD, AEs and/or TEAEs generally occurred more
often in patients in the active medication groups. The most reported AEs in the studies
that investigated stimulants were decreased appetite and weight loss, headache, irritability,
insomnia, and abdominal pain. Atomoxetine treatment was associated with decreased
appetite and weight loss, nausea, dizziness, and diarrhea, and guanfacine treatment was
associated with insomnia, sedation, fatigue, and abdominal pain. In all studies, most AEs
were mild to moderate in intensity. Changes in ECG parameters, pulse rate, and blood
pressure were more prevalent in nearly all active medication groups, but were judged as
not clinically meaningful in all studies. The SAEs in the active medication groups were
absent or rare (≤1 SAE) in all studies.
Planned treatment duration of the double-blind phase in these studies ranged from
2–13 weeks (1 of 12 studies >12 weeks). Open-label extension studies to the previous
trials in adolescents have been conducted for MPH [27,49], LDX [40], MAS-XR [40,41], and
atomoxetine [44], with follow-up periods ranging from 2–12 months. In these follow-up
studies, efficacy was maintained, and side-effects and tolerability were consistent with those
found in the antecedent, controlled studies. However, we cannot draw firm conclusions
about the long-term safety and efficacy of these medications from these studies, due to their
open-label character and given that only a selection of subjects of the antecedent studies
participated in these follow-up studies.
We rated the risk of bias as low in the randomized studies of Findling et al. (2011) [42],
Newcorn et al. (2017b) [34], and Spencer et al. (2006) [25], and as high in all other studies
(Table 2).
To conclude, 12 randomized trials with a total of more than 2600 adolescent patients
with ADHD without SUD comorbidity show robust, moderate-to-large effects on ADHD
symptoms of both stimulant and non-stimulant medications compared with placebo.
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3.3. Childhood ADHD and Later SUD
We also reviewed the literature on childhood ADHD as a risk factor for develop-
ing SUD in adolescence and early adulthood, as well as the literature on the effect of
pharmacological ADHD treatment for children on the development of later SUD.
3.3.1. Childhood ADHD and the Risk of Later SUD
To evaluate the association between childhood ADHD and the risk of develop-
ing a SUD during adolescence or early adulthood, we reviewed four (partly overlap-
ping) meta-analyses of longitudinal studies that compared children with and without
ADHD [1,2,50,51], and two large-scale (n = 547 to 1017) prospective cohort studies [51,52].
In all four meta-analyses, childhood ADHD was associated with an increased risk of
SUD in adolescence or early adulthood, compared with non-ADHD controls, with mean
odds-ratios (OR) ranging from 1.34 to 3.48 (small-to-moderate association) for different
types of SUD. In the prospective case-control study of Groenman et al. (2013) [52], child-
hood ADHD was associated with an increased risk of developing SUD in adolescence,
and with a hazard ratio (HR) of 1.77 compared with the healthy controls. Risk of SUD
was the highest in children with concurrent ADHD and CD, but children without the CD
comorbidity were still at increased risk. In the Multimodal Treatment Study of Children
with ADHD (MTA) [53], childhood ADHD was associated with more frequent use of
cigarettes and cannabis in young adulthood, but no differences were found for alcohol or
illicit drug use.
3.3.2. Stimulant Treatment of Childhood ADHD and the Risk of Later SUD
In the first meta-analysis of six longitudinal studies on the association between (mostly
stimulant) pharmacotherapy for childhood ADHD and later risk of SUD in adolescence or
early adulthood, Wilens et al. (2003) found a significantly lower risk of later SUD (mean
OR = 1.9) in ADHD-children who had received stimulant treatment compared with those
who had not [54].
However, in the meta-analysis of 15 longitudinal studies by Humphreys et al. (2013),
the studies on ADHD-children with and without stimulant medication showed inconsistent
outcomes with positive, neutral, and negative outcomes, but overall, they had a similar
risk of developing SUD later in life [55]. Moreover, this review did not consider possible
differences in ADHD-severity and comorbid CD between ADHD children that were or
were not treated with stimulants.
We also reviewed four prospective cohort studies that were published after Humphreys’
meta-analysis. Molina et al. (2013) compared children in the MTA-cohort with high versus
low exposure to stimulant treatment and found no indications for a harmful or beneficial
effect of treatment for developing SUD in adolescence [56]. In a prospective follow-up
study by Groenman et al. (2013), stimulant treatment of childhood ADHD was associated
with a lower risk of later SUD, but not of nicotine dependence, even after controlling for
comorbid CD (HR = 1.91) [57]. Dalsgaard et al. (2014) prospectively followed children and
adolescents with ADHD and found that those with later vs. earlier stimulant treatment ini-
tiation had a higher risk of developing SUD in adulthood (HR = 1.46) [58]. Groenman et al.
(2019) distinguished three mutually exclusive subgroups of ADHD-children with distinct
stimulant medication trajectories and found that a stimulant treatment profile characterized
by an early start, high dose, and long duration was associated with a reduced risk of SUD
in adolescence [59].
Lastly, we reviewed two large health care registry studies that investigated the longitu-
dinal association between stimulant ADHD medication and later substance-related events
(e.g., death, crime, and emergency department visits). Chang et al. (2014) studied linked
national registers that included nearly 39,000 patients with ADHD, and found stimulant
ADHD medication to be associated with a 31% lower rate of substance-related events three
years later. Moreover, a longer duration of medication was associated with lower rates
of events [60]. Quinn et al. (2017) conducted within-individual analyses of registered
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health care data from nearly three million individuals with ADHD and found that ADHD
medication—mostly stimulants—was associated with a 14 to 19% reduction in the odds
of an SUD-related emergency department visit two years later, with the largest reduction
among adolescents [61].
Taken together, we conclude that (1) childhood ADHD is a serious risk factor for
developing SUD in adolescence and early adulthood, (2) studies strongly suggest that
stimulant treatment of childhood ADHD does not increase the risk of developing SUD in
adolescence, and (3) stimulant treatment of childhood ADHD may have a protective effect
on the development of SUD in adolescence and early adulthood. The overall effect size
of the reduced risk is probably small, but one of the studies suggests that an early start of
stimulant treatment with adequate doses is associated with a moderate to large protective
effect. It should be noted, however, that a naturalistic prospective study—which is probably
the only suitable and feasible method to study the long-term effects of stimulant treatments
in children with ADHD—does not allow for causal inferences and may be affected by
unmeasured confounders [59].
3.4. Psychosocial Interventions
Psychosocial interventions to treat ADHD include CBT and behavioral therapeutic
approaches, motivational interviewing (MI), psychoeducation, parent training, and training
to improve planning, organizational skills, social skills, and academic/homework skills.
These interventions can be aimed at adolescents themselves or at their social environment
(e.g., parents) and effects are often evaluated across different targets, settings, and outcome
measures, including ADHD symptoms, social, planning and organizational skills, academic
performance, etc.
3.4.1. Adolescents with Concurrent ADHD and SUD
There are no meta-analyses or RCTs on the efficacy of psychosocial treatments in
adolescents with concurrent ADHD and SUD.
3.4.2. Adolescents with ADHD but without SUD Comorbidity
Our literature search on psychosocial interventions yielded 13 trials, with 1812 par-
ticipants (range 46–326) fulfilling our selection criteria (Table 3). Five studies examined
psychosocial interventions provided to students with ADHD in a school setting [62–66] and
eight studies tested psychosocial interventions in a clinical setting [67–74]. The studies in-
cluded family-focused parenting interventions or adolescent-focused cognitive behavioral
and/or MI-based interventions either with or without a parent component. All interven-
tions targeted ADHD symptoms, as well as social, organization, planning, and academic
skills. We rated risk of bias (ROB 2, see Table 4) as high for 10 studies and as having “some
concerns” for three of the 13 studies. The main sources of bias were lack of blinding, no
independent outcome assessors, no predefined analysis and primary outcome measure,
and missing outcome data.
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Table 3. Controlled studies (n > 40) of psychosocial treatment in adolescents with ADHD published since 2000.
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In five of the six trials with a non-active control condition (waiting-list control group),
participants in the intervention group showed stronger post-treatment improvements in
ADHD-symptoms compared with participants in the control group [62–65,73,74]. In con-
trast, seven of the nine studies that included an active control condition (e.g., treatment
as usual) did not find any differences in ADHD symptom ratings between the interven-
tion and the control treatment [65,67–72]. Limitations of the reviewed studies include
the large variation in concomitant medication use and the lack of control of additional
psychosocial interventions, which are likely to confound the study outcomes. Furthermore,
studies showed great diversity in the setting, content, intensity, and duration (if reported)
of treatment.
In sum, randomized trials of psychosocial treatment in adolescents with concurrent
ADHD and SUD are non-existent, and the results from psychosocial trials in ADHD ado-
lescents without concurrent SUD are mixed, suggesting that some benefit from treatment
when compared with non-active control conditions, but no benefits compared with active
control treatments. Between-study heterogeneity was high and the overall study quality
was low. Hence, the evidence on psychosocial treatment in ADHD adolescents—with
or without concurrent SUD—does not allow for conclusions about which treatments are
(most) effective and should be preferred.
Table 4. Risk of bias in the included studies on psychosocial and complementary intervention.
Bias Arising from/Due to: Rnd Int Mis Mea Sel Overall
Psychosocial Interventions
1 Barkley, 2001 [67]
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w ek ), and n  subs quen  xt n ion studies were conducted to investigate the long-term 
eff cts of ADHD medication in th  tudy samples. Henc , pertaining to adolescents with 
c morbid ADHD and SUD, nly ata on th  short-t rm eff cts of ADHD medication are 
vail le t  date. We as ess d the risk of bias s being low in the studies of Riggs (2011) 
a d Th rst e (2010), a d as high i  the studies of Szobot (2008) and Riggs (2004), mainly 
due to issing utc me data (Table 2). 
T ble 2. Risk of bias in the included studies on pharmacological interventions. 
St dy Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolesce ts with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
N te:          l w risk/high risk/some concerns. Rn —randomization proces; Int—intended 
interv ntions; Mis—missing outcom  data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To con lude, the evidence bas  on ph rmacological ADHD treatment in adolescents 
with concurrent and SUD is l mit , with le s than 500 patients included across 
four cont lled trials of a shor  duration, one of which showed a robust treatment effect 
o  either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth have been 
onducted in mixed s mples of childr  nd adolescents at an age group typically ranging 
from 5 o 18 y ars, without se rat  nalysis or reporting of outcomes in the adolescent 
subgr up. Our s lect d literature included a meta- nalysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing s mulan  and non-stimulant medications with placebo in children 
and dolescents with ADHD [48]. Only four of hese, 15 trials focused on adolescents only. 
2 Boyer, 2015 [68]
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studies, with no excess of SAEs in any active medication group compared with placebo. 
Adverse pharmacological interactions between the study medication and the adolescent’s 
substance use at the same day were only reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the patients taking OROS-MPH and placebo, 
respectively. In the three trials that investigated stimulants, no indication was found that 
stimulant medication led to SUD deterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequent extension studies were conducted to investigate the long-term 
effects of ADHD medication in the study samples. Hence, pertaining to adolescents with 
comorbid ADHD and SUD, only data on the short-term effects of AD D medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the incl ed studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]      
Note:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
interventions; Mis—missing outcome data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, the evidence base on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patients included across 
four controlled trials of a short duration, none of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth have been 
conducted in mixed samples of children and adolescents at an age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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studies, with no excess of SAEs in any active medication group compared with placebo. 
Adverse pharmacological interactions between the study medication and the adolescent’s 
substanc  use at the sam  day were only reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) nd three (2.1%) of the patients taking OROS-MPH and placebo, 
r spectively. In the three trials that investigated stimulants, no indication was found that 
stimulant medication led to SUD deterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequent extension studies were conducted to investigate the long-term 
effects of ADHD medication in the study samples. Hence, pertaining to adolescents with 
comorbid ADHD and SUD, only data on the short-term effects of ADHD medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due t  missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on ph rm cological int rve tions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]      
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findl ng, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
No e:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
interventions; Mis—missing outcome data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclu e, th  evidence base on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is limited, with less than 500 patients included across 
four controlled trials of a short duration, none of which showed a robust treatment effect 
on either ADHD r SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth have been 
conducted in ixed samples of children and adolescents at an age group typically ranging 
from 5 to 18 yea s, without sep rate analysis or reporting of outcomes in the adolescent 
subgroup. O r selected liter ture included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J. Clin. Med. 2021, 10, x FOR PEER REVIEW 12 of 34 
 
 
studies, with no excess of SAEs in any active medication group compared with placebo. 
Adverse ph rmacological interactions betwee  t  study medication and the adolescent’s 
su stance use a  the same day were only reported in the trial of Riggs et al. (2011) [37], 
nd only by four (2.8%) and thr e (2.1%) of the patie ts taking OROS-MPH and placebo, 
respectively. In the three trials hat investigated stimulants, no indication was found that 
stimulant medication led to SUD deterioration. 
Plann d treatm nt uration in these trials rang  from 6–16 w eks (1 of 4 studies >12 
weeks), and no subs quent xtension studies were conducted to investigate the long-term 
eff c s of ADHD m dica ion n the study samples. Hence, pertaining to adolescents with 
comorbid ADHD and SUD, only dat  on th  short-term effects of ADHD medication are 
available o ate. We as essed the risk of bias as being low in the tudies of Riggs (2011) 
and Thurstone (201 ), and s high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studie  o  ph rmacological inter ntions. 
Study Bias Arising from/Du  to:  
 Rnd Int Mis Mea Sel Overall 
Adol cents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurs one, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Bi derman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:         low r sk/high risk/some concerns. Rnd—randomization proces; Int—intended 
interventions; Mis—missing outcome data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, t e evidence bas  on pharmacological ADHD treatm nt in adolescents 
with concurrent ADHD and SUD is limited, wi h less th n 500 patien s i clud d acr ss 
f ur cont lled trials of a short duration, none of which showed a robust treatment effect 
o  either ADHD or SUD. 
3.2.2. A olescents with ADHD but without SU  Comorbidity 
Most tr als n the efficacy of pharmacologic l ADHD t eatment in outh have been 
c ducted in mixed samples of children and adolescents at an age group typically ranging 
fr m 5 to 18 years, without separate analysis or reporting of utcomes in the adolescent 
ubgr u . Our selected iterature included a eta-analysis by Cerrillo-Urbina et al. (2018) 
f 15 RCTs comparing stimula t and non-stimulant medications with placebo in children 
nd adol sce ts with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with no excess of SAEs in ny active medication group compared with placebo. 
Adv rse pharmacologi l nteractions b tween the study medication and the adolescent’s 
substance us  at the same day were ly reporte  in the trial of Riggs et al. (2011) [37], 
nd only by four (2.8%) and th ee (2.1%) of the patients taking OROS-MPH and placebo, 
resp ctively. In the three trials th t i vestigated stimulants, no indication was found that 
stimula t medication led to SUD deterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequen  exten ion studies were conducted to investigate the long-term 
effects of ADHD medication in the study samples. Henc , pertaining to adolescents with 
comorbid ADHD and SUD, nly data on the short-t rm effects of ADHD medication are 
vaila le t  date. We assess d the risk of bias as being low in the studies of Riggs (2011) 
and Th rst ne (2010), a d as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outc me data (Table 2). 
Table 2. Ri k of bias in the includ d studies on ph rmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolesce ts with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Fi dling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
N te:          low risk/high risk/some concerns. Rn —randomization proces; Int—intended 
interv ntions; Mis—missing outcome data; Mea—measurement of the ou come; Sel—selection of 
the reported result. 
To con lude, the evidence base on ph rmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is l mite , with le s than 500 patients included across 
four controlled trials of a short duration, ne of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatm nt in youth have been 
o ducted in mixed s mples of childr  and adolescents at an age group typically ranging 
from 5 to 18 y ars, without separat  analysis or reporting of outcomes in the adolescent 
subgroup. Our select d literature included a meta- nalysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing s mulan  and non-stimulant medications with placebo in children 
and dolescents with ADHD [48]. Only four of hese, 15 trials focused on adolescents only. 
3 Evans, 2007 [62]
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studies, with no excess of SAEs in a y active me ication gr p compare  with lace . 
Adv rse pharmacological interactions b twe n the st dy m dic tion and the ad lescent’s 
substance use at the same day were only reported in the trial of Riggs t al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of th  pati nts taking OROS-MPH and pl c bo, 
respectively. In the thre  trials that inv stig te  stimula ts, o indicatio  was found that 
stimulant medication led t  SUD deterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (1 f 4 studies >12 
weeks), and no subs quent extension studies were conducte  to investigate the long-term 
effects of ADHD medication in t e study samples. Hence, pertaining to adolescents with 
comorbid ADHD and SUD, only data on the short-ter  effects of ADHD medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 nd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]      
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD      
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]      
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:          low risk/high risk/some concerns. Rnd—randomizatio  proces; Int—intended 
interventions; Mis—missing outcome data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, the evidence base on p armacological  treatment in adolesce ts 
with concurrent ADHD and SUD is limited, with less than 500 patient  included across 
four controlled trials of a short duration, none f which show d a obust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but witho t SUD Comorbidi y 
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixed samples of children and adolescents at an age grou  typically rangi g 
from 5 to 18 years, without separate an lysis or reporting of utcomes in th  adolesc nt 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studi s, with o exc s  of SAEs in ny activ  me ic tion gr  compare  with l c . 
Adv rse pharma ologi l interactions b tween e st dy medicatio  and the ad lescent’s 
substance use  th  sam  da ere ly repor e  i  t  tr al of Riggs et l. (2011) [37], 
nd only by four (2.8%) and th e (2.1%) f the pati nts taki  OROS-MPH and plac bo, 
resp ctiv ly. In th  thr  trials that i v stigated stimul ts, no indicatio  wa found that 
s imula t medicati n led t  SUD deterioration. 
Planned treatment duration in th se ri ls ra g d from 6–16 w eks (1 of 4 stud es >12 
weeks), nd no su s qu nt xtension stu ies were onducte  to inv stigate th  long-term 
effects of ADHD medic tion in t  study amples. Henc , pertaining o ad lescents with 
comorbid ADHD a d SUD, only data on the short-ter  effects of ADHD medicatio  are 
available t  dat . We assess d the risk of bias s being low in the studies of Riggs (2011) 
and Thurst ne (2010), a d as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outc me data (Table 2). 
Table 2. Risk of bias in the included studies on pharmacological interve tions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolesce ts with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 20 8 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]      
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sall e, 2009 [46]       
Wile s, 2015 [47]       
Newcorn, 2017  [34]       
Newcorn, 2017b [34]      
Note:          low risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
interventions; Mis—missing utcome data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To c lude, the ev dence base on ph rmacological  treatment in adol scents 
with concurrent  and SUD is limited, with less than 500 patients included across 
four controlled trials of a short duration, one of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on th  efficacy f phar c logical ADHD tre tment in youth h ve een 
onducted in ixed sample  of child  a d lesce ts at an ge grou  t p cally rangi g 
from 5 to 18 years, wi hout eparat  a lysis r reporti g of utcome in t  ad lescent 
subgroup. O select d literature inclu ed a meta- nalysis by Cerrill -Urbin  et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and dolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studi s, with o xc ss of SAE in y ac v  medication group com red with l c . 
Ad rse harmacolo cal interactions b tween th s y m dic tio  a  t e ad lescent’s 
ubs ance se t  sam  d y wer  only repor ed in the trial of Riggs t l. (2011) [37], 
and only by four (2.8%) and thr e (2.1%) of th  pati nts taking OROS-MPH and pl cebo, 
respectively. In th r  trials at inv stig te stimul ts, o indication w found that 
t mula t edicatio l d t  SUD det ri ration. 
Pl ed treatm nt durati n in thes  trials ranged from 6–16 weeks (1 f 4 tudies >12 
week ), and no subs que t xtension stu es w re co duc ed investi at  the long-term 
eff cts of ADHD medication in t  study samples. He ce, p rtaining o dolescents with 
comorbid ADHD  SUD, only ata on the shor -term effects of ADHD m dication are 
av ilable t  date. We assessed the ri k of bias as being low in the studies of Riggs (2011) 
a d Thursto e (2010), a d as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to issing utcom  data (Table 2). 
Table 2. Risk of bias in the included studies on ph rmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Se  Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
A olescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Ne corn, 2017a [34]       
Newcor , 2017b [34]       
Note:         low ri k/high risk/some concerns. Rnd—rand mization proces; Int—intended 
int rventions; Mis—missing outcome data; Mea—measurement of th  outcome; Sel—selection of 
t e reporte  result. 
To con lude, th  ev dence bas n p rma ological A HD treatment in adol scents 
with concurre t  and SUD is limit d, with less tha  500 pati nts i cluded across 
four contr lled trials of a hort duration, none f which showed  robust tr atment ffect 
 either A HD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on th  efficacy f p rm cological ADHD treatment in youth h ve been 
c nducted i  ixed s mples of hildr d a olescents at an age grou  typically ranging 
from 5 t  18 y ars, without se rate lysis r r porting of utcom in t  a olesc nt 
s bgr up. Our selected lit rature included a meta-an lysis by Cerrill -Urbina et al. (2018) 
of 15 RCTs co paring stimulant and non-stimulant medications w th placebo in children 
a d adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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s udi s, with o exc ss of SAEs i  a y c v  m dication group com red with placebo. 
Adverse pharmacolog cal inter tions betwee  the s u y me ication a  t e adolescent’s 
s bst nce use at th  sam d y w re only reported i the tri l f Riggs et al. (2011) [37], 
d only by four (2.8%) d thr e (2.1%) of the patients taking OROS-MPH and placebo, 
r sp c ively. In the re t l a  i vestig ted stimulants, o in ication w s found that 
stimula t me i ti l d to SUD det rioration. 
Pl ed treatment duration in es  trials ra ged from 6–16 weeks (1 of 4 tudies >12 
w eks), and o s bsequ t x en ion s udies w r  co duc ed investi at  the l ng-term 
effects of ADHD me ication in th study samples. He , p rtaining to dolescents with 
c morbi ADHD  SUD, only data on the shor -term effects of ADHD m dication are 
av ilabl  t  date. We assessed the ri k of bias as being low in the studies of Riggs (2011) 
and T urstone (2010), a d as high in the stu ies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcom  data (Table 2). 
Table 2. Ri k of bias in the included studi s on pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Se  Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
A olescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
B stic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sall e, 2009 [46]       
Wile s, 2015 [47]       
N corn, 2017a [34]       
New rn, 2017b [34]       
Note:        low i k/high risk/s e concerns. Rnd—rand mization proces; Int—intended 
interventions; Mis—missing o tcome data; Mea— easurem nt of th  outcome; Sel—selection of 
the reporte  result. 
To conclude, the evide ce bas n p armacologic l ADHD treatment in adol scents 
with concurre t A HD an  SUD is limited, with less tha  500 pati nts included across 
four co r lled trial  of a short duration, none f which sho ed  robust tr atment effect 
on eit er A HD or SUD. 
3.2.2. Adolesce ts with ADHD but without SUD Comorbidity 
M st rials on the fficacy f ph rm c l gical ADHD tr tment in youth have been 
c nducted in ixed s mpl s of hildr a d adolescents at age group typically r nging 
from 5 t  18 years, withou  separa analys s r r porting of outcom s in the a olescent 
s bgro p. O r selecte  literatur  ncluded a meta-a lysis by C rrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and non-st mulant medicat ons w th placebo in children 
a d adolesce ts with ADHD [48]. Only four of these, 15 trial focused on adolescents only. 
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studies, with o excess of SAEs in any activ  m dication group om ared with l c . 
Adverse pharmacological interactions betwee  t  st y medication a  t e ad lescent’s 
su stance use at the sam  day were only rep rted in the trial of Riggs et al. (2011) [37], 
and o ly by four (2.8%) and three (2.1%) of the pati nts t ki g OROS-MPH and placebo, 
resp ctively. In th  thre  trials that investigated stimulants, no indication was found that 
stimulant medication led t  SUD et rioration. 
Pla ned treatment duration in these trials rang  fr m 6–16 w eks (1 of 4 studies >12 
w eks), and no subs qu n  ext sio  studies were c nducted t  investigate the long-term 
effects of ADHD medication in t  tu y samples. e c , pertaining to dolescents with 
c morbid ADHD nd SUD, only at  on th  short-term effects of ADHD m dication are 
avail ble to date. W  assesse  the risk of bia  as bein  low in the tudies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
T ble 2. Risk of bias in the included studies o  ph rmacological interventions. 
St dy Bias Arising from/Du  to:  
 nd Int Mis Mea Sel Overall 
Adole cents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurs one, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilen , 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederm n, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn, 2017b [34]       
Note:          l w risk/high risk/some concerns. Rnd—randomization proces; Int—intended 
interventions; Mis— issing outcom  data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, the evide ce ba  on pharmacological ADHD treatment in adolescents 
with concurrent ADHD and SUD is limited, with le s t n 500 patients i cluded across 
four contr lled tri ls of a shor  durati n, none of which showed a obust treatm t effect 
on either ADHD or SUD.
3.2 2. Adol sc nts with ADHD but witho t SU  Comorbid ty 
Most trials on th  efficacy of ph rmacologic l ADHD t eatment in outh h ve bee  
c ducted in ixed s mples f childre  a d dolescents at an age grou  typically ranging 
from 5 o 18 years, without s p rat  a al sis or repo ting of utcomes in th  adolescent 
subgr u . Our s lected literature included a eta-an lysis by Cerrillo-Urbin  et al. (2018) 
f 15 RCTs comparing stimulant and no -stimulant medicatio s with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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w ek ), nd no subs qu  exten ion stud es were onducted to investigate the long-term 
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and Th rst ne (2010), a d as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to issing outc me data (Table 2). 
T ble 2. Risk of bias in the includ d studies o  ph rmacological interventions. 
St dy Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolesce ts with ADHD + SUD     
Riggs, 2011 [37]     
Szobot, 2008 [36]     
Riggs, 2004 [38]     
Thurstone, 2010 [39]     
Adolescents with ADHD     
Pelham, 2013 [33]     
Findling, 2010 [27]     
Wilens, 2006 [40]     
Findling, 2011 [42]     
Spencer, 2006 [41]     
Bostic, 2000 [43]     
Bangs, 2007 [44]     
Biederman, 2008 [45]     
Sallee, 2009 [46]     
Wilens, 2015 [47]     
Newcorn, 2017  [34]     
Newcor , 2017b [34]     
N te:         l w risk/high isk/so e concerns. Rn —ra domization proces; Int—intended 
interv ntions; Mis—missing outcom  da a; Mea— easurement of the outcome; Sel—selection of 
t e reported result. 
To c lude, the evidence bas  on ph rma ological ADHD treatment in adolescents 
with concurrent ADHD and SUD is l mite , wit  le s than 500 pati nts included a ross 
four cont lled trials of a shor  duration, one of which showed a robust treatment ffect 
n eith r ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Mo t tri ls on th  efficacy of p ar cological ADHD treatment in youth h ve been 
o ducted i  ixe s mple  of c ild d adolescents at a  age grou  typically ranging 
from 5  18 y ars, wi hout s rat  a alysis or reporting of u comes in th  adolescent 
s bgr up. O s lect d lit rature inclu ed a meta- nalysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing s mulan  and non-stimul nt medications with placebo in children 
and dolescents with ADHD [48]. Only four of hese, 15 trials focused on adolescents only. 
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studies, with o exces  of SAEs in any activ me ication gr  compare  with placebo. 
Advers  harma ological interactions between e study medicatio  and the adolescent’s 
substance use at th  same da  were only reported in the tr al of Riggs et al. (2011) [37], 
and only by four (2.8%) and thr e (2.1%) f the patients taki  OROS-MPH and plac bo, 
r spectively. In the three trials that i v stigated stimula ts, no indicatio  was found that 
stimulant medicati n led to SUD d terioration. 
Planned treatment duration in th e trials ra ged from 6–16 w eks (1 of 4 stud es >12 
weeks), and no su sequent xtension stu ies we conducte  to inv stigate th  long-term 
effects of ADHD medic tion in th  st dy amples. Hence, pertaining to ad lescents with 
comorbid ADHD and SUD, only data on t e short-ter  effects of ADHD medicatio  are 
available to date. We assessed the risk of bias s being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on ph rmacological interve tion .
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]      
Szobot, 20 8 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findl ng, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]      
Biederman, 2008 [45]       
Sallee, 2009 [46]      
Wilens, 2015 [47]       
Newcorn, 2017a [34]       
Newcorn 2017b [34]       
Note:          low risk/high risk/some concerns. R d—randomization r c s; Int—inte ed
interven ions; Mis—missing outcome data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, the evidence base on ph rmacological  treatment i  adolescents 
with concurrent ADHD and SUD is limited, with les  than 500 patients included across
four controlled trials of a hort durati n, none of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents wit  ADHD but without SUD Comorbidity 
M st trials on the effi acy of pharmac logical ADHD tre tment in youth have een 
conduct d in mixed samples of children and d lesce ts at an ge group t p cally rangi g 
from 5 to 18 years, w thout eparat  a alysis o  reporti g of outcomes in the ad lescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbin  et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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studies, with o exc ss of SAEs i  any activ  medication group com red with placebo. 
Adverse pharmacological interactions between the s u y medication a  t e adolescent’s 
subst nce use at th  sam  y w re only reported in the trial f Riggs et al. (2011) [37], 
and only by four (2.8%) and thr e (2.1%) of the patients taking OROS-MPH and placebo, 
r spectively. In the three tr als a  i vestig ted stimulants, no indication was found that 
stimula t m dicatio  led to SUD det rioration. 
Pl ne  treatment duration in these trials ranged from 6–16 we ks (1 of 4 tudi s >12 
weeks), and o s bsequ t extension s udies wer  conducted t  investigate the l ng-term 
eff cts of ADHD medication in th study samples. He , p rtaining to dolescents with 
comorbid ADHD  SUD, only data on the short-term effects of ADHD medication are 
available t  date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and T urstone (2010), and as high in the stu ies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Ri k of bias in the included studi s on ph rmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]      
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
A olescents with ADHD       
Pelham, 2013 [33]       
Findl ng, 2010 [27]       
Wilens, 2006 [40]       
Findl ng, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sall e, 2009 [46]       
Wilens, 2015 [47]       
Ne corn, 2017a [34]       
Newcor , 2017b [34]       
N e:       ow isk/h g  risk/ e co c rns. R d—randomiz tion proces; Int—intended 
int rventions; Mis—missing o tcome data; Mea— easurem nt of the outcome; Sel—selection of 
the reporte  res lt. 
To conclu e, th  vidence base on pharmacologic l ADHD treatment i  adol scents 
with concu rent A HD and SUD is limited, with les  than 500 patients included across 
four controlled trials of a hort durati n, no e of which sho ed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Mo t trials on the efficacy of ph rm cological ADHD treatment in youth have been 
c nducted in ixed s mples of hildre and adolescents at  age group typically r nging 
from 5 t  18 years, without separat  analysis or r porting of outcom s in the a olescent 
subgro p. Our elec ed literature ncluded a meta-a lysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-st mulant medicat ons with placebo in children 
and adolesce ts with ADHD [48]. Only four of these, 15 trial focused on adolescents only. 
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studies, with no excess of SAEs in ny activ  m dication group ompared with l c . 
Adv rse pharmacological interactions between the st y medication and the ad lescent’s 
substance use at the same day were only rep rted in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and th ee (2.1%) of the patients t ki g OROS-MPH and placebo, 
r sp ctively. In th  thre  trials that investigate  stimulants, no i dicati n was found that 
stimula t medication l d t  SUD eterioration. 
Planned treatment duration in the e trials rang d fr m 6–16 w eks (1 of 4 tudies >12 
eeks), and no subs qu nt exte sio  studies ere c nducted to investigate the long-term 
effects of ADHD me ication in t  stu y samples. enc , pertaining to adolescents with 
comorbid ADHD nd SUD, only ata on the short-term effects of ADHD m dication are 
avail ble to date. W  assesse  the risk of bia  as bein  low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studie  o  ph rmacological inter ntions. 
Study Bias Arising from/Due to:  
 nd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wil ns, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederm n, 2008 [45]       
Sallee, 2009 [46]       
W l , 2015 [47]       
Newcorn, 2017a [34]       
Newcor 2017b [34]       
Note:         l w risk/h gh risk/some conc rns. Rnd—randomization roces; I t—inten ed 
interventions; Mis—missing outco e data; Mea—measurement of the outcome; Sel—selection of 
the reported result. 
To conclude, the evidence ba e on pharmacological ADHD treatment in adolescents 
with co current ADHD and SUD is limited, with le s t n 500 p tients includ d across 
four controlled trials of a sh rt durati n, none of which showed a obust treatm t effect 
on either ADHD or SUD. 
3.2 2. Ad l sc ts with ADHD but witho t SUD Comorbid ty 
Most trials o  th  efficacy of pharmacologic l ADHD treatment in youth h ve bee  
onducted in ixed s mples f children and dolescents at an age grou  typically ranging 
from 5 to 18 years, without sep rate a al sis or repo ting of utcomes in th  adolescent 
subgroup. Our selected literature included a meta-an lysis by Cerrillo-Urbin  et al. (2018) 
of 15 RCTs comparing stimulant and no -stimulant medicatio s with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studi s, with no exc ss of SAEs in any a tive me ication group compared with l c . 
Adv rse pharmacologi l intera tions be ween the st y medication and the ad lescent’s 
substance use  th  sam  day were ly report  in the trial of Riggs et al. (2011) [37], 
 o ly by four (2.8%) and th ee (2. %) of the pati nts taking OROS-MPH and placebo, 
resp ctiv ly. In the thre  rials that i v stigated stimulants, no indication was found that 
s imula t m d cation led t  SUD deteri ratio . 
Planned trea ent duration in these ri ls ra g d from 6–16 weeks (1 of 4 studies >12 
w eks), nd no subs qu  extension studies were onducted to investigate the long-term 
effects of ADHD medication i  t e tudy samples. H nc , pertaining to adolescents with 
c m rbid ADHD and SUD, only data on the short-t r  effects of ADHD medication are 
available t  dat . We as ess d the risk of bias as being low in the studies of Riggs (2011) 
and Thurst ne (2010), a d as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outc me data (Table 2). 
T ble 2. Risk of bias in the includ d studies o  ph rmacological interventions. 
St dy Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolesce ts with ADHD + SUD     
Riggs, 2011 [37]     
Szobot, 2008 [36]     
Riggs, 2004 [38]     
Thurstone, 2010 [39]     
Adolescents with ADHD     
Pelham, 2013 [33]     
Findling, 2010 [27]     
Wilens, 2006 [40]     
Findling, 2011 [42]     
Spencer, 2006 [41]     
Bostic, 2000 [43]     
Bangs, 2007 [44]     
Biederman, 2008 [45]     
Sallee, 2009 [46]     
Wilens, 2015 [47]     
Newcorn, 2017  [34]     
Newcorn 2017b [ 4]    
Note:          l w risk/high isk/so e concerns. R d—ra domization roc s; Int—inten ed 
interventions; Mis—missing outco  da a; Mea— easurement of the outcome; Sel—selection of 
the reported result. 
To c clude, the evidence bas  on pharmacological ADHD treatment in adole cents 
with concurrent ADHD and SUD is limited, with less than 500 pat ents included across 
f ur controlled trials of a shor  duration, o e of which showed a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most tri ls on th  efficacy of phar cological ADHD treatment in youth h ve been 
onducted in ixe sample  of c ild  and adolescents at a  age grou  typically ranging 
from 5  18 years, wi hout sep rat  analysis or reporting of u comes in th  adolescent 
subgroup. O s lect d literature inclu ed a meta- nalysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimul nt medications with placebo in children 
and dolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
5 Langberg, 2012 [64]
J. Clin. Med. 2021, 10, x FOR PEER REVIEW 12 of 34 
 
 
studies, with no excess of SAEs in any active me ication gr p compare  with lace . 
Adv rse pharmacological interactions between the st dy medication and the ad lescent’s 
substance use at the same day were only reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the pati nts taking OROS-MPH and plac bo, 
respectively. In the thre  trials that investigated stimula ts, no indicatio  was found that 
stimulant medication led t  SUD deterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and no subs quent extension studies were conducte  to investigate the long-term 
effects of ADHD medication in t e study samples. Hence, pertaining to adolesc ts with 
comorbid ADHD and SUD, only data on the short-ter  effects of ADHD medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 nd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD      
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]       
Bostic, 2000 [43]     
Bangs, 2007 [44]      
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]       
Newcorn, 2017a [34]      
N wcorn, 2017b [34]       
Note:         low risk/high r sk/some concern . Rnd—ran omiza ion proces; Int—intended 
interventions; Mis—missing outcome data; Mea—m asurement of the outcome; Sel—selection of 
the reported result. 
To conclude, the eviden e base on pharmaco ogical  trea ment in ad lescents 
with concurrent ADHD and SUD is limite , with l s  tha  500 patients i clu e  across 
our controlled t ials of a short durati , none f which show d  o ust treat ent eff c  
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but with t SUD Com rbidi y
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixed samples of children and adolescents at an age grou  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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studies, with no excess of SAEs in ny active medication group co pared with placebo. 
Adv rse pharmacological nteractions b tween the study medicatio  and the adolescent’s 
substance us  at the sa e day were only reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and thr e (2. %) f the patients taki  OROS-MPH and placebo, 
respectively. In the three trials th t i v stigated stimulants, no indication was found that 
stimulant m dicati n led to SUD deteri ratio . 
Planned treatment duration in these trials ra ged from 6–16 weeks (1 of 4 studies >12 
weeks), nd no su seque  xten ion studies were conducted to investigate the long-ter  
effects of ADHD medication i  the study samples. Hence, pertaining to adolesce ts with 
comorbid ADHD and SUD, nly data on the short-t rm effects of ADHD medication are 
availa le to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Th rstone (2010), a d as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies o  pharmacological interve tions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adol scents with ADHD + SUD       
Riggs, 2011 [37]       
Sz bot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]      
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilen , 2006 [40]       
Findling, 2011 [42]      
Spencer, 2006 [41]       
Bostic, 2000 [43]      
Bangs, 2007 [44]       
Bi derman, 2008 [45]       
Sallee, 2009 [46]      
Wile s, 2015 [47]      
New rn, 2017a [34]       
Newcorn, 2017b [34]      
N te:         l w risk/high r sk/some concerns. Rn —ran omization proces; I t—in ended
interv ntions; Mis— issing outcome data; Mea—m asureme t of the outcome; Sel—selection of 
the reported result. 
To c n lude, t e vide e bas  on p rmacologi a  ADHD trea m t in adolescents 
with co curr t ADHD and SUD is mite , with l s than 500 p tien s included across 
our controlled t ials of a sh rt durati n, none f w ich how d a robust treatm t eff c  
on either ADHD or SUD. 
3.2 2. A l scents with ADHD but with t SUD Comorbid y 
Most tri ls on the efficacy of pharm cological ADHD tre tment in youth have een 
conducted in mixed s mples of c ildren and dolescents at an age group typically ranging 
from 5 t  18 y ars, without separate analysis or reporting of outcomes in the ad lescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing s mulan  and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of hese, 15 trials focused on adolescents only. 
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studi s, with no excess of SAEs in any ac ve edication group com ared with l ce . 
Adverse pharmacolog cal interactions between the st dy medication and the ad lescent’s 
substance use at the sa  day were only reported in the trial of Riggs et al. (2011) [37], 
and o ly by four (2.8%) and three (2.1%) of the patients taking OROS-MPH and placebo, 
respectively. In the ree trials that investig ted stimulants, o indication w s found that 
stimulant medication led t  SUD deterioration. 
Plan ed treatment duration in thes  trials ranged from 6–16 weeks (1 of 4 studies >12 
w eks), and no subs quen  ext nsion studies w re co duc ed o investi at  the long-ter  
effects of ADHD medication in t e tudy samples. Henc , pertaining to adolescents with 
c morbid ADHD and SUD, only data on the shor -term effects of ADHD m dication are 
av ilable to date. We assessed the ri k of bias as being low in the studies of Riggs (2011) 
a d Thurstone (2010), a d as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcom  data (Table 2). 
T ble 2. Risk of bias in the included studie  on ph rmacological inter ntions. 
St dy Bias Arising from/Due to:  
 nd Int Mis Mea Se  Overall 
Adolescents with ADHD + SUD       
Ri gs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]      
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
W lens, 2006 [40]       
Findling, 2011 [42]      
Spe cer, 2006 [41]      
Bo tic, 2000 [43]      
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wile , 2015 [47]       
Newcorn, 2017a [34]       
Newcorn 2017b [34]       
Note:        l w ri k/high risk/ ome concerns. Rnd—rand mization roc s; I t—inten ed 
interventions; Mis—missing outco  data; Mea—measurement of th  outcome; Sel—selection of 
the reported result. 
To conclude, the evi e e bas  n pharmacological ADHD rea m nt in adolesc nts 
with co curre t ADHD and UD is limite , wi h l ss tha  500 p ti nts includ d acr ss 
our contr lled t i ls of a sh r  durati , none f whi h showed  obust treatm t eff c  
o  either A HD o  SUD.
3.2 2. Adol sc nts with ADHD but with t SUD Comorbid ty 
Most trials on the efficacy f pharmacological ADHD treatment in youth h ve been 
co ducted in ixed samples of childr n a d adolescents at an age grou  typically ranging 
from 5 o 18 years, without sep rat a alysis or reporting of utcomes in the adolescent 
s bgroup. Our s lected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and non-stimulant medications w th placebo in children 
a d adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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B ng , 2007 [44]     
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Salle , 2009 [46]     
W l n , 2015 [47]     
Newc rn, 2017  [34]     
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studies, with no excess of SAEs in a y active edicati  group co p d with placebo. 
Adverse pharmacological interactions betw en t  study medic tion and he dolesce t’s 
substance use at the same day were only reported i  the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the patients taking OROS-MPH and pl cebo, 
respectively. In the three trials that invest gated stim lants, no indicatio  w s found that 
stimulant medication led to SUD deteri rat on. 
Plann d treatment duration in these tri s rang  from 6–16 weeks (1 f 4 studies >12 
weeks), and no subsequent extension studies were conducted to investigate the long-term 
effects of ADHD medication in the study sample . Hence, ertai ing to dol c ts with 
comorbid ADHD and SUD, only data on the short-term effects of ADHD medication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias n the included studies o  phar acological intervention .
Study Bias Arising from/Due to:  
 Rnd Int M s Mea Sel verall
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolesce ts with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]      
Bostic, 2000 [43]     
Bangs, 2007 [44]       
Bi d rman, 2008 [45]      
Sallee, 2009 [46]    
Wilens, 2015 [47]      
Newcorn, 2017a [34]      
N wco n, 2017b [34]       
Note:          low risk/high risk/some conc rns. R —r ndo iz tion pro es; Int— ntended 
interventi ns; Mis—m ssing o tc me data; Mea—me surement of t e outcome; Sel—selection f 
the reported result. 
To c nclude, the evidence base on pharmacological ADHD treatment in adolescents 
with c ncurrent ADHD and SUD is limited, with les  than 500 patients included across 
four controll d trials of a short duration, n ne of w ich sh we  a robust treat e t eff t 
on ither ADHD r SUD. 
3.2.2. Adolescents with ADHD but witho t SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treat ent in youth have been 
conducte  in mixed samples of children and ad lescents at an age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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Wilen , 2006 [40]       
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Bostic, 2000 [43]      
Bang , 2007 [44]      
B ederman, 2008 [45]      
Sallee, 2009 [46]       
Wile s, 2015 [47]       
New n, 2017a [34]      
Newcorn, 2017b [34]       
Note:        l w ri k/hig risk/some conc rns. Rn —r nd m zati n proces; Int—in ende  
inte ventions; Mis—m ssing outc me ata; Mea—me surem nt of th  outc ; Sel—selecti n of 
the reported result. 
To nclude, the vid ce base n pharmacological ADHD treatment in adolescents 
with concur e t AD D d SUD is limited, with les  tha  500 pati nts included across 
four contr lled trials of  shor  duratio , none f which sh wed  robust tr a ment effect 
on either A HD or SUD. 
3.2.2. Adolescents wi h ADHD but with ut SU Comorbidit
Most trials on the efficacy f pharmacological ADHD treatment in youth have been 
conducted in mixed samples of childr n d adolescents t an age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
s bgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and non-stimulant medications w th placebo in children 
a d adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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with concurre t ADHD and SUD is imited, with less tha  500 pati nts included across 
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s udies, wit  no exc ss of SAEs in ny ac ive me icati  group co p red wi h placebo. 
Adv rse pharm col gi al n er ctions b wee  t  stu y medic tion and the adolescent’s 
substance us  at t  am  day wer  only report d in the trial of Riggs et al. (2011) [37], 
a  o ly by four (2.8%) and t ree (2.1%) of the patients taking OROS-MPH and placebo, 
respectiv ly. In the thr e rials th t i vestigated stimulants, no indicatio  w s found that 
stimulant med cation l d to SUD deter oratio . 
Plann  trea ment duration in thes  tri  rang d from 6–16 weeks (1 of 4 studies >12 
w eks), and no subs quen  ext n ion studies ere cond cted to investigate the long-term 
effects of ADHD medication i  the tudy sample . H nce, ertaining to dol sc ts with 
c m rbid ADHD and SUD, nly data on the short-t rm effects of ADHD medication are 
availa le to date. We as essed the risk of bias as being low in the studies of Riggs (2011) 
and Th rstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
T ble 2. Risk of bias in the included studies o  ph r acological interventions. 
St dy Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
A olescents with ADHD + SUD     
Riggs, 2011 [37]     
Sz bot, 2008 [36]     
Riggs, 2004 [38]     
Thurstone, 2010 [39]     
Adolescents with ADHD     
Pelham, 2013 [33]     
Findling, 2010 [27]     
W lens, 2006 [40]     
Findling, 2011 [42]    
Spencer, 2006 [41]     
Bostic, 2000 [43]     
Bangs, 2007 [44]    
Bi d rman, 2008 [45]    
allee, 2009 [46]    
W le , 2015 [47]     
Newc rn, 2017  [34]     
N wco , 2017b [34]     
N te:         l w risk/high isk/so e concerns. R —ra domization pro es; Int—int nded 
nterv nti ns; Mis— ssi g o tc m  a a; Mea—measur m nt of the outcome; Sel—s lection of 
the reported result. 
To con lud , the evidence bas  on ph rmacological ADHD treatme t i  adolesc nts 
ith concu rent ADHD a d UD is l mite , with l s tha  500 patients cluded a ross 
f u  controlled tri s of a sho  duratio , n e w ich showed a robust tr atment effect 
on either ADHD  SUD. 
3.2.2. A olescents wi h ADHD bu with ut SUD Com rbidity 
Most tri ls on the efficacy of pharmacological ADHD treatment in youth have been 
conducted in ixe samples of children an  adolescents at a  age group typically ranging 
from 5 o 18 y ars, without sep rat  analysis or reporting of ou comes i  the adolescent 
subgroup. Our s lected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing s mulan  and non-stimul nt medications with placebo in children 
and adolescents with ADHD [48]. Only four of hese, 15 trials focused on adolescents only. 
7 Schramm, 2016 [65]
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weeks), and no subsequent extension studies were conducte  to investigate the long-term 
effects of ADHD medication in t e study samples. Hence, pertaining t  adolesc nts with 
comorbid ADHD and SUD, only data on the short-ter  effects of ADHD edication are 
available to date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2 08) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the include  studies on pharmacological interven ions. 
Study Bias Ari ing rom/Due to:  
 Rnd Int Mis Mea Sel verall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]      
Adolescents with ADHD      
Pelham, 2013 [33]       
Findling, 2010 [27]      
Wilens, 2006 [40]       
Findling, 2011 [42]     
Spencer, 2006 [41]      
Bostic, 2000 [43]     
Bangs, 2007 [44]      
Biederman, 2008 [45]      
Sallee, 2009 [46]       
Wilens, 2015 [47]      
Newcorn, 2017a [34]      
Newcorn, 2017b [34]       
Note:          low risk/high risk/some concerns. Rnd—randomizati n proces; I t—inten e  
interventions; Mis—missing outc me data; Mea— easu em nt of the out o e; Sel—selecti n of 
the reported result. 
To conclude, the eviden e base on p ar acological  trea ment in adolesce ts 
with concurrent ADHD and SUD is limite , with l s  tha  500 patients included across 
our controlled t ials of a short duratio , none of which show d a robust treatment effec  
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but with t SUD Com rbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth h ve been 
conducted in ixed samples of children and ad lescents at an age grou  typically rangi g 
from 5 to 18 years, without separate an lysis or reporting of utc mes i  the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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s udi s, with no xcess of SAEs in a activ  medication group comp red with pl cebo. 
Adverse phar acological inter tions b tween the s udy m dication and the adolesce t’s 
s bstanc  use at th same d y were only reporte  in the tria  f Riggs et al. (2011) [37], 
nd only by four (2.8%) nd thr e (2.1%) of he p e ts taking OROS-MPH and placebo, 
resp c ively. In the re t i l at investig t d stimulants, no in ication was found that 
stimula t me i ti  l d to SUD d terioration. 
Pla d treatment u at on n ese tr als ra ge  fr m 6–16 we ks (1 of 4 tu ies >12 
weeks), and no subseque t x en ion studies were conduc ed t  inv s igate the long-term 
effects of ADHD me ication in th  study samples. Hence, p rtaining to adolescents with 
c morbi  ADHD  SUD, only data on the short-term effects of ADHD medication are 
availabl  t date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due o mis ing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on pharmacological interventions. 
Study Bias rising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolesce ts with ADHD + SUD      
Riggs, 2011 [37]      
Sz bot, 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
A olescents with ADHD      
Pelham, 2013 [33]       
Findl ng, 2010 [27]       
Wilens, 2006 [40]       
Findling, 2011 [42]       
Spencer, 2006 [41]     
B stic, 2000 [43]       
B ngs, 2007 [44]      
Bi erman, 2008 [45]       
Sall e, 2009 [46]       
Wile s, 2015 [47]       
e corn, 2017a [34]     
Newc rn 2017b [34]       
N e:       ow risk/high risk/ me co cerns. R d—randomiz tion roc s; Int—inten ed 
int rvention ; Mis—missing outc me data; Mea—measurement f the tcome; Sel—selection of 
the reporte  res lt. 
To conclu e, th  evide e b se on p armacol gical ADHD rea m t in ad lesc nts 
with concu rent  n  SUD is limit , with l s th  500 patients included cross 
r co troll t ial  of a hort duratio , n e of whi h sho ed a robust treatment eff c  
on eit  ADHD r SUD. 
3.2.2. Ad le ce ts with ADHD but with t SU Comorbidity 
M st rials n the efficacy of pharmac logical ADHD tr tment in y uth have been 
c nducted in mixed sampl s of hildren and adolescents t an age group typically ranging 
from 5 t  8 years, withou  separa e alys s or r porting of out om s in the a olesce t 
subgroup. O r s lecte  literatur  included a meta-an lysi  by C rrillo-Urbina et l. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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avail ble to date. We assesse  the risk of bia  as being low in the studies of Riggs (2011) 
and Thurs one (2010), an  as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
T ble 2. Risk of bias n the include  studies on pharmacological interventions. 
St dy Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]       
Szobo , 2008 [36]       
Riggs, 2004 [38]       
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]       
l ns, 2006 [40]      
Findling, 2011 [42]       
Spencer, 2006 [41]      
Bo tic, 2000 [43]      
Bangs, 2007 [44]       
Bied rm n, 2008 [45]      
Sallee, 2009 [46]      
Wil , 2015 [47]     
New r , 2017a [34]      
Newcorn 2017b [34]      
Note:          l w risk/high risk/some concerns. Rnd—randomization roc s; I t—in en ed 
nterventi ns; Mis—m ssi g outcom  d ta; Me —measur m nt f the outcome; Sel—sel ction of 
the reporte  result. 
To conclude, the eviden e bas  on pharmacological ADHD trea ment in adolesc nts 
with co current ADHD nd UD is limite , wi h l s  t an 500 p tients includ d acr ss 
our controlled t ials of a sh r  duration, none of which showed a robust treatment eff c  
o  either ADHD o SUD. 
3.2.2. Adolescent  with ADHD but with t SUD Comorbidity 
Most trials on th  efficacy of ph rm cologic l ADHD treatment in outh h ve bee  
c ducted in ixed s mples f childre  a d dolescents at an age grou  typically ranging 
from 5 o 18 years, without sep rat  a alysis or rep rti g of utcomes in the a olescent 
subgroup. Our s lected literature included a meta-an lysis by Cerrillo-Urbin  et al. (2018) 
of 15 RCTs comparing stimulant and no -stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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ubs a  se  h  same d y were ly report d in the trial f Riggs et al. (2011) [37], 
 only by four (2.8%) and th ee (2.1%) of the patients taking OROS-MPH and placebo, 
resp c iv ly. In the r e i l  that i vestigated stimulants, no in ication was found that 
s mula  med cation led to SUD deteri ration. 
Planned t e m nt durati n in th ri ls ra g d from 6–16 weeks (1 of 4 studies >12 
week ), nd o subsequ t xtensio  stud es were onducted to investigate the long-term 
effects of ADHD medication i  the study samples. H nc , pertaining to adolescents with 
com rbi  ADHD a d SUD, only data on the short-t r  effects of ADHD medication are 
avail ble t  dat . We as ess d the risk of bias as being low in the studies of Riggs (2011) 
and Thurst ne (2010), a d as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to issing outc me data (Table 2). 
Table 2. Risk of bias in the included studies o  pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolesce ts with ADHD + SUD     
Riggs, 2011 [37]     
Sz bot, 2008 [36]     
Riggs, 2004 [38]     
Thurstone, 2010 [39]     
Adol scents with ADHD     
Pelham, 2013 [33]     
Findling, 201  [27]     
ilens, 2006 [40]     
Findling, 2011 [42]     
Spencer, 2006 [41]    
Bostic, 2000 [43]     
Bangs, 2007 [44]     
Biederman, 2008 [45]     
Sallee, 20 9 [46]     
Wil s, 2015 [47      
N wcorn, 2017  [34]     
Newc r  2 17b [ 4]    
Note:          low risk/hig isk/so e concerns. Rnd—ra domizati n roc s; Int—inte ed 
interventi s; Mis—m ssi g outc e da a; Mea— easurement f the ou come; Sel—selection f 
the reported result. 
T c lude, the evide e bas  on p ar a ological ADHD trea ment in ad lescents 
wit concur nt ADHD a d S D is limite , wi h l ss than 500 patients included across 
ur ont lle  t i ls of a sh rt durati , o  of w ic  showed a robust treatment eff c  
n ei r ADHD  SUD. 
3.2.2. Ad lescents with ADHD but with t SUD C morbidity 
Mo t ri ls on th  efficacy of p ar ac logical ADHD tr tm nt in youth have been 
onducted i  mixe sample  of child nd adolescents at a age group typically ranging 
from 5 o 18 y ars, wi hou  se ra  a alys s or reporting of ou comes in the adolescent 
s bgr up. O s lect d lit ratur  inclu ed a meta- nalysis by C rrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimul nt medications with placebo in children 
and dolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with no excess of SAEs n any active m dic ti  gr p compare  with lace . 
Adv rse pharm cological interactio s betw en t  study m dic tio  and the d le cent’s 
substance use at the same day wer  only reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) nd thr e (2.1%) f  patients taki  OROS-MPH and plac b , 
respectively. In the three trials that i vestigated stimula ts, no indicatio  was foun  that 
stimulant medicati n led t  SUD deteriorat on. 
Plann d treatment duration in these tri s rang d from 6–16 weeks (1 of 4 studies >12 
weeks), and no su seque t extension stu ies were conducte  t  investigate the long-term 
effects of ADHD medication in t e study samples. Hence, pertaining to adolescents with 
comorbid ADHD and SUD, nly data n the short-ter  effects of ADHD edication are 
available to date. We assessed the risk f bias as being low in the studies of Riggs (2011)
and Thurstone (2010), and a  hig  in t e studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies o  phar acological i terventions. 
Study Bias Arisi g from/D e t :  
 Rnd I t Mis Mea Sel Ov rall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]     
Szobot, 2008 [36]     
Riggs, 2004 [38]     
Thurstone, 2010 [39]      
Adolesce ts with ADHD      
Pelham, 2013 [33]      
Findling, 2010 [27]      
Wilen , 2006 [40]      
Findling, 2011 [42]      
Spencer, 2006 [41]     
Bostic, 2000 [43]      
Bangs, 2007 [44]    
Bied rma , 2008 [45]    
Sallee, 2009 [46]    
Wilens, 2015 [47]      
Newco n, 2017a [34]      
N wco n, 2017b [34]      
Note:          low risk/high risk/so e concer . R d—rand m z tion proces; Int—intended
interventi ns; Mi —missing o tc me data; Mea—me su emen  of t e o tcom ; S l— el ction f 
the report d result. 
To conclude, the evidence base on pharmacologi al treatment in adolescents 
with concurrent ADHD and SUD is limited, with les  than 500 patients included cross 
four controlled trials of a short duration, n ne of which showe  a robust treatment effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD tre tment in youth h ve een 
conducted in ixed samples of children nd d lescents t an age grou  typically rangi g 
from 5 to 18 years, without separate analysis or reporting of utcomes in the ad lescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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studies, with no xcess SAEs n a activ  me ication group c mp red with pl cebo. 
A verse phar acolog cal in er ctions b tween the s udy m dication and th  adolesce t’s 
subst c  u e at the sa e day were only reported in the tria  f Riggs et l. (2011) [37], 
nd ly by four (2.8%) nd thre  (2.1%) of he p e s taking OROS-MPH and plac bo, 
resp c iv ly. In the re t i l  that i v stig t d st mulants, o i ication was found that 
stimula t me ic tio  led to SUD d terioration.
Pla n d tre tm n  uration n th e tr als ra ge  fr m 6–16 we ks (1 of 4 stu ies >12 
weeks), d o subs quent xtensi n studies we  conduc ed t  inv s igate the long-term 
fect of ADHD m ication in the study samples. Hence, pertaining to adolescents with 
c morbi  ADHD a d UD, only dat  n the hort-ter  effects of ADHD medication are 
v ilable t date. W  a se sed the risk of bias s being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
du  o mis ing outcome data (Table ). 
Table 2. Risk of bias in the included studies on ph rmacological interventions. 
Study Bias rising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolescents with ADHD + SUD      
Riggs, 201  [37]   
Szobot, 2008 [36]    
Riggs, 2004 [38]    
Thu ston , 2010 [39]    
Adol scents with ADHD      
Pelham, 2013 [33]   
Findl g, 2010 [27]    
ile s, 2006 [40]      
Fi dling, 2011 [42]       
Spencer, 2006 [41]     
B stic, 2000 [43]       
B ngs, 2007 [44]      
Bi erman, 2008 [45]      
Sallee, 2009 [46]       
Wil s, 2015 [47]       
ewcor , 2017a [34]     
N wc n, 2017b [34]      
N e:       ow risk/hig  risk/ ome con rns. Rnd—ran omiza ion proc s; I t—i end d 
int rventi ns; Mis—m ssing utcome data; Mea—measureme t f the tcome; S l—selecti n f 
the reported result. 
To co clu e, th  vide e se on p armacol gical ADHD trea ment in adolesc nts 
with c ncurrent  a  SUD is limit , with l s th n 500 patients i cluded cross 
r c roll t i l  of a hort duratio , n e f which sho ed a robust treatment ff c  
n eit  ADHD or SUD. 
3.2.2. Adolesce ts with ADHD but with t SU Comorbidity 
M st rials n the efficacy  phar ac logical ADHD tr tment in y uth have been 
conducted in mixed sampl s f children and adolescents t an age group typically ranging 
from 5  8 years, withou  separa e alys s or reporting of out omes in the adolesce t 
subgroup. Ou  s lect d literatur  inc ud d a m ta-analysi  by C rrillo-Urbina et l. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
J. Clin. Med. 2021, 10, x FOR PEER REVIEW 12 of 34 
 
 
stud es, i h o excess of SAEs i  any c ive m ication group o ar d wit  pla b . 
Ad erse pharmacol gical i ter ctio s betw e  th  s u y medication a  t e a olescent’s 
substanc  use at the sam  d y were only r p rted in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) d thr  (2.1%) of the pati s taki g OROS-MPH and placebo, 
resp ctively. In the three trials that nvestigated stimulants, no indication was found that 
stimul nt medicat on le o SUD terior ti . 
Pl ned t e tme t duratio in th e trials rang d fr m 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequ nt exte sion s udi s were c nducted t  i vestigate the long-term 
effects of ADHD me ication  the stu y samples. He c , pertaining to adolescents with 
c morbid ADHD nd SUD, only ata on the sh rt-term effects of ADHD m dication are 
avail ble t  dat . We assesse  the risk  bia  as being low in the studies of Riggs (2011) 
and Th rstone (2010), and as high in the tudies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2).
Table 2. Risk of bias in the included studies on ph rmacological interventions. 
Study Bias Arising from/Due to:  
Rnd Int Mis Mea Sel Overall 
A olescents with ADHD + SUD    
Riggs 11 37
Szobot, 8 [36]
Riggs, 2004 [38] 
Thur tone, 2010 [39] 
Adolescents with ADHD       
Pelham, 3 [3 ] 
Findling, 0 [27] 
ilens, 2006 [40]       
Findling, 2011 [42]      
Spe cer, 2006 [41]      
Bo tic, 2000 [43]      
Bangs, 2007 [44]    
Biederm n, 2008 [45]    
Sallee, 2009 [46]     
W l , 2015 [47]      
N wcorn, 2017a [34]      
Newcor 2017b [34]      
Note:       ow risk/h gh risk/ ome co r s. Rnd—ra domiza ion roces; I t—inten ed 
in rventi ns; M s— ssing utco at ; Me — a ur m t f he outco ; Sel—sel ction of 
the reported result. 
To conclude, the evi e e b se o  pharmacological ADHD trea ment in adolescents 
with c current ADHD nd SUD is limite , with l t an 500 p tients includ d across 
our controlled t ials of a sh rt duration, non  of which showed a robust treatment eff c  
on either ADHD or SUD. 
3.2.2. Adolesce t  with ADHD but with t SUD Comorbidity 
Most trials on th  effic cy of ph rmacol gic l ADHD treatment in outh have bee  
c ducted in ix d mples f childre  and dolesce ts at an age group typically ranging 
from 5 to 18 years, with ut separate a alysis r rep rti g of outcomes in the a olescent 
subgroup. Our selected literature included a meta-an lysis by Cerrillo-Urbin  et al. (2018) 
of 15 RCTs comparing stimulant and no -st mulant medications with placebo in children 
a d adolescent  with ADHD [48]. O ly f ur of these, 15 trials focused on adolescents only. 
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s ud s, with no xcess of SAE  in y a i  e ication group compared with placebo. 
Adverse harmaco ogi l int r tions be ween the stu y medication and the adolescent’s 
bs ce use t h  same d y were ly report d in the trial f Riggs et al. (2011) [37], 
 ly by four (2.8%) and th ee (2.1%) of the patients taking OROS-MPH and placebo, 
res c iv ly. I  he e i  that i vestigated stimulants, no in ication was found that 
st mula t med cation led to SUD deteri ration. 
Planne  t e m t durati n in  trial  ra ged from 6–16 weeks (1 of 4 studies >12 
week ), and o s bs que t x ensio  stud es were conducted to investigate the long-term 
effect of ADHD medication i  the study samples. H nc , pertaining to adolescents with 
c m rbi  ADHD a d SUD, only data on the short-t rm effects of ADHD medication are 
available t  dat . We as ss d the risk of bias as being low in the studies of Riggs (2011) 
and Thur t ne (2010), a d as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to issing outc me data (Table 2). 
Tab e 2. Risk of bias in the included studies o  ph rmacological interventions. 
Study Bias Arising from/Due to:  
Rnd Int Mis Mea Sel Overal  
Adolesce ts with ADHD + SUD     
Riggs 11 37
Sz bot, 8 [36]
Riggs, 2004 [38]
Thu stone, 2010 [39] 
Adolescents with ADHD     
Pelham, 3 [3 ] 
Findli g, 0 [27] 
ilens, 2006 [40]     
Findling, 2011 [42]     
Spencer, 2006 [41]     
Bostic, 2000 [43]     
B ngs, 20 7 [44]     
Biederman, 2008 [45]    
Sallee  2009 [46]     
Wil s, 2015 [47]     
N wc r , 2 17a [34]     
New rn, 2 17b [34]     
Note:       l w r k/hig  isk/ o e concer s. R d—r domization proc s; Int—intended 
int rvent ns; Mis—m ssing tc me a a; M a— easureme t of the tc me; Sel—selection of 
t e reporte  result. 
To co clude, th  evide e bas  on p ar a ological ADHD trea me t in ad le cents 
with co cur nt ADHD and SUD is limite , wi h l ss than 500 pat nts included acr ss 
ur contr lle  t ials of a sh rt durati , o e of w ich showed a robust treatment eff c  
n ei r ADHD  SUD. 
3.2.2. Adolescents with ADHD but with t SUD C morbidity 
M st ri ls on the efficacy of p armac logical ADHD tr tment in youth have been 
onducted  mixe sampl s of childr nd adolescents at a age group typically ranging 
from 5 to 18 y ars, withou  se ra  a alys s or reporting of ou comes in the adolescent 
s bgr up. O r s lect  lit ratur  included a meta- nalysis by C rrillo-Urbina et al. (2018) 
of 15 RCTs comp ring stimulant and non-stimul nt medications with placebo in children 
and dolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J. Clin. Med. 2021, 10, x FOR PEER REVIEW 12 of 34 
 
 
studi s, with no excess of SAEs in a y activ  me ication group comp red with lace . 
Adverse phar acological in era tions between the s dy medication and the ad lescent’s 
s bstance use at th  same d y were only reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) a d thr e (2.1%) of he pati s taking OROS-MPH a d plac bo, 
respectively. In the three trials at i vestig ted st mulants, o i icatio  was found that 
stimula t medicatio  l d t  SUD deterioration. 
Planned tre tment du at on n e tr als ra ge  fr m 6–16 weeks (1 of 4 tudies >12 
weeks), and no subseque t ex ension studies were conducted t  investigate the l ng-term 
effects of ADHD medication in t e study samples. Hence, p rtaining to adolescents with 
c morbid ADHD d SUD, only data on the short-term effects of ADHD medication are 
av ilable t  date. We assessed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
du  to mis ing outcome d ta (Table 2). 
Table 2. Risk of bias in th  included studi s on ph rmacological interventions. 
Study Bias rising from/Due to:  
 Rnd Int Mis Mea Sel Overall 
Adolesce ts with ADHD + SUD       
Riggs, 201  [37]    
Sz bot, 2008 [36]     
Riggs, 2004 [38]     
Thurston , 2010 [39]     
A ol scents with ADHD       
Pelham, 2013 [33]    
Findl ng, 2010 [27]     
ilens, 2006 [40]       
Findli g, 2011 [4 ]       
Spencer, 2006 [41]      
B stic, 2000 [43]       
B ngs, 2007 [44]       
Biederman, 2008 [45]      
Sall e, 2009 [46]       
Wil s, 2015 [47]       
Ne c r , 2017a [34]     
N wcorn, 2017b [34]      
No e:       ow risk/hi  risk/som  con rns. Rnd—randomiza ion proc s; Int—i end d 
int rventi n ; Mis—missing utcome data; Mea—measurement of the tcome; S l—selecti n f 
th reporte  res lt. 
To conclu e, th  evidence s on phar acological ADHD treatme t in ad lescents 
with concu rent A HD nd SUD is limit d, with less th n 500 pa i n s i cluded across 
four co troll tr als of  hort duration, n  of which sho ed a robust treatment ffect 
on eith r ADHD r SUD. 
3.2.2. Ad le ce ts with ADHD but without SUD Co orbidity 
M st trials on the efficacy of pharmacological ADHD treatment in youth have been 
c nducted in ixed sampl s of hildren and adolescents at an age grou  typically r nging 
from 5 t  18 years, without separate analysis or r porting of utcom s in the a olescent 
subgroup. O r selecte  literature included a meta-an lysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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stud es, wi h no excess of SAEs in ny c iv  m ication group ompar d wit  la . 
Adv rse pharmacol gical inter ctions between the st y medication and the ad lescent’s 
substance use at th  sa e d y were nly r p rted in the rial of Riggs et al. (2011) [37], 
a d o ly by four (2.8%) and th ee (2.1%) of th  pati nts taki g OROS-MPH and placebo, 
respectively. In the three trials that i v stigated s imulants, no indication was found that 
stimulant medicat on le  SUD teri ratio . 
Planned tre tme t duration in th e trials rang d fr m 6–16 weeks (1 of 4 studies >12 
weeks), and no subsequ nt exte sion studies were conducted to investigate the long-ter  
effects of ADHD medicatio  in t e stu y samples. Henc , pertaining to adolescents with 
com rbid ADHD nd SUD, only ata on the short-term effects of ADHD m dication are 
avail ble to date. We assesse  the risk of bi as being low in the studies of Riggs (2011) 
and Thurstone (2010), and as high in the tudies of Szobot (2008) and Riggs (2004), mainly 
due o missing outcome data (Table 2). 
Tabl  2. Risk of bias n the included studies on ph rmacological interventions. 
Study Bias Arising from/Due to:  
nd Int Mis Mea Sel Overall 
Adol scents with ADHD + SUD      
Riggs 11 37
Szobo , 8 [36]
Riggs, 2004 [38] 
Thurstone, 2010 [39] 
A olescents wit  ADHD       
Pelham, 3 [3 ] 
Findling, 0 [27]
l , 2006 [40]       
Findling, 2011 [42]      
Sp ce , 2006 [41]      
Bo tic, 2000 [43]      
Bangs, 2007 [44]       
Bied rm n, 2008 [45]      
allee, 2009 [46]      
W l , 2015 [47]      
Newcor , 2017a [34]       
New r , 2017b [34]       
Note:       ow risk/h gh risk/ ome co c rns. R d—ra domiz ion proces; Int—intend d 
interve i ns; Mis— issi g utco  t ; Mea— a ur m t f the outco ; Sel—selection of 
the repo te  result. 
To conclude, the evi e e base on pharmacological ADHD rea m nt in adolesc nts 
with co current ADHD nd UD is limite , wi h l ss t an 500 p tients includ d acr ss 
our controlled t ials of a sh t duration, no e of whi h sh wed a obust treatment eff c  
o  either ADHD o  SUD. 
3.2.2. Adolescents with ADHD but with t SUD Como bidity 
Most trials on th  efficacy of pharmacologic l ADHD treatment in youth h ve bee  
co ducted in ixed samples f children a d dolescents at an age grou  typically ranging 
from 5 to 18 years, without separate a alysis or reporti g of utcomes in the adolescent 
subgroup. Our selected literature included a meta-an lysis by Cerrillo-Urbin  et al. (2018) 
of 15 RCTs comparing stimulant and no -stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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stu i s, with no exc ss of SAEs in a y a ive e ication group compared with lace . 
Adverse pharmacologi l inter ctions be ween the st y medic tion and the ad lescent’s 
substa ce us   th  same day were ly report  in the trial of Riggs et al. (2011) [37], 
an  ly by four (2.8%) and th ee (2.1%) of the patients taking OROS-MPH and placebo, 
resp ctiv ly. In the three ri s that i vestigated s imulants, no indication was found that 
s imula  me cation led t  SUD deterioration. 
Planne  t e me t duration in th ri l  rang d from 6–16 weeks (1 of 4 studies >12 
weeks), nd o su sequ t extensio  studies were onducted to investigate the long-term 
effects of ADHD medication i  t e study samples. H nc , pertaini g to adolescents with 
com rbid ADHD and SUD, only data on the short-t r  effects of ADHD me ication are 
available t  dat . We as ess d the risk of bias as being low in the studies of Riggs (2011) 
and Thurst ne (2010), a d as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outc me data (Table 2). 
Table 2. Risk of bias in the included studies o  ph rmacological interventions. 
Study Bias Arising from/Due to: 
Rnd Int Mis Mea Sel Overall 




Thu stone, 2010 [39] 
Adol scents with ADHD     
Pelham, 3 [3 ] 
Find i g, 0 [27] 
ilens, 2006 [40]     
Findling, 2011 [42]     
Spencer, 2006 [41]   
Bostic, 2000 [43]     
B ngs, 2007 [44]     
Biederman, 2008 [ 5]     
Sallee, 2009 [46]     
Wil s, 2015 [47      
Newc rn, 2017  [34]     
New rn, 2 17b [ 4]    
Note:        l w r k/hig  isk/ o e concer s. R d—r domization proces; Int—inte ded 
interven s; Mis—missi g tc me a ; M a— easureme t of the ou c me; Sel—selection f 
th  reported result. 
To c lude, the evide ce base on phar acological ADHD treatme t in ad le cents 
wit concurrent ADHD d SUD is limited, with l ss than 500 pat ents included across 
f ur ontr lle  tr als of sh rt duration, o  of which showed a robust treatment effect 
on eith r ADHD  SUD. 
3.2.2. Adolesc nts with ADHD but without SUD Comorbidity 
Mo t tri ls on th  efficacy of phar acological ADHD treatm nt in youth h ve been 
onducted in ixe sample  of child  and adolescents at a  age grou  typically ranging 
from 5 to 18 years, wi out separat  analysis or reporting of u comes in the adolescent 
subgroup. O s lect d literature inclu ed a meta- nalysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimul nt medications with placebo in children 
and dolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with no excess of SAEs n a y active dic ti n group co pared with lace . 
Adv rse pharm cological interactions between the st dy medication and the ad lescent’s 
substance use at the same day were nly reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the patients taki g OROS-MPH and placeb , 
respectively. In the three trials that investigated stimulants, no indication wa  found that 
stimulant medication led t  SUD deterioration. 
Plann d treatment duration in these tri s rang  from 6–16 w eks (1 f 4 stu ies >12 
weeks), and no subsequent extension studies were conducted to investi ate the long-term 
effects of ADHD medication in t e study sample . Hence, pertai ing to adol cents with
comorbid ADHD and SUD, only data on the short-term effects of ADHD medication are 
available to date. We assessed th  ri k of bias a  being low in the studies of Riggs (2 11) 
and Thurstone (2010), and a  high in t  studies f Szobo  (2008) and Riggs (2004), mainly 
due to missing out ome data (Table 2). 
Table 2. Risk of bias in the included studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int M s ea Sel verall 
Adolescents with ADHD + SUD      
Riggs, 2011 [37]     
Szobot, 2008 [36]      
Riggs, 2004 [38]     
Thurstone, 2010 [39]     
Adolesce ts with ADHD     
Pelham, 2013 [33]     
Findling, 2010 [27]       
Wilen , 2006 [40]      
Findling, 2011 [42]     
Sp ncer, 2006 [41]    
Bostic, 2000 [43]     
Bangs, 2007 [44]     
Bied rma  2008 [45]      
Sallee, 2009 [46]    
Wilens, 2015 [47]      
Newco n, 2017a [34]     
N wco n, 2017b [34]     
Note:          low risk/high risk/so e co cer s. R d—rand miz tion proces; Int—intended 
i erventi ns; Mi —missi g o tc me data; Mea— e su emen  of t e o tcom ; S l— el ction f 
the report d result. 
To conclude, the eviden e bas  on pharmacologi al ADHD trea ment in adolescents 
with concurre t ADHD and SUD is limite , with l s  tha  500 patients included across 
our controlled t ials of  short duratio , none of which how  a robust tre me t eff  
on either ADHD r SUD. 
3.2.2. Adolescents with ADHD but with t SU  Com rbidit
Most trials on the efficacy of pharmacological ADHD treat ent in youth h ve been 
conducted in ixed samples of children and ad lescents at an age grou  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studi s, w th o excess f AEs in any ac ve edication group co ared with placebo. 
Adverse phar acolog cal interactio s between the stu y medication a d t e adolescent’s 
substance use t the sam  day wer  only reported in the trial of Riggs et al. (2011) [37], 
a d only by four (2.8%) and three (2.1%) of  patients taking OROS- PH and placebo, 
respectively. I  the re  trial that investig ted stimulants, o indica ion w s foun  that 
stimulant medication le  to SUD deterioration. 
Pl e  treatment duratio  in thes trial  range from 6–16 weeks (1 f 4 studies >12 
weeks), and no subsequent extension studies w re co duc ed investi at  the long-term 
effects of ADHD medicati  in t e study samples. He c , pertaini g to adolescents with 
comorbid ADHD and SUD, nly da a n the shor -term effect  of ADHD m dication are 
av ilable to date. We assessed the ri k f bias as being low in the studies of Riggs (2011) 
a d Thursto e (2010), a  a  hig  in t e studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outco  data (Table 2). 
Table 2. Risk of b as in the included studies on pharmacological i terventio . 
Study Bias Arising from/D e to:  
 nd I t Mis Mea Se  Overall
Adol scents with ADHD + SUD      
Ri gs, 2011 [37]    
Sz bot, 2008 [36]    
Riggs, 2004 [38]    
Thurstone, 2010 [39]    
Adol sce ts wi h ADHD    
Pelham, 2013 [33]    
F ndli g, 2010 [27]     
Wile , 2006 [40]      
Findling, 2011 [42]     
Spence , 2006 [41]      
Bostic, 2000 [43]     
Bang , 2007 [44]       
B derman, 2008 [45]      
Sallee, 2009 [46]      
Wil s, 2015 [47]       
Ne co n, 2017a [34]      
New or , 2017b [34]       
Note:       low ri k/hig risk/ ome conc rn . Rnd—r nd zati n proces; Int—intende
inte v ntions; Mis—missing o tc me ata; Mea— e surem  of th  o tcome; S l—sel ction of 
t e reported result. 
To conclude, the vide e bas  n pharmacologi al ADHD rea m nt in ad lescents 
with concur e t AD D nd SUD is limite , with l s  tha  500 pati nts i clude  across 
our contr lled t ials of  short durati , no e f whi h how d  robust tr atment eff c  
on either A HD r SUD. 
3.2.2. Adolescent  with ADHD but with t SUD Comorbidity
Most trials on the efficacy f ph rm cological ADHD treatment in youth have been 
c nducted in ixed s mples of childr  d adolescents t an age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
s bgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and non-stimulant medications w th placebo in children 
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stud es, wi h no excess of SAEs i any ac ive edication group compared with lace .
Ad erse pharmacol gical interactio s between th  s dy medication and the ad lescent’s 
subst nc  use at the sa  ay w re only reported in the trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and thr  (2.1%) of the patients taking OROS-MPH and placebo, 
resp ctively. In the three tr als tha  nv stigated s imulants, no indication was found that 
stimul nt medication le  t  SUD deteri ration. 
Pla ned t e tme t uration in th e tr al ranged from 6–16 weeks (1 of 4 studies >12 
weeks), and o s bsequ nt extension s udi s were conducted to investigate the long-ter  
effects of ADHD medication  t e stu y samples. Hen , pertaining to adolescents with 
com rbid ADHD and SU , only data on the sh rt-term effects of ADHD medication are 
av ilable to d t . We assessed the risk  bi s as being low in the studies of Riggs (2011) 
and T rs one (2010), and as high in the tu ies of Szobot (2008) and Riggs (2004), mainly 
due o missing outcome data (Table 2).
Table 2. Ri k of b as n the included studi s on ph rmacological interventions. 
Study Bias Arising from/Due to:  
nd Int Mis Mea Sel Overall 
A ol scents with ADHD + SUD      
Riggs 11 37
Szo o , 8 [36]
Riggs, 2004 [38] 
Thursto e, 2010 [39]
A olescents wit  ADHD      
Pelham, 3 [3 ] 
F n ling, 0 [27]
lens, 2006 [40]       
Fin ling, 2011 [42]      
Spe ce , 2006 [41]      
Bo tic, 2000 [43]   
Bangs, 2007 [44]      
Bi rman, 2008 [45]      
Sall e, 2009 [46]     
W l , 2015 [47]      
New r , 2017a [34]      
Newcor 2017b [34]      
Note:      l w isk/h gh risk/so e concer s. Rnd—ra domization roc s; I t—in en ed 
in rventi ns; M s— issi g o tco  t ; Mea— ea urem t f he out ome; Sel—sel ction of 
the repo te  result. 
To conclude, t e evi ce b se o  phar acol gic l ADHD reatm nt in adolesc nts 
with c ncurrent ADHD nd UD is limited, with le than 500 patien s included across 
f r controll d trial of a sho t duration, n  of whi h sh wed a obust treatment effect 
on eithe  ADHD or SUD. 
3.2.2. A olesc nts with ADHD but with ut SUD Como bidity 
Most trials on the effic cy of pharmacological ADHD treatment in youth h ve been 
co ducte  in ix d mples of children and adolesce ts at  age grou  typically ranging 
from 5 to 18 years, with ut separate a alysis r reporting of utcomes in the adolescent 
subgro p. Our selected literature ncluded a meta-a lysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-st mulant medicat ons with placebo in children 
a d adolesce t  with ADHD [48]. O ly f ur of these, 15 trial focused on adolescents only. 
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studies, with no excess of SAEs n ny ctive medic tion g oup co p r d with placebo. 
Adv rse ph rm cological n er ctions b tween the s udy medic tion and the adolescent’s 
substance us at the sam  day we e only repo ted in the trial of Riggs et al. (2011) [37], 
and o l  by four (2.8%) and three (2.1%) of he patients taking OROS- PH and placebo, 
respectively. In the thre  trial th t i vestigated stimulan s, o indication was found that 
stimula  medication l d to SU  de erioratio . 
Plan  t e tme t dura ion in th  tri ranged from 6–16 weeks (1 of 4 stud es >12 
w eks), and o subs quen  ext n io  studies ere cond cted to investigate the long-term 
effects of ADHD medication in the tudy sam l . H ce, ertaining o dol sc ts with 
c morbi ADHD and SUD, nly data on the short-t rm effects of ADHD medication are 
availa l to dat . We as essed the risk of bias as being low in the studies of Riggs (2011)
and Th r tone (2010), and a  high in t e studies of Szobot (2008) and Riggs (2004), mainly 
due to issi g outcome data (Table 2). 
T le 2. R sk of bias in the ncluded studies  phar acological interventions. 
St dy Bias Arising from/Due to:  
 Rnd Int Mis Mea Se Overall 
Adolescents with ADHD + SUD      
Riggs, 2011 [37]    
Sz bot, 2008 [36]    
Riggs, 2004 [38]   
Thurstone, 2010 [39]    
A ol scents with ADHD       
Pelham, 2013 [33]    
Fi dli , 2010 [27]       
len , 006 [40]     
Fin ling, 2011 [42]    
Sp ncer, 2006 [41]     
Bostic, 2000 [43]       
Bangs, 20 7 [44]     
B ed rma , 2008 [45]       
Sallee, 2009 [46]     
Wil , 2015 [47]      
N wc n, 2017 [34]      
N wc r , 2017b [34]       
N te:        l w risk/high risk/ ome concerns. R —rand mization proces; Int—int nd d 
i erv nti n ; Mi — ssi g ou c m  ta; Me —m surem t f the outcom ; S l—s l ctio  of 
the report d resul .
To c n lude, the eviden e bas  n p rmacological ADHD trea me t in adolesc nts 
with concur t AD D and UD is l mite , wi h l s tha  500 patie ts included a ross 
ou  controlled t ials of a sh rt durati , non  of w ich showed a robust tr atment eff c  
on ei her ADHD  SUD. 
3.2.2. Ad lescents wi h ADHD but with t SUD C m rbidity 
Most trials on the efficacy of ph rmacological ADHD treatment in youth have been 
co ducted in ixed samples of children a  dolesc nts at an age group typically ranging 
from 5 o 18 y ars, without sep rat  a alysis or reporting of outcomes i  the adolescent 
subgroup. Our s lected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
f 15 RCTs comp ring s mulan  and on-stimula t medications with p ac bo in children 
and adolescents with ADHD [48]. Only four of hese, 15 trials focu ed on adolescents only. 
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studies, with o exc ss of SAEs in a y active medication group compared with placebo. 
Adver e pharmac l gical i teractions b twe n the study m i tio  nd the adolescent’s 
substance use at e sam  day were only repor ed n the tri l of Riggs t l. (2011) [37], 
and only by four (2.8%) and thr e (2.1%) f th  patie s t ki  OROS-MPH and pl cebo, 
respectively. In th  thr e trials that i ve igate s imul ts, o indication wa  found that 
stimula t medicati n led to SUD deterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (1 f 4 studies >12 
weeks), a d no su seque t exte si n tu ies were conducted t  investigate the long-term 
effects o  ADHD medication in the study samples. H nce, pertaining o adolescents with 
comorbid ADHD a d SU , only data on the short-term effects of ADHD medication are 
v ilable to d te. We as e ed the risk of bias as being low in the studies of Riggs (2011) 
and Thurst ne (2010), and as high in t e studies of Szobot (2008) and Riggs (2004), mainly 
du  to mis ing outc me d ta (Table ). 
Table 2. Risk of bias in th  included studies on pharmacological interventions. 
Study Bias Ari in  from/Due to:  
 Rnd I t Mis Mea Sel Overall 
Adolescents with ADHD + SUD      
Riggs, 2011 [37]     
Szobot, 2008 [36]      
Riggs, 2004 [38]       
Thurs o , 2010 [39]       
Adolescents it ADH     
P lham, 2013 [33]    
Fi d ng, 2010 [27]       
Wil s, 2006 [40]       
Findl g, 2011 [42]      
Spencer, 2006 [41]      
B stic, 2000 [43]       
Bangs, 2007 [44]      
Biederma , 2008 [45]       
Sall , 2009 [46]       
Wilens, 2015 [47]       
Newc rn, 2017a [34]      
N wcor , 2017b [34]       
No e:        ow risk/hi  risk/some c rn Rnd—r omiz ion proces; Int—i te ed
int rven ion ; Mis—missi g utc me ta; Mea—m a urement of the u c me; Sel—sel ct o  of 
the reported result. 
T  c n lu e, th  ev dence s  on p rmacologi al A HD treatment i  ad l scents 
with concurre t  and S D is limit d, wit  l s  th  500 patients i clu e  a ross 
four controlled tri ls of h rt durati , ne of which h e  a robust treatme t ffect 
n eith  ADHD r SUD. 
3.2.2. Adolesc nt  with ADHD but without SUD Co orbidity 
Most trials on th  efficacy f pharm cological ADHD tre tment in youth have een 
conducted in mixed samples of children a d olescents at an age group typically ranging 
from 5 to 18 years, without separate an lysis r reporting of outcome in t e ad lescent 
subgroup. Our selected literature included a meta-analysis by Cerrill -Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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studies, with no excess of SAEs in any ac ive edication group compared with lace .
Adv r e pharmacol gical interaction  betwee  t  st dy medication and the ad lescent’s 
su stance use at e sa e day were only reported in the trial of Riggs et al. (2011) [37], 
and o ly by four (2.8%) and thr e (2.1%) of th  patie s taking OROS-MPH and placebo, 
respectively. In the three trials that inv stigated s imulants, no indication was found that 
stimula t medication led t  SUD deterioration. 
Pla ned treatm nt uration th se tr al rang  fr m 6–16 w eks (1 of 4 studies >12 
weeks), and no subsequent extension studies were co ucted to investigate the long-ter  
effects of ADHD medication i  t e study samples. Hence, pertaining to adolescents with 
comorbid ADHD and SU , only dat  on th  short-term effects of ADHD medication are 
available t  d te. We assessed the ri k of bias as being low in the tudies of Riggs (2011) 
and Thurstone (2010), and as high in the tudies of Szobot (2008) and Riggs (2004), mainly 
due o missing outcome ata (Table 2). 
Tabl  2. Risk of bias the nclude  studies on ph rmacological interventions. 
Study Bias Arising from/Du  to:  
nd Int Mis Mea Sel Overall 
Adol c nts with ADHD + SUD   
Riggs 11 37
Szobo , 8 [36]
Riggs, 2004 [38] 
Thur o e, 2010 [39]
Adolesce s wit ADHD      
Pelh m, 3 [3 ] 
Fin ling, 0 [27] 
W l , 2006 [40]     
Findli g, 2011 [42]      
Sp cer, 2006 [41]      
Bostic, 2000 [43]      
Bangs, 2007 [44]       
Bi d rman, 2008 [45]       
allee, 2009 [46]    
W l , 2015 [47]     
New r , 2017a [34]    
New r 2017b [34]     
Note:          l w risk/high risk/ ome co cerns. Rnd—ra domization roc s; I t—in en d 
int rve ions; M s— issi g outco e d t ; Mea— surem t f he outcome; Sel—sel ction of 
the reporte  result. 
To conclude, t e vide e base on phar acological ADHD trea m nt in adolesc nts 
with c ncurrent ADHD nd UD is limite , wi h l ss th n 500 patien s includ d acr ss 
our controlled t ials of a short duration, none of which showed a obust treatment eff c  
o  either ADHD o  SUD. 
3.2.2. A olescents with ADHD but with t SU Comorbidity 
Most trials on the efficacy of pharmacologic l ADHD t eatment in outh h ve been 
c nducted in ixed samples of children and adolescents at an age grou  typically ranging 
from 5 to 18 years, without separate analysis or reporting of utcomes in the adolescent 
subgr u . Our selected literature included a eta-analysis by Cerrillo-Urbina et al. (2018) 
f 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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stu i s, w th no ex ss f AEs in y ac ive medic tion group compared with l ce .
Adv r e pharmac logi l nt r ctio s b tween the st dy medic tion and the ad lescent’s 
substance us   e same day were ly r porte  in the trial of Riggs et al. (2011) [37], 
d o ly by four (2.8%) and th ee (2.1%) of the patients taking OROS-MPH and placebo, 
resp ctiv ly. In the three ri s th t i vestigated s imulants, no indication was found that 
s imula t me ication led t  SUD deterioration. 
Planned treatment duration in these ri ls rang d from 6–16 weeks (1 of 4 studies >12 
weeks), d no su sequ  exten i n studies were nducted to investigate the long-term 
effects of ADHD medication in t e study samples. He c , pertaining to adolescents with 
comorbid ADHD and SU , nly data on the short-t r effects of ADHD medication are 
availa le t  d te. We assess d the risk of bias as being low in the studies of Riggs (2011) 
and Th rst ne (2010), d as high in the studies of Szobot (2008) and Riggs (2004), mai ly 
due t missing outc me data (Table 2). 
Table 2. Risk of bias in the included studies on pharmacological interventions. 
Study Bias Arising from/ ue to: 
Rnd Int Mis Mea Sel Overal  
Adol sce ts with ADHD + SUD      
Rigg 11 37
Sz bot, 8 [36]
Riggs, 2004 [38] 
Thu sto e, 2010 [39] 
Adol sce ts wit  ADHD      
Pelh m, 3 [3 ] 
Fi dli , 0 [27] 
W l s, 2006 [40]       
Findling, 2011 [4 ]    
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs 20 7 [44]     
Biederman, 2008 [ 5]       
Sallee 2009 [46]       
Wi s, 2015 [47        
Ne corn, 2017  [34]      
N w orn 2 17b [ 4]     
Not :          l w r k/hig risk/ ome conc r s. R —r domizati  roces; Int—inte ed 
int rv ntio s; M s—missi g utcome dat ; M a—measureme t f th  ou c me; Sel—sel ction f 
the reported result. 
T  c lude, the evide e base on ph rmacological ADHD trea ment in ad le cents 
wit  concur t ADHD a d S D is l mite , wi  l s tha  500 pat ents included a r ss 
ur contr lle  t i ls of a sh rt durati , n  of w ich showed a robust treatment ff c  
n ei h r ADHD  SUD. 
3.2.2. Adolesce ts with ADHD but with t SUD C morbidity 
Most trials on th  efficacy of phar acological ADHD treatm nt in youth h ve been 
onducted in ixed s mple  of child  and adolescents at an age grou  typically ranging 
from 5 to 18 y ars, wi out separat  analysis or reporting of utcomes in the adolescent 
subgroup. O select d literature inclu ed a meta- nalysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing s mulan  and non-stimulant medications with placebo in children 
and dolescents with ADHD [48]. Only four of hese, 15 trials focused on adolescents only. 
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s udies, with no exces  of SAE in a y activ  medication grou  co p red ith placebo. 
Adverse pharmacol gical inter ctio s between e s y medication and the dolescent’s 
substance use at th  sam  d  w r  only r port d in the tr al f Rigg  et al. (2011) [37], 
nd only by four (2.8%) and thr e (2.1%) of th  patients taking OROS-MPH and placebo, 
resp c iv ly. I  the r t i at i v ig ed im la ts, no ndicati w s foun th t
stimula t medicatio l d o SUD deterioration. 
Plann d treatment duration in h se trials rang  fr m 6–16 w eks (1 f 4 tud es >12
weeks), and o sub eque t xtensio  studies were c n ucted to investigate th  long-term 
effects of ADHD med c ti  in t e study amples. Hence, p r aining t ad lescents with 
co orbi  ADHD d SU , only ata o the sh rt-term effects of ADHD m dicatio  are 
available t  d te. We assessed the risk of b as s b ing low in the studies of Riggs (2011) 
and Thurston  (2010), and as h h in the studies of Szobot (2008) and Riggs (2004), mainly
du  to missin  outcom  d ta (Table 2). 
Table 2. Risk of bias in th  include  studies on pharmacological int r e tions. 
Study Bias Arising from/Due to:  
 R d Int Mis ea Sel Overall 
Adolesc nts w th ADHD + SUD       
Riggs, 11 [37]      
Szobot, 20 8 [36]      
Riggs, 2004 [38]       
Th rsto , 2010 [ 9]       
A ol scents wit ADHD    
Pelham, 2013 [33]      
Findling, 201  [27]       
Wilens, 2006 [40]      
Findling, 2011 [42]       
Spencer, 2006 [41]     
B stic, 2000 [43]      
Bangs, 2007 [44]     
Bie er an, 20 8 [45]       
S ll e, 2009 [46]      
Wile s, 2015 [47]      
Ne c r , 20 7a [34]       
Newc r , 2017b [34]      
Not :          l w r sk/high isk/ om  conc r . R d—r d z ti n pr ces; Int—in e d d 
interven io s; M s—missi g utc e ta; M a—me sure e t of th  tcome; S l—sel ctio  of 
the reporte result. 
To c nclude, the evide ce b s  p rm cologic l ADHD treatme t in adoles ents 
with co current A HD nd SUD is limit d, with l ss th  500 patients includ d across
four controlled t als of  short duration, o  of w ic sho e  a robust trea ment effect 
on eit r ADHD or SUD.
3.2.2. Adolescents wit  ADHD but withou  SU  Com rbidit
Most rials on the efficacy of pharmac logical ADHD tr tment in outh have been
c nducted in mixed samples of hildren and adol sc ts at n ge group t p cally ranging 
from 5  18 years, withou  epara e a alys s or porti g of outcom s in the a olescent 
subgroup. Our selected literatur  includ d a meta-an lysis by C rril o-Urbin  et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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studies, with o excess of SAEs in a y c ive ication gr up ompar d with la .
Ad er e pharmac l gical i ter ction  between the st dy medication and the a lescent’s 
substance use at e same d y were only r ported in the trial of Riggs et al. (2011) [37], 
and only by four ( .8%) d thr  (2.1%) of th  pati s taking OROS-MPH and placebo, 
respectively. In th three trials that inv stigated s imulants, no indication was found that 
stimulant medication led  SUD terioratio . 
Pl nn d t e tme t du at o n th  trials ranged fr m 6–16 w eks (1 of 4 stud es >12 
weeks), and no subseque t extensio stu ies were c ucted to i vestigate the long-term 
effects of ADHD me ication i  t  s udy samples. ence, pertaining to adolescents with 
com rbid ADHD a d SU , only data on the short-term effects of ADHD medication are 
ava lable to d te. W  assessed the risk f bi s as bein low in the studies of Riggs (2011) 
and Thurs one ( 010), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due o missi g outcom  at  (Table 2).
Table 2. Risk of bias  the included studies on ph rmacological i terventions. 
Study Bias Arising from/D e to:  
Rnd I t Mis Mea Sel Overall 
A ol sc nts with ADHD + SUD      
Riggs 11 37
Szobot, 8 [36]
Ri gs, 2004 [38] 
Thur to e, 2010 [ 9]
A olesce ts wit  ADHD       
Pelham, 3 [3 ] 
Fin li g, 0 [27]
l , 2006 [40]      
Fin li g, 2011 [42]      
Spe cer, 2006 [41]       
Bo tic, 2000 [43]    
Bangs, 2007 [44]      
Bi rman, 2008 [45]      
Sall e, 2009 [46]     
W l , 2015 [47]     
N w rn, 2017a [34]     
N wcor 2017b [34]      
Note:          w risk/h gh risk/ ome co rns. Rn —ra domiza ion roc s; I t—in en ed 
int rventi ns; Mis— issi g outco e dat ; M a—m asur m t f th  outco ; Sel—sel ction of 
the repo ted result. 
To conclude, t e vid e ba e on pharmacological ADHD trea m nt in adolesc nts 
with c current ADHD and UD is limite , with l s th n 500 p tien s included across 
our controlled t ials of a sh rt duration, none of which showed a robust treatment eff c  
on either ADHD or SUD. 
3.2.2. A olesc ts with ADHD but with t SUD Comorbidity 
Most trials on the effic cy of pharmacol gical ADHD treatment in outh h ve bee  
co ducted in ix d s mples of children and adolesce ts at an age grou  typically ranging 
from 5 to 18 years, without sep rate anal sis r rep ting of utcomes in the a olescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medicatio s with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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s ud s, with no exc s of SAEs in a y active medication group compared with placebo. 
Adverse pharmaco ogi l int r tio s betwee  the study medication a d the adolescent’s 
s bst nce use  e sa day were ly r ported in the trial f Riggs et al. (2011) [37], 
nd o ly by four (2.8%) and th ee (2.1%) of the patients taking OROS-MPH and placebo, 
res c iv ly. In he i  that i vestigated s mulants, no in ication was found that 
s imula t me ication led to SUD deterioration. 
Plann  tre t ent duration in ri l  ra g d from 6–16 weeks (1 of 4 studies >12 
w eks), nd o subs qu n x ensio studies were nducted to investigate the long-term 
effects of ADHD medication in the tudy samples. Henc , pertaini g to adolescents with 
c morbi  ADHD a d SU , only data on the short-ter effects of ADHD me ication are 
availabl  t  d t . We assess d the risk of bias as being low in the studies of Riggs (2011) 
and Thurston  (2010), a d as high in the studies of Szobot (2008) and Riggs (2004), mai ly 
due to missing outc me data (Table 2). 
T b e 2. Risk of bias in the includ d studies on ph rmacological interventions. 
St dy Bias Arising from/Due t :  
 Rnd Int Mis Mea Sel Overal  
Adolesce ts with ADHD + SUD       
Riggs, 11 [37]      
Sz bot, 2008 [36]      
Riggs, 2004 [38]      
Thu sto e, 2010 [ 9]      
A ol sce ts wit  ADHD      
Pelham, 2013 [33]      
Fi dli , 2010 [27]      
l s, 2006 [40]      
Findlin , 2011 [42]     
Spencer, 2 06 [41]       
B stic, 2000 [43]      
Bangs, 2007 [44]     
Bie e man, 20 8 [45]      
S ll , 20 9 [46]       
Wi , 2015 [47        
Newc r , 2 17  [34]      
Newc rn  2 17b [34]       
Not :         l w r sk/hig risk/ ome concer s. R d—r ndomizati n roc s; Int—inte e  
interventio s; M s—missi g utc me ata; M a—me surement f the tc me; Sel—sel cti n f 
th  r porte  result. 
T  c clude, th  evide e bas  on p armacological ADHD trea ment in ad le cents 
with concur t ADHD d S D is limite , wi  l ss tha  500 pat nts included a r ss 
u  controlle  t i ls of a sh rt durati ,  of w ich showed a robust treatment ff c  
n i r ADHD  SUD. 
3.2.2. Adol scents with ADHD but with t SUD C morbidity 
M st rials on th  efficacy of phar ac logical ADHD tr tment in youth have been 
onducted  mixed sampl  of child  and adolescents at an age group typically ranging 
from 5 o 18 years, wi hou  sep ra  analys s or reporting of outcomes in the adolescent 
s bgr up. O s lect  literatur  inclu ed a meta- nalysis by C rrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and dolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with o exc ss of S Es i y active medicatio group compared with lace . 
Adv rse phar ac l ical i teractions b twe n the st dy m dic tio  a d the d lescent’s 
substanc use at e sam  day were only repor ed in the trial of Riggs t l. (2011) [37], 
and only by four (2.8%  and three (2.1%) of th  pati nts taking OROS-MPH and pl cebo, 
respectively. In th  thr tr al that i vestigate st mul t , o i dic t on w found hat
stimula t medication led t  SUD deterioration. 
Plann d t eatm nt duratio  in thes trial ranged from 6–16 weeks (1 f 4 studies >12 
week ), and no sub equent extensi n stu ies were conducted to investigate the long-term 
effects of ADHD medicati  in t e study samples. H nce, pertaining o adolescents with 
comorbid ADHD a d SUD, only data on the short-term effects of ADHD medication are 
v ilable t  date. We a e se the risk of b as as being low in the studies of Riggs (2011) 
nd Thurst ne (201 ), and as high in the studies of zobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in th  included studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd I t Mis Mea Sel Overall 
Adolescents with ADHD + SUD     
Riggs, 201  [37]     
Szobot, 2008 [36]      
Rig s, 2004 [38]      
Thurs on , 2010 [39]     
dol scents ith ADHD   
P h m, 2013 [33]     
Fi d ng, 2010 [27]      
Wil s, 2006 [40]      
Findli g, 2011 [42]       
Spencer, 2006 [41]       
B stic, 2000 [43]       
Bangs, 2007 [44]      
Biederma , 2008 [45]     
Sall e, 2009 [46]       
Wil , 2015 [47]      
Newc n, 2017a [34]      
Newcor , 2017b [34]    
No e:       low risk/hi  risk/so e concerns. Rnd—ran o ization proc s; Int—inte d d 
int rven ion ; Mis—missi g outc me d ta; Mea—m a urem t of th  out me; Sel—select on of 
the reported result. 
T  c n lu e, th  ev dence as  on p rmacologi al A HD treatment in ad l scents 
with concurre t  and S D is limited, wit  less th  500 patients i clu e  a ross 
four controlled tri ls of  short durati , ne of which howe  a robust treatment ffect 
n eithe  ADHD r SUD. 
3.2.2. Adolescent  with ADHD but without SUD Co orbidity 
Most trials on th  efficacy f pharm cological ADHD treatment in youth h ve been 
conducted in ixed samples of children a d a olescents at an age grou  typically ranging 
from 5 to 18 years, without separate an lysis r reporting of utcome in t e adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrill -Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studi s, with o excess of SAEs i a y ac v  medication group com red with placebo. 
Adverse ph r acolog cal interactions between the s u y medication a  t e adolescent’s 
substance us  at  sam  d y were only reported n the tri l f Riggs et al. (2011) [37], 
and only by fo r (2.8%) a d thr e (2.1%) of the patients taking OROS-MPH and placebo, 
res ectively. In the ree tr als at i vestig t d st mulants, o indicatio  w found that 
stimula t medicatio l d to SUD deterioration. 
Pl n ed tre tment duration n th  tr als ra ge  from 6–16 weeks (1 of 4 tudies >12 
weeks), and n  subseque t extension studies w re co duc ed investi at  th  l ng-term 
eff cts o  ADHD medication in the study samples. He ce, p rtaining to adolescents with 
comorbid ADHD  SU , only data on the shor -term effects of ADHD m dication are 
v ilable t  d te. We a sessed the ri k of b as as being low in the studies of Riggs (2011) 
a d Thurst e (2010), a d a  high in the studies of Szobot (2008) and Riggs (2004), mai ly 
u  to mis ing outcom  data (Table 2). 
Table 2. Risk of bias in th  included studies on pharmacological interventions. 
Study Bias rising from/Due to:  
 Rnd Int Mis Mea Se  Overall 
Adolesce ts with ADHD + SUD      
Riggs, 11 [37]    
Sz bot, 08 [36]     
Ri gs, 20 4 [38]      
Thu s on , 2010 [ 9]      
les e ts wit  ADHD       
Pelham 2013 [33]   
Findl g, 2010 [27]      
il s, 2006 [40]      
Fin l ng, 2011 [4 ]    
Spencer, 2006 [41]      
B stic, 2000 [43]      
B n s, 2007 [44]    
Biederma , 2008 [45]     
Sall , 2009 [46]       
W s, 2015 [47]      
Ne corn, 2017a [34]      
N wcorn, 2017b [34]      
N te:       l w ri k/hi h risk/ m  concern . Rnd—rand mization proc s; Int—intended 
int rventi s; Mis—missi g outcom  data; Mea—measureme t of th  tc me; Sel—se ction f 
th r porte res lt. 
To conclude, th  eviden e se n phar acological ADHD trea me t i  ad lesc nts 
with concu re t A HD  SUD is limit , with l s  t  500 pati nts i cluded cross 
our co tr ll t ials of a hort durati , n e f which sho ed  robust tr atment ff c  
on eith r A HD r SUD. 
3.2.2. Adolesce t  with ADHD but with t SU  Comorbidity 
Most trials on the efficacy f ph rm cological ADHD treatment in youth have been 
c nducted in ixed s mples of hildr a d adolescents at an age group typically r nging 
from 5 t  18 years, without separate analysis or r porting of outcom s in the a olescent 
s bgroup. Our selected literature included a meta-an lysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and non-stimulant medications w th placebo in children 
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studi s, wit  no exc ss of SAEs in y a tive me ication group compared with lace . 
Adv rse pharmacological nt ractio s b wee  the st y medication a d the ad lescent’s 
substance us   same day were only r port d in the trial of Riggs et al. (2011) [37], 
an  only by four (2.8%) and three (2. %) of the patients taking OROS-MPH and placebo, 
re ectiv ly. In the th e  rial  that i vestigated st mulants, no indication was found that 
s imula t me cation led t  SUD deteri ratio . 
Plann  tre ent duration in th ri l  ra g d from 6–16 weeks (1 of 4 studies >12 
weeks), nd o subsequ exten io studies were onducted to investigate th  long-term 
effects of ADHD medication i  t e study samples. H ce, pertaining to adolescents with 
com rbid ADHD and SU , nly data on the short-t r effects of ADHD medication are 
availa le to d te. We as essed the risk of bias as being low in the studies of Riggs (2011) 
and Th rstone (201 ), and as high in the studies of Szobot (2008) and Riggs (2004), mainly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies o  ph rmacological interventions. 
Study Bias Arising from/ ue to: 
 Rnd Int Mis Mea Sel Overal  
Adol scents with ADHD + SUD    
Rigg , 11 [37]   
Szobot, 08 [36]    
Riggs, 20 4 [38]    
Thu sto e, 2010 [ 9]    
A ol scent wit  ADHD     
Pe ham, 2013 [33]    
Findli , 2 10 [27]    
l s, 2006 [40     
Fi ling, 2011 [42]    
Spencer, 2006 [41]     
B stic, 2000 [43]     
B ngs, 20 7 [44]      
Bie e man, 2008 [ 5]     
S ll e  2009 [46]     
Wil s, 2015 [47      
Newc rn, 2 17  [34]     
Newc rn, 2 17b [ 4]    
N t :         low ri k/hig  isk/ o e concerns. R —r domization proces; Int—inte ded 
interv n i s; M s—missi  outc me a a; Mea— e surement of the o c me; Sel—sel ction f 
th  reporte  result. 
To c lude, the eviden e base on ph r acological ADHD trea me t in ad le cents 
with concur t ADHD a d SUD is l mite , wi  l s than 500 pat ents included a r ss
ur contr lle  t ials of a sh rt duratio , non  of w ich showed a robust treatment ff c  
on ei h r ADHD SUD. 
3.2.2. Adolescents wit  ADHD but with t SUD C morbidity 
Most tri ls on th  efficacy of phar cological ADHD treatm nt in youth h ve been 
conducted in ixe s mple  of c ild en and adolescents at a  age grou  typically ranging 
from 5 t  18 y ars, wi hout separate analysis or reporting of u comes in the adolescent 
subgroup. O s lected literature inclu ed a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing s mulan  and non-stimul nt medications with placebo in children 
and adolescents with ADHD [48]. Only four of hese, 15 trials focused on adolescents only. 
Complementary Interventions
14 A e , 201 [75]
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studies, with no excess of SAEs in any activ  medic tion group compared ith placebo.
Adverse pharmacological interactions bet een the stu y i i d th  a lesce t’s 
substance use at the same day were only reporte  in the t ial of Riggs et l. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the patie ts t king OR S-MP  and placebo, 
respectively. In the thr e trials that investigat d stimulants, no i ication s fou  that
stimulant medication led to SUD deteriorati n. 
Planned treatment duration in these trials rang  fro  6–16 we ks 1 f 4 studi  >12
weeks), and no subsequent xtension studi s w re c n uct d to vestigate the lo g-ter
effects of ADHD medication in the study s mples. He ce, pertain  t  adolescents with
comorbid ADHD and SUD, only da a on t  short-t r  eff cts of ADHD dication ar
available to at . We assessed the risk of bias as being ow in t e st i s of Riggs ( 011)
and Thurston  (201 ), and a  high in th  stud s of Szobot (2008) a d Riggs (2004), ma nly
due to missing out ome data (Table 2). 
Table 2. Risk of bias in t e included stud es n h rmac logical i terventions. 
Stu y Bias ri in  fr /Due to:  
 R d I t Mi  Mea Sel Ove all 
Adolescents with ADHD + SUD      
R ggs, 2011 [37] 
Szobot, 2008 [36] 
Riggs, 20 4 [38] 
Thurst e, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]   
Findling, 2010 [27]   
Wilens, 2006 [40]     
Findli g, 2011 [42]      
Spencer, 2006 [41]       
Bostic, 2000 [43]      
Bangs, 2007 [44]       
Biederma , 2008 [45]     
Sallee, 2009 [46]   
Wilens, 2015 [47]     
Newcorn, 2017a [34]      
Newcorn, 2017b [34]    
Note:          low risk/ igh risk/some concerns. Rnd—rando ization proces; Int—intended 
interventions; Mis—missing outcome data; Mea—meas ement f the outcom ; Sel—selecti n of 
the reported result. 
To conclude, the vidence base on pharmacological DHD treatment in ad lesce ts
with concurrent ADHD and SUD is limited, with less than 500 patients inclu e  cr s 
four controlled trials of a short uration, none of which showed a robust treatment eff ct 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment i  youth have been 
conducted in mixed samples of children  l sc ts at an age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, with no xcess of S Es i  any active medication group compared with pl c bo.
Adverse pharmacol gi al nterac ions betw en the study medi ation n  th  ad lescent’s 
substance use at the s me day were ly r porte  in t e t ial of Riggs et al. (2011) [37], 
nd only by four (2.8%) and h e (2. %) of th p ient  taking OROS-MP  and pl cebo, 
res ctively. In the three trial  th t investigated stimulants, no i dicatio  was found that
sti ula t medication led to SUD deterioration. 
Planne  treat t uration in these tr ls ra ged from 6–16 week  (1 of 4 studies >12 
weeks), nd no subs que t ext sion studi s were conduct  to nvestigate the long-term 
effects of ADHD medication i  th  study samples. Henc , pertain g t  adolescents with
comorbid ADHD and UD, only d ta on the short-ter  effects of DHD medicatio  are
av ilable t  dat . We ssess d the risk of bias s being low in the studies of Riggs (2011) 
an  Thurst ne (2010), a d as h gh i  the tu ie  of Szobot (2008) and Riggs (2004), mainly
due to missing outc m  data (T bl 2). 
Table 2. Risk of bi s in the included studie  on pha macological interventions.
S udy Bias Arising fro /Due to:  
 Rnd I t Mis Mea Sel Ov rall
Ad le ce ts w th ADHD + SUD     
Rig s, 2011 [37]     
Szobot, 2008 [36] 
Riggs, 20 4 [38] 
Thurs on , 2010 [39] 
Adol sce ADHD       
P l am, 13 33  
Fi dling, 2 1  [27] 
Wile s, 2006 [40] 
Fi dl g, 2011 [42] 
Spenc , 2 06 [41] 
B stic, 2000 [43] 
B gs, 20 7 [44] 
Bi er a , 2008 45  
Sall e, 2009 [46]      
Wile s, 2015 [47]       
Newcorn, 2017  [34]      
Newc n, 2017b [34]    
Note:          low ri k/ igh risk/som  concerns. R d—r ndomization proces; Int—i tended 
in rventio s; Mis—missing outcom ata; M —measurem nt f the outcom ; S l—s lectio  f 
th  re orte  result. 
To co clude, t e vidence base o  pharmacological AD D treat e t in ad lesc nts 
with co current ADHD and SUD is limited, ith less than 500 patients inclu ed acr ss 
four controlled trials of a hort duration, one of which showed a r bust treatment effect 
on either ADHD or SUD. 
3.2.2. dolescents with ADHD but ithout SUD Comorbidity 
ost trials on the efficacy of pharmacological ADHD treatment in youth have been 
onducted in mixed samples of childr  and adolescents at an age group typically ranging 
from 5 to 18 years, without separat  analysis or reporting of outcomes in the adolescent 
subgroup. Our select d literature included a meta- nalysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and dolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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st i s, with n  xc ss of SAEs n any ac ve medic i n gr up c m re  with pl cebo. 
Ad erse ph aco g cal interactio s b tw n the tu y m dicatio  and the ad lesc nt’s 
substance se at th  am d y w r  nly rep rted in th  trial f Ri gs et al. (2011) [37], 
and nly by four (2.8%) a d hree (2.1%) of patients taking OROS-MPH and placebo, 
respectivel . In the ree trials t  investig ted sti ulants, no indication w s found that 
timulant edicatio led t  SUD deteri ration. 
Planned treatm t dur tion in th s  trial ranged fro  6–16 we ks (1 f 4 studies >12 
week ), and o subs quent extension studi  w re co duc ed o investi at  the long-term 
eff ts of DHD edication in th  study samples. Hen e, pertai ing to adolescents with 
com rbid ADHD and UD, nly a a on the hor -te  effects of ADHD m dication are
av ilab e to dat . We assessed t e ri k of bias as b ing low in the studi s of Riggs (2011) 
d Thurst e (2010), a d as h gh in the stud es f zobo  (2008) an  Riggs (2004), in y 
due t  mis ing ut m  d ta (Table 2). 
Ta le . isk f bias n the included studies on pharmacological interventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mi  Mea Se  Overall 
Adol sc ts with ADHD + SUD    
Ri gs, 2011 [37]     
Szo t, 2008 [36]     
Riggs, 2004 [38]       
Thu s one, 201 [39]       
A l sc t  with       
Pelham, 2013 [33]     
Fi dling, 2010 [27]      
Wil s, 2006 [40]    
Findl g, 2011 [42]    
S ncer, 2006 [41]       
Bostic, 2000 [43]      
B g , 2007 [44]      
Bi a , 2008 [45]       
S ll e, 2009 [46]       
Wil s, 2015 [47]       
Newc rn, 2017  [34]      
Newc n, 2017b [34]      
Note:         low r k/high risk/some conc rns. Rn —rand mization proces; Int—i ended 
interventi s; Mis—missing out om  ata; M —measur m nt of t  outco ; Sel— lectio  f 
the rep r ed es lt
To co clu , the evid nc  bas  n pharmac logical ADHD treatm nt in ad lescents 
with concurre t  and SUD is limit d, with less tha  500 pati ts i cluded across 
four contr lle  tr als of a hort d ration, n ne f which showed  robust tr atment effect 
o  either A HD o  SUD. 
3.2.2. d lescents with ADHD b  ithout SUD Comorbidity 
Most trials on the efficacy f pharmacological ADHD treatment in youth have been 
conducted in ixed samples of childr n d adolescents at an age group typically ranging 
from 5 to 18 years, without se arate nalysis or reporting of outcomes in the adolescent 
s bgr up. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and non-stimulant medications w th placebo in children 
a d adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studies, wi h o excess of SAE  i  ny ac v edi ation group c m ar d with placeb .
Adverse phar acolog c l inter ctio s between the tudy medication and the a olescent’s
s bst nce use at the m  ay w re only r port d in the tri l f Rigg et al. (2011) [37],
d only by four (2.8%) and three (2.1%) of the patients taking OROS-MPH and placeb , 
r s ect vely. In the ree tr als tha  inv sti ted stimula ts, o indication w s found that 
sti ulant me i ti l d to SUD deteriorati n. 
Pla ned tr tment ration in thes  trials ra ed from 6–16 weeks (1 of 4 studies >12 
weeks), nd o s bs qu nt exte sio  udi s w re co duc ed o inv sti at  th  long-term 
f ts f ADHD medicat on i t study samples. Hen , pertai ing to d lescents with 
com rb d ADHD and SUD, nly data on the sh r -term eff c s of ADHD m dication are 
av ilab e to dat . We ss ssed th ri k of bias as being low in the studies of Riggs (2011) 
n T urst n (2010), d as hi  in the stu ies of Szob t (2008) and Riggs (2004), mainly 
u to missing outcom  data (T bl  2). 
Ta le 2. Ri k of bias i  the inclu ed studi s on pharmacological interventions. 
Study Bias Arising from/Due to:  
 R d Int Mis Mea Se  Overall 
Ad le c ts w th ADHD + SUD      
Ri gs, 2 11 [37]     
Szob t, 2008 [36]   
Riggs, 2004 [38]    
Thurston , 010 [39]    
Adole cent with ADHD     
Pelham, 2013 [33]    
Fi dling, 20 0 [27]    
Wile s, 2006 [40]   
Fi dl g, 2011 [4 ]    
Sp c , 2006 [41]     
B st c, 2000 [43]     
Ban , 2007 [44]    
Bi er a , 2008 [45]     
S ll e, 2009 [46]       
Wile s, 2015 [47]     
Newcor , 2017a [34]      
Newcorn, 2017b [34]     
No e:        low i k/high risk/s  concern . Rn —rand mization proces; Int—intended 
interventi ; Mis—mi sing tc me data; Me — asurem n  of th  o tco ; S l—s le tion of
t e e rted esu t. 
To o clude, th  evidence ba e on pha acologic l ADHD tre tment  adolescen s 
ith oncurre t ADHD an  SUD is limited, with less tha  500 pati nts included acr ss 
fo r co tr lled tr al  of  short ratio , none f which sho ed  robust tr atme t effect 
on eit er A HD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy f pharmacological ADHD treatment in youth have been 
conducted in ixed s mples of childr n a d adolescents at  age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
s bgro p. Our selected literature ncluded a meta-a lysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and non-st mulant medicat ons w th placebo in children 
a d adolesce ts with ADHD [48]. Only four of these, 15 trial focused on adolescents only. 
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studi s, with o xc ss of SAEs i  ny ac iv  m dicati n roup mpare  wit  placebo.
Adverse p armacolog cal int r i s betwee  t stu y medication the ad l scent’s
su stance s  at th  s  day w re ly rep rt d in h  trial of Ri gs t al. (2011) [37],
and ly by four (2.8%) and th e (2.1%) of the patie t  t ki g OROS-MPH nd placebo, 
resp ctively. In h thr trials t a inv tig ted stimul ts, no dication was f und hat 
stimula t me ic tion led to SUD et rior ti n.
Pl nned tr a m nt dur tion in t se rials rang  fr m 6–16 w eks (1 of 4 studies >12 
w eks), and o subs qu n  ext sio studie  were conducte to inv stigat  the l ng-ter  
effe ts f ADHD m dication  th tu y samples. en , pertai ing t  adolesc nts with 
c m rbid ADHD nd SUD, only at  o  th  short-term effects of ADHD m dication are 
ava lable to at . W  ss s th  risk of bia  as bei  ow in the tudies of Riggs (2011) 
and Thurs on  (201 ), and as high in th  studi  of Szobot (2008) and Riggs (2004), ma nly 
due to missing outcome ata (T ble ). 
T ble 2. Risk f bias in t e i cluded studies on ph rmac logical interventions. 
St dy Bias Arising fr /Du to:  
 Rnd Int Mis Mea Sel Overall 
A ol cents wit A HD + SUD      
R ggs, 2011 [37] 
Sz bot, 2008 [36]
R ggs, 20 4 [38]
Thu s e, 2010 [39] 
Adolesce ts wit ADHD       
Pelham, 13 33  
F ndlin , 10 [27]
il , 2006 [40] 
F dli g, 2011 [42]
Sp c r, 2 06 [41] 
Bost c, 2000 [43] 
Ba g , 20 7 [44] 
Bi der , 2008 45
S lle , 2009 [46]    
W l ns, 2015 [47]     
Newcorn, 2017a [34]     
Newcorn, 2017b [34]  
Note:          l w risk/high risk/so e concerns. nd—rando izatio  proces; Int—int nded 
i terve tions; Mis—missing outco  data; Mea—measurement of the outcom ; Sel—sel ct on of 
the rep rted result. 
To conclude, the evidence ba  on phar acolog cal ADHD treatment in adolesc nts 
wit  co curr nt  and SUD is limited, with le s t n 500 patien s i cluded acro  
four contr lled trials of a shor  duration, none of which showed a robust treatm t effect 
on eith r ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SU  Comorbidity 
Most trials on th  efficacy f pharmac logic l ADHD t eatme t in o th hav  bee  
c nducted in mixed s mples f childr n a d dolescents at an age gr up typically ranging 
from 5 o 18 years, without sep rat  a al sis or repo ting of utcomes in the adolescent 
subgr u . Our s lected literature included a eta-an lysis by Cerrillo-Urbin  et al. (2018) 
f 15 RCTs comparing stimulant and no -stimulant medicatio s with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studi s, with  xc s f SAEs in y a ive m ication group compared with placebo.
Advers  pha macologi l n era io s b wee  th  stu y m dication and the ad lesce ’s
ub tan s  at h  s m day w re ly rep rt in the trial of Ri gs et al. (2011) [37],
ly by four (2.8%) and th ee (2.1%) of the patien s taking OROS-MPH and placebo, 
resp ctiv ly. In the three rials t t i vestig ted stimulants, no in ication was fo nd that 
stimula t med cation led to SUD deterioration. 
Planned trea ent dur ti n in these trials rang d from 6–16 weeks (1 of 4 tudies >12 
w eks), and no subs quen  ext n ion studies were conducted to i vestigate the long-term 
effects f ADHD medica ion i  the tudy samples. H n , pertai ing to ad lescents with 
c m bid ADHD and SUD, nly data the short-t rm effects f ADHD medication re 
av il le t  d t . We as ess d the risk of bias as being low in the st dies of Riggs (2011) 
a d Th rst n  (2010), a d as h gh  the studie  of Szobot (2008) and Riggs (2004), mainly 
due t issing outc me data (Table 2). 
T ble 2. isk of bias in the included studies o  pharmacological interventions. 
St dy Bias Arising from/Due to:  
 Rnd Int Mis Mea Sel Overal  
Adol sce ts with ADHD + UD     
Riggs, 2011 [37]    
Szobot, 2008 [36] 
Riggs, 20 4 [38] 
Thu stone, 2010 [39]
A ole ce ts wit ADHD     
P lham, 013 33  
Findling, 2 10 [27] 
Wilens, 2006 [40]
F dli g, 2011 [42] 
encer, 2 06 [41] 
B sti , 2000 [43] 
B ngs 20 7 [44] 
Bi er an, 2008 45  
S l ee, 2009 [46]     
W l s, 2015 [47]     
N c rn, 2 17a [34]    
Newc n, 2017b [34]     
N te:          l w r k/high isk/so e concerns. Rn —ra domizati n pro es; Int—intende  
int rve s; Mis—miss g outc m  a a; Me — asurement of th  outco ; Sel— electio  of 
th  rep rte  result. 
To co l e, t e vid c  bas  on ph r acological ADHD treatment in adolescents 
with co current ADHD a d SUD is l mite , with le s than 500 pati n s included across 
fo r cont olled trials of a shor  d rati n, one of which showed a robust treatme t effect 
on either ADHD or SUD. 
3.2.2. dolescents with ADHD but without SUD Comorbidi y 
Most tri ls on the efficacy of pharmacological ADHD treatment in youth have been 
onducted in ixe s mples of childr n and adolescents at a  age group typically ranging 
from 5 o 18 y ars, without sep rat  analysis or reporting of ou comes in the adolescent 
subgr up. Our s lect d literature included a meta- nalysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing s mulan  and non-stimul nt medications with placebo in children 
and dolescents with ADHD [48]. Only four of hese, 15 trials focused on adolescents only. 
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studies, with no exce s of AEs in ny ac ve medica i  group compare wit placeb .
Adverse ph rmac ogical teractions b e  the study m dication d th  adole cent’s
substance use t t e m  day w re o ly rep e  in the trial f Riggs et al. (2011) [37],
and only by four (2.8%) and thr e (2.1%) of th  patients tak ng OR S-M H and placebo, 
respectively. In the three trials that nvestigat d stimulants, no in ication was fou that 
stimulant medication led to SUD deterioration. 
Planned treatment durati n in th s  trial  ranged from –16 eeks (1 of 4 tudies >12
weeks), and no subsequent x n io  stud es were conducted to investigate the lo g-ter
effects of ADHD medicatio  in the study samples. He c , pertaining to ad lescents with 
comorbid ADHD and SUD, only da a on t e sh rt-term eff cts of ADHD medication are
available to ate. We assessed the risk of bias as b ing l in the studies f R ggs (2011) 
and Thur ton  (201 ), and a h gh in the stud  of Szobot (2008) an  Riggs (2004), mainly
due to missing ou come data (Table 2). 
Table 2. Risk of bias in t e nclud d stu ie  o phar ac logical i t rventio s.
Study Bia  Ar ing from/Du t : 
 Rnd Int is Mea Sel Ov rall 
Adolescents with ADHD + SU       
R ggs, 2011 [37] 
Szobot, 2008 [36]
R ggs, 20 4 [38] 
Thu st ne, 2010 [39]     
Adolescents wi h ADH       
Pelham, 2013 [33]    
Fin ling, 2010 [27]   
Wilens, 006 [40]     
Findli g, 2011 [42]   
Sp cer, 2006 [41]    
Bostic, 2000 [43]     
Bangs, 2007 [44]   
B ed rma , 2008 [45]      
Sallee, 2009 [46]     
Wilens, 2015 [47]      
Newcorn, 20 7a [34]     
Newco n, 2017b [34]   
Note:          low risk/high risk/some c ncerns. Rnd—rando ization pro es; Int—inte ded 
interventions; Mis—missing outcom  data; ea—measurement o  the outcom ; Sel—se ect on of 
the reported result. 
To conclude, the videnc  base on phar acological ADHD treatment in ad lescents 
with concurrent ADHD and SUD is limited, with less than 500 pat ents i cluded acr ss 
four controlle  trials of a short duration, none of whic  showed a robust treatme t effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy of pharmacological ADHD treatment in youth have been 
conducted in mixed samples of children and adolescents at an age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studi s, with o excess f AEs in y ac ve m dication group c red with placebo.
Adv rs  pharmacol cal terac o s bet en the study med cation and the ’s
substance use t t e s me day were only reported in  tria of Riggs et al. (2011) [37],
and only by four (2.8%) and three (2.1%) of t p ie ts taking OR S-MPH and plac bo, 
respectively. In th  ree tri ls that inv stig ted stimulants, o i dication w s f und tha  
stimulan  m dication led t  SUD det ri ration. 
Plan ed tr atment dur tion i  thes  trials r nged from 6–16 w eks (1 of 4 studies >12 
weeks), and no subsequ nt xt nsio  st ies w re co duc ed investi at  the long-term 
effects of ADHD medicatio in the study samples. H nce, pertai  to adolescents with 
comorbid ADHD an  SUD, only d a on the sh r term ff cts of ADHD m dication are 
av ilable to ate. We ass ss d th ri k f bias as b ing low in the studies f R ggs (2011) 
a d Thurs o (201 ), a d a h gh in th  studies of zobot (2008) and Rigg  (2004), mainly 
due to missing out o ata (Ta le 2). 
Table 2. Risk f bias in he ncl ded studi  on phar ac logical i tervent on . 
Stu y Bias Arisi g rom/Due to:  
 Rnd I t M s  Se  Overall 
Ado scents with ADHD + SUD      
R ggs, 2011 [37] 
Sz bot, 2008 [36]
Riggs, 20 4 [38] 
Thu stone, 2010 [39]      
A olesce ts with ADHD       
P lha , 2013 [33]     
Findli g, 2010 [27]    
W lens, 2006 [40]    
Fin ling, 2011 [42]  
Spe cer, 2006 [41]    
Bostic, 2000 [43]      
Ba gs, 2007 [44]      
B derm , 2 08 [45]       
Salle , 2009 [46]      
Wile s, 2015 [47]     
Newcorn, 2017a [34]    
Newcorn, 2017b [34]      
Note:         low ri k/ igh ri k/some concerns. Rnd—r mizatio  pr ces; Int—intended 
interventions; Mis—missing outc me dat ; Mea—measureme of th  outcome; Sel—selectio  of 
the reported result. 
To conclude, the evidence bas  n phar acol gical ADHD treatment in adol scents 
with concur e t AD D a d SUD is limited, with less tha  500 pati ts i cl ed across 
four contr lled trials of a short duration, n ne f which showed  r bust tr atme t effect 
on either A HD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy f pharmacological ADHD treatment in youth have been 
conducted in mixed samples of childr n a d adolescents at an age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
s bgroup. Our selected literatur  included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and non-stimulant medications w th placebo in children 
a d adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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studi s, with n xces f SAEs in a y ac ve m dica ion group com ared with placeb . 
Adv rse ph rmaco c l interacti ns b twe n th tudy i i a the adolescent’s 
subst nce us  t t e am day w re ly repor e in he tri l f Rigg et l. (2011) [37], 
and nly y four (2.8%) and three (2.1%) of th  patients taking OROS-MPH and placebo,
r spectively. In he ree tr ls th  inv tig ted stimulants, o icatio  w s foun  that 
stimula t me ic tion led t SUD deterioration. 
Pl e  treat ent uration in thes  tri ls ranged f om 6–16 weeks (1 of 4 studies >12 
wee s), and o s bsequ t extension s udies w re c duc ed i vesti at  the l g-ter  
effects of ADHD medicatio  in the study samples. Hen , pe ta ing to ad l scents with 
c morbi ADHD a d SUD, only data on t e shor -t r  effects of ADHD m dication are 
av ilable t ate. We ass ssed th ri k f bias as bei  low in the studies f Riggs (2011) 
and T u s on  (201 ), a d a  h gh in th  stu es of Szobot ( 08) an  Rigg  (2004), mainly 
du to missing out om ata (Table ). 
Tabl 2. R k f bias in t e incl d d studi s o  phar acological interv tions. 
Stu y Bias Ari i g from/ ue to:
 Rnd Int Mis Mea Se  Ov rall 
A olesc nts wit  A H  + SUD     
R gg , 2011 [37] 
Sz bo , 2008 [36]
Ri gs, 20 4 [38] 
Thurs o e, 2010 [39]      
Adolescents wit  ADHD      
Pelham, 2013 [33]     
Findling, 2010 [2 ]   
Wil n , 006 [40]      
F dling, 2011 [42]   
pe ce , 2006 [41]      
Bostic, 2000 [43]      
B g , 2007 [44]     
Bi d rm , 2008 [45]      
Sall , 2009 [46]      
Wil n , 2015 [47]       
N wcor , 2017a [34]       
Newcor , 2017b [34]    
Not :       low i k/ igh risk/s me concerns. Rn —ra d izatio  proces; Int—int nd  
i terventions; Mis—missi g o tcom dat ; Mea— asure of th  outcome; Sel—selec ion of 
the reported result. 
To c nclude, he evidence base n pharmacologic l ADHD treatment i  ad lescents 
with co curre t ADHD a d SUD is limited, with less tha  500 pati nts i cluded across 
four contr lle  trials of a short duration, none f which showed  robust tr atment effect 
on either A HD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the efficacy f pharmacological ADHD treatment in youth have been 
conducted in mixed s mples of childr n a d adolescents at  age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
s bgro p. Our select d literature ncluded a meta-a lysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and non-st mulant medicat ons w th placebo in children 
a d adolesce ts with ADHD [48]. Only four of these, 15 trial focused on adolescents only. 
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tudi s, wi no exc s f SAEs i ny ac ve medication gr up co ared with placebo.
A v rse ph rm col g c l int ra i s betwee  th s udy medication and the ad l scent’s
subst nc  e at  s m  ay w e nly reported in th  tr l of Ri gs t al. (2011) [37],
and nly y f u  (2.8%) a d thr e (2.1%) of patient  takin OROS-MPH and placebo, 
r sp ctively. In he ree tr ls t a nvesti ted stimul nts, no i d cation w s found hat 
sti ul t me ic tion led to SUD deteriorati n. 
Pla ed tr a ment duration in thes  rials r nged from 6–16 weeks (1 of 4 studies >12 
weeks), an  no subsequ nt ext nsion s udi  w re conduc e  o investi at  the l n -term 
effects of ADHD m dication  the stu y samples. Hen , pertai ing to adolesc nts with 
c morbid ADHD and , only data o  th  s r -term effects of ADHD m dication are 
av lab e o dat . We ass ss d the ri k  bia  as being low in the studies of Riggs (2011) 
a d T s on (201 ), a d as high in the stu ies of Szobot (2008) and Riggs (2004), ainly 
d  o missin  outcom at  (Table ). 
Tabl . Ri k f b as in t  cl ded stud  ph r acological inter nti ns.
Stu y Bias Arising fr /Due to:  
 Rnd Int Mis Mea Se  Overall 
A olescents with A H  + SUD       
R ggs, 2011 [37]      
Sz bo , 008 [36]      
R ggs, 2004 [38]       
Thu to e, 2010 [39]     
Adolescents with ADHD       
Pelham, 2013 [33]     
Findling, 2010 [2 ]     
il , 2006 [40]       
Findli g, 2011 [42]      
Spe c r, 2006 [41]      
Bostic, 2000 [43]       
Bang , 2007 [44]    
Bi derm n, 2008 [45]      
Sall , 2009 [46]     
W l ns, 2015 [47]    
N w or , 2017a [34]      
N wcorn, 2017b [34]     
N t :        low i k/h gh risk/ o e con r s. Rnd—rand mization proce ; Int—intended 
in e ventions; Mis— i sing o come data; Mea— easur m nt of th outcome; S l—s l ct on f 
the rep rted result. 
To concl de, the vidence b se  phar acologic l ADHD treatment in adolesc nts 
with co curre t ADHD a d SUD is limited, with le tha  500 pati nts i cluded across 
four contr lled trials of a short duration, non  f which showed  robust tr atme t effect 
on either A HD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most trials on the effic cy f pharmacological ADHD treatment in youth have been 
conducted in mix d mples of childr n a d adolescents at  age group typically ranging 
from 5 to 18 years, with ut separate a alysis r reporting of outcomes in the adolescent 
s bgro p. Our selected literature ncluded a meta-a lysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs co paring stimulant and non-st mulant medicat ons w th placebo in children 
a d adolesce t  with ADHD [48]. O ly f ur of these, 15 trial focused on adolescents only. 
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studi , with no xc s of SAEs in y iv me ica i  g oup comp r d with placebo.
Adv r  ph rmac logical ctio b wee the s u y m dicatio  a d the adol scent’s
substa ce us at t  s  day w  o l repo t  i  the trial of Rigg et al. (2011) [37],
a o ly by four (2.8%) nd three (2.1%) of he patients taking OROS-MPH and placebo,
respectively. In the three rials th t i vestigated sti ulan s,  indication was fou that 
stimul t med cation l d to SUD deterioration. 
Plan e  t ea me t duration in these trials ranged from 6–16 weeks (1 of 4 tudies >12 
w ks), and o subs quen  ext n io  studies were conducted to investi ate the l g-term 
e fects f ADHD m dicatio  i  the tudy sam l s. H ce, pertaining o adolesc nts ith 
c m rbi ADHD an  SUD, nly data on the short-t rm effects of ADHD medication are 
ava la  to ate. We as es ed the risk f b as as being low in the studies f Riggs (2011) 
and Th rsto (201 ), and a  high i  the s udies of Szobot (2008) nd Rigg  (2004), mainly 
due to missi g ou co e data (Table 2). 
T le 2. sk f bi s in the cluded studies phar a ological interve tions. 
St dy Bias Ari ing from/ ue to: 
Rnd Int Mis Mea Se Overall 
A ol scents it  ADHD + SU     
R gg , 2011 [37] 
Szobot, 2008 [36]
R ggs, 20 4 [38]
Thu st e, 2010 [39]   
Adolescents with A HD     
Pelha , 2013 [33]    
Fin ling, 2 10 [27]   
W lens, 006 [40]  
F ndl g, 2011 [42]  
p nc r, 2006 [41]   
Bostic, 2000 [43]    
B ngs, 2007 [44]   
Bi d r a , 008 [45]     
S llee, 2009 [46]   
W lens, 2015 47]     
Newcorn, 2017a [34]    
Newcorn, 2017b [34]     
N te:          l  risk/high i k/ me concerns. Rn —ra domizatio  pr c ; Int—inte d  
i terv ntions; Mis— iss g outcom  d a; Mea— asur ment of the outcom ; Sel—sel ction of 
th  reporte result. 
To con lude, the evide ce bas  n ph r acological ADHD treatment in adolesc nts 
with co curre t ADHD and SUD is l mite , with le s t a  500 patients included across 
four controlled trials of a sh r  uratio , none of which showed a robust treatme t effect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
Most tri ls on the efficacy of ph rmacological ADHD treatment in youth have been 
conducted in mixe s mples of children and dolesc nts at a  age group typically ranging 
from 5 o 18 y ars, without sep rat  analysis or reporting of ou comes in the adolescent 
subgroup. Our s lected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
f 15 RCTs comp ring s mulan  and on-stimul t medications with p ac bo in children 
and adolescents with ADHD [48]. Only four of hese, 15 trials focu ed on adolescents only. 
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studies, with n  excess of SAEs in a y act ve m dica ion gro p co p re  wit  placeb .
Adverse pharmacological inter cti ns between the study di t on an  th  a ole nt’  
substance use at the same day were only rep ted in th  trial of Riggs et al. (2011) [37], 
and only by four (2.8%) and three (2.1%) of the patien  taking OROS-M H and pl cebo, 
respectiv ly. In th  three tri ls that i vestigat d imulants, no in ication was foun that
stimulant m dicat on le  t  SUD d terioration. 
Planned treatment dur ti n i  th trials rang d from –16 we ks (1 of 4 tudies >12 
we ks), and no subsequ nt extension studi s ere c d cted to nvesti ate the l ng-t rm 
effects of ADHD medicatio  in the tudy sampl s. Henc , pertaining to ad lescents with
co orbid ADHD an  SUD, only data on the sh rt-ter  ff cts of ADHD medication are
available to date. We assessed the risk f bia  s b in  l in the studies of Riggs (2011) 
and Thur tone (2010), and as high in th  st di  of zobot (2 08) and Riggs (2004), mainly
ue to missing out ome data (Table 2). 
Table 2. Risk f bias in the includ d stu ie  on ph r acolo ical int rvention .
Stu y Bia  Ari i g fro /Du to: 
 nd I t is ea Sel Ov rall 
Adolescents with ADHD + SU       
Riggs, 2011 [37]      
Szob t, 2008 [36]      
Riggs, 2004 [38]       
T urst ne, 2010 [39]      
Ad lescents wi h ADH       
Pelham, 2013 [33]    
Fin ling, 2010 [27]   
W lens, 2006 [40]    
indli g, 2011 [42]     
Sp ncer, 2006 [41]    
Bostic, 2000 [43]      
Bangs, 2007 [44]     
B ed rman, 2 08 [45]       
Sall e, 2009 [46]       
Wilen , 2015 [47]      
Newc rn, 2017  [34]      
Newco n, 2017b [34]      
Note:          low risk/ igh ri k/some co cerns. Rnd—randomization pr ces; Int—inte ded 
interventions; Mis—missing outcome data; ea—measurement o  the outcome; Sel—se ect on of 
the reported result. 
To conclude, the evidenc  base on pharmacological DHD treatment in adol sce ts 
with concurrent ADHD and SUD is limited, with less than 500 patients included acro s 
four controlled trials of  short duration, none of w ic  showed  robust tre t e t eff t 
on either ADHD r SUD. 
3.2.2. Adolescents with ADHD but with ut SUD Com rbidity 
Most trials on the efficacy of pharmacological ADHD tr at ent in youth have been 
conducted in ixed samples of children an  ad lescents at an age group typically ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes i  the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
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studies, with o xc ss of SAEs i  y c ive medication gro p compared with l ce .
Adv rs  pharm col g cal int ra o s bet een h  s dy me ication and the ’s
substanc  se at th  s e day were nly r ported in h  trial of Riggs t al. (2011) [37],
and nly by f ur (2.8%) a d three (2.1%) of the patient  taking OR S-MPH and placebo, 
resp ctively. In h three tri ls tha nv ti ated stimul nts, no dication was found hat 
stimul  ation led t SUD deteriorati n.
Planned treat ent duration in th se t ials ranged from 6–16 weeks (1 of 4 studies >12 
wee s), an  o sub equ t extension s i  were conducte to investigate the l n -ter  
effects of ADHD m dicatio   t e stu y sa ples. Hence, pertaining to adolesc nts with 
c morbid ADHD a d SUD, only data o  the s rt-term eff cts of ADHD medication are 
ava lable to at . We ass ss d th  risk  bias as being low in the studies of Riggs (2011) 
and Th rs on  (201 ), and a  high in the studies of Szobot (2008) and Riggs (2004), ainly 
du  to missing out ome data (T ble 2). 
Table . Risk of b as in t e i cl de  stud es on ph r acological interv ntions.
Stu y Bias Arising fr /Due to:  
 nd Int Mis Mea Sel Overall 
A ol scents with ADH  + SUD       
R gs, 2011 [37] 
Sz b , 2008 [36]
R ggs, 20 4 [38]
Thu sto e, 2010 [39]      
Adolescents with ADHD       
Pelham, 2013 [33]    
F ndling, 010 [27]   
l n , 2006 [40]     
F ndli g, 2011 [42]    
Sp cer, 2006 [41]      
Bostic, 2000 [43]       
Bang , 2007 [44]    
Bi derm , 2008 [45]       
S llee, 2009 [46]      
W l , 2015 [47]    
N w or , 2017a [34]       
N wcor , 2017b [34]      
Note:          low ri k/ gh risk/some con r s. nd—randomization proce ; Int—intended 
in erventions; Mis— issing outcome data; Mea—measurement of the outcome; Sel—sel ct on of 
the rep rted result. 
To conclude, t e evide ce b se o  pharmacological ADHD treatm t in adolesc nts 
with co current ADHD and UD is limit d, wi h le than 500 p tien s i cluded acros  
four controlled tri ls of a sh rt durati n, non  of which showed a obust treatm t effect 
on either ADHD or SUD.
3.2 2. A ol sc nts with ADHD but witho t SUD Comorbid ty 
Most trials on the effic cy of pharmacological ADHD treatment in youth h ve been 
co ducted in ix d amples of children a d adolescents at an age grou  typically ranging 
from 5 to 18 years, with ut separate a alysis r reporting of utcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-st mulant medications with placebo in children 
a d adolescent  with ADHD [48]. O ly f ur of these, 15 trials focused on adolescents only. 
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stu ie , with n  exce s of SAEs i  any ctiv m dicati  g up co p r d with placebo. 
Advers  ph rm c l gical ractions be wee the s u y m dic tion a d the adolescent’s 
substance us at the sa  day w e only repo t  in th  tri l f Riggs e  al. (2011) [37], 
and o ly by four (2.8%) nd thr e (2.1%) of he patie ts taking OROS-MPH and pla ebo,
respec iv ly. In t three trials that investigated stimulan s, o indication was fou that 
stimul t m dication l d to SUD deterioration. 
Plan e  t eatme t dura ion i  thes trials ranged from 6–16 weeks (1 of 4 tu ies >12 
w k ), and o subs qu n  ext nsio studies ere cond cted to investi ate the l g-term
effects of ADHD medication in th  tudy sam l s. H ce, pertaining o adolescents with 
c orbi ADHD n  SUD, only data on the short-t rm effects of ADHD medication are 
availab  to dat . We as essed the risk of bias as being low in the studies of Riggs (2011) 
and Thurstone (2010), and a  h gh in the studies of Szobot (2008) and Riggs (2004), ainly 
ue to missi g outco e data (Table 2). 
T le 2. Risk f bi s in the nclud d studie   ph r acological interve tions. 
St dy Bia  Arisi g from/Due to:  
Rnd Int Mis Mea Se Overall 
A o escents with ADHD + SU       
R gg , 2011 [37]    
Sz bot, 2008 [36]    
R gs, 2004 [38]       
T urs one, 201 [39]    
Ad lescents with ADHD       
Pelham, 2013 [33]     
Fi dli g, 2010 [27]    
W lens, 20 6 [40]     
F dl g, 2011 [42]      
S ncer, 2006 [41]     
Bostic, 2000 [43]       
B ng , 2007 [44]      
B r an, 008 [45]       
Sall , 2009 [46]      
Wilen , 2015 [47]      
Newc rn, 2017  [34]      
Newcorn, 2017b [34]      
Note:         l w risk/high ri k/ ome concerns. Rnd—randomization pr c ; Int—inte d  
interventions; Mis— issi g outcom  d ta; Mea—measurement of the outcom ; Sel—select on of 
the rep rted result.
To conclude, the ev denc  bas  n ph rmacologi al ADHD treatment i  adolescents 
ith co cur ent AD D and SUD is l mite , with l ss t a 500 patie ts ncluded across 
f u  controlled tri s of a sh  duratio , n ne of w ich showed a robust tr atment effect 
on eith r ADHD r SUD. 
3.2.2. A olesce ts wi h ADHD but w th ut SUD Com rbidity 
Most trials on the efficacy of ph rmacological ADHD treatment in youth have been 
c ducted in ixed samples of children an  dolesc nts at an age group typically ranging 
from 5 o 18 years, without sep rat  analysis or reporting of outcomes i  the adolescent 
subgroup. Our s lected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
f 15 RCTs comp ring stimulant and on-stimula t medications with p ac bo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focu ed on adolescents only. 
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udies, wit   xc s o SAE n a activ medi ation group c mp r d with pl ceb . 
Adv s ph rmacolo ic l interactio s b tween the udy m dication and the adolesce t’s 
subst nc u e at th a e d y were o ly reported in the tri  f Rigg et al. (2011) [37], 
nd ly y four (2.8%) nd thr e (2.1%) of he p e ts taking OROS-MPH and placebo, 
resp c vely. I  t e re t ial at investigat d stimulants, no in ication was found that 
stimula t medic tio  l d to SUD d ter oration.
Plann d tr atm n  dura io n th e trials ra ed from 6–16 we ks (1 of 4 tu ies >12 
week ), and o subs que t xtensio tudies we  conduc d to inv s igate th  long-te m 
f ct of A HD me ication in the study samples. Hence, p rtaining to adolescents with 
co rbi  ADHD  SUD, only dat o the hort-ter  effects of ADHD medication r  
vailab e t ate. W  assessed the risk of bias as being low in the studies of Riggs (2011) 
nd Thurst (201 ), a  as high i the studi  of Szob t (2008) a d iggs (2004), ma nly 
due to iss ng utcome data (Table 2). 
Tabl  2. Risk of bias i  th  included studies on pharmacological interventions. 
Stud  Bia rising from/Due to:  
 Rnd Int Mis Mea Sel Overal  
Ad le ce ts with ADHD + SUD     
R ggs, 2011 [37]
Szob t, 2008 [36] 
Rigg , 20 4 [38]
T urs n , 201 [39]       
olescent with ADHD    
Pelha , 2013 [ 3]     
Findl ng, 2010 [27]     
ile s, 2006 [40]   
Findl , 2011 [42]    
Spencer, 2006 [41]     
B stic, 2000 [43]      
B ng , 2007 [44]     
B eder a , 2008 [45]       
Sall , 2009 [46]       
Wile s, 2015 [47]      
e corn, 2017a [34]      
Newc r 2017b [34]       
N e:         ow risk/h gh risk/ me co c rns. R d—randomiz tion roces; Int—inten ed 
int rventions; Mis—missing utc me ata; M a—m asurement f th  outcome; Sel—s le tion of
the por e  r sult. 
To concl e, th  vide ce b se on p armacol gical ADHD tre tme t i  adol scents 
with co curre t  a d SUD is limited, with less tha  500 patients i cluded across 
four controlled trials of a hort duration, no e of which showed a robust treatment ffect 
on eit er ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
M st rials n the efficacy  phar ac logical ADHD tr tment in y uth have been 
c nducted in mixed samples f hildren and adolescents t an age group typically ranging 
from 5  8 years, withou  separa e alys s or r porting of out om s in the a olesce t 
subgroup. Our s lect d literatur  inc ud d a meta-an lysi  by C rrillo-Urbina et l. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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stud es, with o excess f SAEs in ny c ive m dication group com ared wit  lace .
Ad erse p arm colo ical i teracti ns between the st y me icatio  a d t e a lescent’s
substance s  at the s m  d y were only r p rted in the trial of Riggs et al. (2011) [37],
and nly by four (2.8%) a d thr  (2.1%) of the pati nts taki g OROS-MPH and placebo, 
respectively. In he three tri ls that i vesti ated stimulants, no indication was found that 
stimula t me tion led t SUD deterioration.
Pl nned treatment duratio  in these ials rang d f m 6–16 weeks (1 of 4 studies >12 
weeks), an  no subsequ nt exte sion studie  were conducted t  i vestigate the l ng-term 
effects of ADHD m icatio  i  t e stu y sa ples. He c , pertaining to adol sc nts with 
c m rbi  ADHD nd , only ata o  t e s rt-term effects of ADHD m dication are 
ava lab e t  ate. We ssess  th  risk of bia as being low in the studies of Riggs (2011) 
and Thurs o (201 ), and a  high i  the stu es of zob t (2008) a d Riggs (2004), ainly 
d to issin  outcom ta (Table 2). 
Tabl 2. Risk of bias in t includ  stud s n ph r acological interv nti ns.
Stu y Bias Arising fr / ue to:  
 Rnd I t Mis Mea Sel Overall 
A l sc nts with ADH  + SUD      
gs, 2011 [37] 
Sz b , 2008 [36]
Riggs, 20 4 [38]
Thu t e, 2010 [39]    
Adolesce ts wit  ADHD       
Pelham, 2013 [33]    
F ndling, 2010 [27]    
W l n , 2006 [40]      
Findl ng, 2011 [42]      
Sp cer, 2006 [41]     
Bo tic, 2000 [43]       
B ng , 2007 [44]      
Biederm , 2008 [45]    
Sall e, 2009 [46]      
W l , 2015 [47]    
N w r , 2017a [34]      
N wcorn 2017b [34]     
N t :         l w ri k/high risk/some con rns. Rnd—rand ization roc ; I t—in en ed 
interventions; Mis—missing outco e data; Mea—measurement f the outcome; Sel—sel ction of 
the reported result. 
To conclude, the vi e ce base on phar acolog cal ADHD treatment in adolesc nts 
with c current ADHD and UD is limited, wi h less t an 500 p tients includ d acr s  
four controlled trials of a sh rt duration, none of which showed a robust treatme t effect 
o  either ADHD or SUD. 
3.2.2. Adolesce t  with ADHD but without SUD Comorbidity 
Most trials on th  effic cy of ph rmacol gic l ADHD treatment in outh h ve bee  
c ducted in ixed s mples f childre  and dolesce ts at an age grou  typically ranging 
from 5 to 18 years, without separate alysis r rep rti g of utcomes in the a olescent 
subgroup. Our selected literature included a meta-an lysis by Cerrillo-Urbin  et al. (2018) 
of 15 RCTs comparing stimulant and no -stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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s ud s, with o xc ss of SAEs in y a ive m icat on group compared with placebo.
Adv rs  ph rm co o i l inter ions be ween the stu y m dication and the adolescent’s
s bs nce use  h  s me d y were l  rep rt d in the trial f Riggs et al. (2011) [37],
only by four (2.8%) and th ee (2.1%) of the patients taking OROS-MPH a d pl cebo, 
resp c iv ly. In he r i l  that i vestigated stimulants, no in ication was fo nd that 
s mula t med ation led to SUD deterioration. 
Planned tr a nt dur ti n in es ri ls ra g d from 6–16 we ks (1 of 4 tudies >12 
week ), n no subsequ nt x ension stud es were onducted to i vestigate the l ng-term 
effects f ADHD medication i he study samples. H nc , pertaining to ad lescents with 
c m rbi  ADHD a d SUD, only data o the short-t r  effects f ADHD medication re 
availab e t  at . We as ess d the risk of bias as being low in the st dies of Riggs (2011) 
and Thurst n  (201 ), a d a high i  the studies of Szob t (2008) and Riggs (2004), mainly 
du  to mis i g utc me data (Table 2). 
Table 2. Risk of bias in the included studies o pharmacological interventions. 
Study Bias Arising from/ ue to:  
 Rnd Int Mis Mea Sel Overal  
Adol sce ts with ADHD + SUD     
R ggs, 2011 [37] 
Szob t, 20 8 [36] 
R ggs, 20 4 [38] 
Thurst ne, 2010 [39]     
Adol cents with ADHD    
P lha , 2013 [33]    
Fi dling, 2010 [27]     
ilens, 2006 [40]     
Fi dling, 2011 [42]     
Spencer, 2006 [41]     
Bosti , 2000 [43]     
B , 20 7 [44]     
Bi e a , 2008 [45]    
Sallee, 2009 [46]     
W l ns, 2015 [47]    
N wc rn, 2017  [34]     
Newc rn 2 17b [34]     
Note:          low risk/hig isk/so e concerns. Rnd—ra domizati n ro es; Int—inten e  
interventions; Mis—mi s g outc e da a; Mea— easurement f the ou com ; Sel—selection f 
t  reporte resu t. 
T  c clud , t  vide ce bas  on p ar a ological ADHD treatme t in adole cents 
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f ur controlled trials of a sh rt duration, o  of which showed a robust treatme t ffect 
n eit er ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comorbidity 
M st ri ls on th  efficacy of p ar ac logical ADHD tr tm nt in youth have been 
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studies, with no excess of SAEs in any active medication group c mpared with laceb . 
Adverse pharmacological interactions between the study medic tion a d the adolesc nt’  
substance use at the same day were only reported in the trial f Riggs et al. (2011) [37],
and only by four (2.8%) and three (2.1%) of the patients t ki g OROS-MPH and pla eb , 
respectively. In the three trials that investigated stimul ts, o indication was found that
stimulant medication led to SUD deterioration. 
Planned treatment duration in these trials ranged from 6–16 weeks (1 of 4 stu i  >12
weeks), and no subsequent extension studies were conduct d to investigate th  long-term 
effects of ADHD medication in the study samples. Hence, pertaining to adole cents with 
comorbid ADHD and SUD, only data on the short-term effects of ADHD medic tion are 
available to date. We assessed the risk of bias as being low i  the studies of Riggs (201 )
and Thurstone (2010), and as high in the studies of Szobot (2008) and Riggs (2004), m inly 
due to missing outcome data (Table 2). 
Table 2. Risk of bias in the included studies on pharmacological in erventions. 
Study Bias Arising from/Due to:  
 Rnd Int Mi  Mea Sel Overall 
Adolescents with ADHD + SUD       
Riggs, 2011 [37]     
Szobot, 2008 [36]       
Riggs, 2004 [38]     
Thurstone, 2010 [39]       
Adolescents with ADHD       
Pelham, 2013 [33]       
Findling, 2010 [27]     
Wilens, 2006 [40]       
Findling, 2011 [42]      
Spencer, 2006 [41]       
Bostic, 2000 [43]       
Bangs, 2007 [44]       
Biederman, 2008 [45]       
Sallee, 2009 [46]       
Wilens, 2015 [47]      
Newcorn, 2017a [34]       
Newcorn, 2017b [34]     
Note:          low risk/high risk/some concerns. Rnd—randomization proc s; Int—i tended 
interventions; Mis—missing outcome data; Mea—measureme t of the outcome; Sel—selection of 
the reported result. 
To conclud , the evidence base on pharmacological ADH  treatment in d le cents
with concurrent ADHD and SUD is limited, with less than 500 patients include  acros  
four controlled trials of a short duration, none f which how d a robust re tment f ect 
on either ADHD or SUD. 
3.2.2. Adolescents with ADHD but without SUD Comor idity 
Most trials on the efficacy of pharmacological ADHD treatment in you h have been 
conducted in mixed samples of children and adolescents at an age group typ cally ranging 
from 5 to 18 years, without separate analysis or reporting of outcomes in the adolescent 
subgroup. Our selected literature included a meta-analysis by Cerrillo-Urbina et al. (2018) 
of 15 RCTs comparing stimulant and non-stimulant medications with placebo in children 
and adolescents with ADHD [48]. Only four of these, 15 trials focused on adolescents only. 
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3.5. Complementary Interventions
The potential benefits of a wide range of complementary interventions have been stud-
ied in patients with ADHD, including computerized cognitive training programs (working
memory training such as Cogmed), neurofeedback, dietary interventions (e.g., elimination
diets, and herbal, mineral, and vitamin supplements), meditation/mindfulness-based
therapies, physical exercise, and traditional medicine.
3.5.1. Adolescents with Concurrent ADHD and SUD
There are no meta-analyses or RCTs on the efficacy of complementary interventions in
adolescents with concurrent ADHD and SUD.
3.5.2. Adolescents with ADHD but without SUD Comorbidity
Our systematic literature search and an additional investigation of the available meta-
analyses on complementary interventions in mixed age groups resulted in five randomized
trials that examined the effectiveness of complementary treatment in adolescents with
ADHD without concurrent SUD (Table 5). Two trials examined the effects of the Cogmed
working memory training in adolescents with ADHD [66,77], one trial reported on the
effectiveness of EEG-neurofeedback as an adjuvant therapy to treatment as usual [76], one
trial tested the effectiveness of a 12-week regimen with Omega-3/6 fatty acids [78], and
one trial examined the potential benefits of a 10-week physical exercise program to reduce
ADHD symptoms in adolescents with ADHD [75]. None of the studies showed robust
beneficial effects and the study quality was generally low.
We conclude that randomized trials on complementary treatment in adolescents with
concurrent ADHD and SUD are absent and that the methodological quality in the few trials
in ADHD adolescents without concurrent SUD is insufficient to draw firm conclusions
about their efficacy.
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Table 5. Controlled studies (n > 20 per condition) of complementary interventions in adolescents with ADHD published since 2000.
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4. Discussion
Despite the high rate of concurrent ADHD and SUD among adolescents in both
addiction and mental health treatment services, the evidence pertaining to the efficacy of
treatments for this comorbidity is limited and does not allow for strong recommendations.
Concerning pharmacotherapy, the results of the reviewed randomized trials in ado-
lescents with concurrent ADHD and SUD were equivocal, with contradictory findings
between the primary and secondary outcome measures pertaining to ADHD [37,38] and
SUD [37], overall negative findings for both ADHD and SUD [39], and a small sample
size [36]. Hence, none of the pharmacological trials in this comorbid adolescent population
showed a robust between-group effect of treatment on either ADHD or SUD. In contrast,
virtually all trials in ADHD adolescents without concurrent SUD showed a significant
effect of the medication—MPH, LDX, MAS-XR, GXR, and atomoxetine—on ADHD, with
effect sizes in the moderate to large range.
Notably, the overall negative and/or equivocal outcomes in concurrent ADHD and
SUD adolescent samples were also found among adults with concurrent ADHD and
SUD, except for two trials [79,80] in which a dose much higher than the standard dose
of stimulant medication was prescribed (Table S3 in Supplementary Materials). Hence,
whereas there is ample evidence to support the efficacy of pharmacological interventions in
adolescents with ADHD without concurrent SUD, the evidence of ADHD pharmacotherapy
pertaining to both ADHD and substance abuse outcomes in patients with comorbid ADHD
and SUD is virtually absent (adolescents) or limited at best (adults).
Several factors may account for or contribute to the discrepancy in the study findings
between the concurrent SUD and non-SUD ADHD samples, which include possible dif-
ferences in (1) patient characteristics other than SUD per se, (2) treatment retention and
adherence to the study treatment regimen, (3) medication dose, and (4) the nature of and
response to the control or concomitant psychosocial treatment.
Firstly, concerning patient characteristics, the adolescent samples with and with-
out concurrent SUD predominantly included males, and showed similar ADHD symp-
tom severity and a similar ADHD subtype distribution at study entry. However, adoles-
cents with SUD comorbidity were on average nearly two years older than their non-SUD
counterparts—which likely reflects the increasing prevalence of SUD with increasing age—
and had a high prevalence of concurrent CD, which was mostly absent in the non-SUD
samples. However, evidence suggests that age plays a minimal role in moderating the
efficacy of stimulant treatment in children, adolescents, and adults with ADHD [35,81],
and several studies in children found that ADHD outcomes of pharmacological treatment
were similar among those with and without concurrent CD [82–84]. In addition, in the
trial of Riggs et al. (2011), comorbid CD in adolescents with ADHD and SUD (one-third
of the study sample) did not moderate the effect of OROS-MPH vs. placebo on ADHD
outcomes [85]. Hence, differences in patient characteristics other than SUD, including
age and CD comorbidity, are unlikely to account for the discrepancy in ADHD outcomes
between the SUD and non-SUD studies reviewed.
Secondly, medication adherence, if reported, was similarly high (>82%) among adoles-
cents with and without SUD, as was the overall rate of treatment completers in the active
medication groups (Table 1).
Thirdly, several authors have suggested that efficacious stimulant treatment may
require higher doses in ADHD patients with comorbid SUD [36,86,87], because of decreased
brain dopamine function resulting from chronic drug use [10]. As mentioned above, the
only two trials with a significant effect on both ADHD and SUD outcomes to date indeed
used a much higher than the standard dose of stimulant medication [79,80]. In search
for an explanation for these findings, a single photon emission computed tomography
(SPECT) study in 24 ADHD patients with (n = 8) and without (past) cocaine dependence
(n = 16) showed a lower striatal dopamine transporter (DAT) occupancy by MPH in
cocaine dependent compared with non-dependent ADHD patients after two weeks of
MPH treatment. This group difference in DAT occupancy was significantly associated with
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self-reported impulsivity and craving, but not with the reduction in ADHD symptoms
following MPH treatment [88]. However, the sample was small and larger studies are
needed to better explain the differences in the effect of stimulant treatment in ADHD
patients with and without SUD.
Fourthly, in the reviewed trials, adolescents with and without concurrent SUD showed
similar mean ADHD symptom reductions in the active medication groups, but the symp-
tom reductions in the placebo control groups were much larger among those with comorbid
SUD [37,39] than in their non-SUD counterparts. A high response to control treatment was
also observed in several trials among adults with SUD comorbidity. This suggests that not a
lack of medication effect, but rather an inflated placebo response is responsible for the lack
of effect on ADHD in the pharmacotherapy trials in patients with concurrent ADHD and
SUD. However, it should be noted that control treatment in most of these trials consisted of
both placebo and behavioral treatment—CBT/MET for SUD—which was also provided as
concurrent treatment in the active medication groups, whereas most control treatments in
the non-comorbid samples consisted of placebo only. Hence, given that CBT and MET are
effective treatments for SUD and have shown promise in the treatment of ADHD in both
adolescents [73] and adults [89] with SUD, CBT/MET, placebo, or both may have caused a
ceiling effect, which in turn may have contributed to the failure of pharmacotherapies to
separate from the control treatment in the trials on comorbid ADHD and SUD.
Concerning psychosocial treatment, no randomized trials or meta-analyses have been
conducted to date in youth with concurrent ADHD and SUD. Although a few trials in
ADHD adolescents without concurrent SUD provide some indication of a small beneficial
effect, the study quality was too low to draw a firm conclusion about the efficacy of the
psychosocial treatment of ADHD in adolescents either with or without concurrent SUD.
Given the recommendations in national guidelines that ADHD pharmacotherapy should
be embedded in psychosocial treatment, it is obvious that further research is needed to
investigate the efficacy of psychosocial treatment in this specific age group. Finally, for
complementary interventions, research on adolescents with concurrent ADHD and SUD
was absent as well, and the literature on adolescents with ADHD without concurrent SUD
was too limited to provide additional clues about treatment efficacy.
5. Conclusions
Treatment of adolescents with concurrent ADHD and SUD remains challenging.
ADHD is one of the main developmental risk factors for early substance use, misuse, and
SUD in adolescence and early adulthood. Early treatment of childhood ADHD (especially
with stimulants) may have a small protective effect against the development of SUD in
ADHD patients, although the mechanism of such potential protection is unknown and
confounds are still possible.
Treatment of adolescents with comorbid ADHD and SUD is still in its infancy, however,
pharmacotherapy with higher than standard doses if needed should be explored within
the context of a beneficial psychosocial environment and without unnecessary exposure of
these adolescents to unpleasant complementary treatment [90]. In addition, we need more
research investigating the efficacy of psychosocial and complementary inventions both in
ADHD-only patients and in patients with comorbid ADHD and SUD.
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